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ABSTRACT
The in vivo fate and toxicity of the novel copper-based anticancer agent casiopeina II 
([Cu(4,7-dimethyl-l,10-phenanthroline)(glycine)NO3]), and in vitro mode of cell 
death induced in two cancer cell lines were investigated. After a single intravenous 
administration of ^H-casiopeina II (5mg/kg dose) in the rat the complex was rapidly 
distributed to tissues, the ^H-phenanthroline was excreted via urine and faeces whilst 
the copper appeared to be predominantly retained with a small amount being excreted 
via faeces. Differences in tissue copper retention and ^H-phenanthroline elimination 
suggest an in vivo dissociation of the complex.
The major toxic effect attributed to casiopeina II administration was haemolytic 
anaemia (reduced haemoglobin concentration, red blood cell count and packed cell 
volume as well as leukocytosis and neutrophilia) observed at 12 hours and 5 days 
after administration can be attributable to direct erythrocyte oxidative damage. 
Increased reticulocyte levels and the presence of normoblasts in peripheral blood 5 
days after administration indicated an effective erythropoietic response and tendency 
towards recovery at 15 days. Increase in spleen weight was attributed to an increased 
uptake of damaged erythrocytes by the reticuloendothelial system. Older rats (10- 
week old) appeared to be more susceptible to the haemolytic damage than younger 
rats (6-week old) possibly due to a reduced erythrocytic tolerance. Erythropoietin 
pretreament before casiopeina II administration reduced the haematological effects.
Cell death by apoptosis, induced in vitro in CHI human ovarian carcinoma and L1210 
murine leukaemia cells after casiopeina II treatment, was observed by cell 
morphology, DNA integrity and caspase activation. Cisplatin resistant and 
susceptible forms of CHI and L1210 cells were equally sensitive to casiopeina II 
apoptosis induction. The mechanism by which casiopeina II activates caspases in the 
two cell lines, although unclear, suggests an intracellular trigger such as 
intramitochondrial ROS generation by the Cu(II) moiety of casiopeina II.
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Chapter 1. General Introduction
1.1 Cancer Chemotherapy - Brief history of the development of cancer therapy 
and latest discoveries
In the quest for more effective therapies against cancer, scientists are working on the 
development of new treatments and the improvement of the already-known ones. Until 
now current treatment cannot completely eradicate cancer, but rather prolong survival 
surrounding ordinary tissue, and the tendency to spread throughout the body (through 
the blood stream establishing itself at other distant sites i.e. metastasis) (Heilman and 
Yokes, 1996). In the last two decades important discoveries in cancer cell biology have 
provided an insight into the molecular mechanisms of cancer, facilitating the search for 
more effective therapies. Some of the fundamental cellular and extracellular processes 
that are known to be deregulated in cancer cells include cell cycle control, signal 
transduction pathways, apoptosis, angiogenesis and interactions with the extracellular 
matrix (Boral et al, 1998).
Currently the most effective clinical therapies for cancer have been the combination of 
surgery, radiation and chemotherapy. Surgery and radiotherapy are effective for 
eradicating primary or localised cancer, however when treating metastasis and 
completely eliminating all the cancer cells they may exhibit limitations (Heilman and 
Yokes, 1996). In addition the ability to reach more sites and to attack tumours that have 
metastasised makes chemotherapy a highly effective alternative against cancer and 
plays an important role in the delay of tumour recurrence, thereby prolonging survival 
(De Yita, 1997). Despite the beneficial effects of cancer chemotherapy it presents 
certain constraints, such as drug resistance, toxic side effects and the limited types of 
cancers that respond to chemotherapeutic agents which have all contributed to the 
search of more effective and specific targeted drugs (DeGeorge et al, 1998). Moreover 
effective cancer chemotherapy requires a better understanding of the mechanisms of 
cancer development (Egorin, 1998).
Chemotherapy in cancer has been defined as “the treatment of cancer using specific 
chemical agents or drugs that are selectively destructive to malignant cells” (Heilman,
1998). The idea of a compound that would specifically target cancer cells is not always
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feasible due to the fact that cancer is more a group of diseases rather than a single 
disease (Heilman and Yokes, 1996). In the early 1940s the first chemotherapeutic agent 
used against cancer was a nitrogen mustard, which proved to be most effective against 
haematopoietic neoplasms such as Hodgkin’s disease and lymphocytic lymphoma 
(Rhoads, 1946). This event marked the start of the chemotherapeutic era, and since that 
time a variety of chemotherapeutic agents effective against cancer have been developed.
During the 1950s and 1960s effective treatments of some leukaemias, testicular and 
breast tumours and neuroblastomas were discovered with the use of methotrexate, 
vincristine (Johnson et a l, 1963), 5-fiuorouracil (Kaye, 1998), cytosine arabinoside, 
daunorubicin, aminopterin and actinomycin D amongst others. In the 1970s other 
cytotoxic agents such as bleomycin, mitomycin C, adriamycin and procarbazine were 
used against lymphomas, solid tumours, head and neck, breast, testicular and ovarian 
cancer, amongst others. In addition cisplatin, a metal-based anticancer agent, was 
initiated for the treatment of testicular, ovarian, bladder and head and neck cancers. In 
the last two decades more cytotoxic agents against leukaemia, ovarian, testicular and 
bladder cancer and have been introduced, these include etoposide, carboplatin, 
ifosfamide, mitoxantrone. Other agents such as paclitaxel, satraplatin and the use of 
gene therapy (immunological vaccines), GMK and MGY, are now being used against 
melanoma of the skin, lung, pancreatic, prostate and colorectal cancer amongst others 
(Ferrante et a l, 1999) (Table 1.1). Furthermore the use of chemopotentiators to 
enhance the cytotoxic effect of chemotherapeutics against cancer has become another 
strategy, with DPPE being used together with doxorubicin, cyclophosphamide and 
cisplatin (Ferrante et a l, 1999). In the last 50 years research on drug anticancer 
chemotherapy has become an extensive area of investigation due to the some of the 
positive results achieved for the treatment of this disease.
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Table 1.1. Historical development of chemotherapeutic agents
DATE AGENT TYPE OF CANCER
1940-1949 Nitrogen mustard Lymphomas and solid tumours
1950-1959 Actinomycin D, Aminopterin, 
Antifolates, Busulfan, 5-Fluorouracil 
6-Mercaptopurine, Methotrexate
Acute leukaemia, neuroblastoma, 
choriocarcinoma, chronic 
myelocytic leukaemia, testicular 
tumours, carcinoma of GI tract, 
advanced carcinoma of the breast
1960-1969 L-Asparginase, Cytosine arabinoside, 
Daunorubicin, Melphalan, Progestins, 
Vinblastine and Vincristine (Vinca 
alkaloids)
Lymphomas, reticuloendothelial 
malignancies, acute leukaemia, 
choriocarcinoma, endometrial 
carcinoma, leukaemias, 
carcinoma of gut
1970-1979 Bleomycin, Cisplatin, Dimethyl 
triazeno-immidazole carboxamide. 
Doxorubicin (Adriamycin), 
Mitomycin C, Nitrosoureas, 
Procarbazine
Lymphomas, brain tumours and 
solid tumours, head and neck 
cancers, breast cancer, sarcomas 
and a wide range of other 
malignancies, lymphoma, 
melanoma, testicular, ovarian and 
bladder
1980-1990 Carboplatin, Etoposide (VP-16), 
Ifosfamide, Mitoxantrone
Ovarian cancer and leukaemias, 
testicular, ovarian, bladder, and 
head and neck cancers
1990- Capecitabine, Gemcitabine, Gene 
therapy (immunological vaccines), 
Irinotecan, Ocreotide, Paclitaxel, 
Raltitrexed, Satraplatin, Taxorete, 
Topotecan
Melanoma of the skin, colorectal 
cancer, pancreatic cancer, solid 
tumours, lung cancer, bladder, 
prostate, breast and ovarian 
cancer
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Chemotherapeutic agents can be classified into different groups according to their 
mechanisms of cytotoxicity (Table 1.2) (Heilman and Yokes, 1996). Some of them 
may exhibit more than one cytotoxic effect and thus may be allocated to more than one 
group. In addition recent evidence supports that chemotherapeutic agents may induce 
apoptotic cell death in cancer cells (Kamesaki, 1998), this topic is covered with more 
detail in Section 1.4. Antimetabolites are compounds that interfere with the normal 
metabolic processes within cells, through the inhibition of vital enzymes or acting as 
nucleoside analogues interfering with DNA and/or RNA, e.g. fluorouracil, methotrexate 
and the currently introduced gemcitabine (Kaye, 1998). Topoisomerase inhibitors 
interfere in DNA strand cleavage and reattachment during division, subsequently 
causing cell death, amongst these are doxorubicin, camptothecin, actinomycin D and 
bleomycin (Pommier and Tanizawa, 1993). Plant alkaloids bind to tubulin, promoting 
microtubule function thereby inhibiting the mitotic process and in some cases inducing 
apoptosis, amongst these are vincristine, vinblastine, vinorelbine and paclitaxel 
(Ferrante et a l, 1999). Some Hormones such as prednisolone inhibit cell division by 
interfering with DNA synthesis, or may have an antagonistic activity in tumours whose 
growth depends on hormone activity, such as tamoxifen used for oestrogen-dependent 
tumours (Patterson et a l, 1981; DeGeorge et a l, 1998). Alkylating agents, such as 
cyclophosphamide, melphalan, chlorambucil and busulphan interact non-specifically 
with DNA base pairs by cross-linking, impairing cell division and thus triggering cell 
death, however in some cases these agents induce DNA damage in healthy cells, thus 
triggering a negative effect of tumour initiation, such is the case of nitrosamines (Colvin 
and Chabner, 1990). Other miscellaneous agents bind to specific DNA sites interfering 
with its sequencing avoiding synthesis and subsequently causing cell death. Such is the 
case of mitomycin C that forms a covalent bond with guanine-N2 (Hartley and 
Souhami, 1993) and cisplatin whose mechanisms of DNA interaction are explained in 
more detail in section 1.2.2.
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Table 1.2. Classification of chemotherapeutic agents according to their mechanism of
action
FAMILY MECHANISM OF ACTION AGENTS
ANTIMETABOLITES Interference with DNA by Methotrexate,
behaving as fake substances in Fluorouracil,
biochemical reactions of cells and Gemcitabine,
thus preventing DNA synthesis. Cytarabine,
Mercaptopurine,
Thioguanine.
TOPOISOMERASE DNA interaction by the inhibition Doxorubicin
INHIBITORS OR of the ability of topoisomerase (Adriamycin),
ANTIBIOTICS enzymes to reattach the broken Camptothecin,
ends of DNA strands during cell Actinomycin D,
division, which causes cells to Bleomycin,
die. Dactinomycin
PLANT ALKALOIDS They inhibit mitosis by binding to Vincristine,
tubulin (protein that forms Vinblastine,
microtubular fibres) during cell Paclitaxel,
division. Cocetaxel,
Vinorelbine
HORMONES Inhibit cell division by interfering Prednisolone
with DNA synthesis or they (glucocorticoid).
exhibit antagonistic hormonal Tamoxifen (anti­
activity. oestrogen).
ALKYLATING They react with DNA bases Melphalan,
AGENTS preventing cell division by cross- Cyclophosphamide,
linking with the double helix, and Chlorambucil,
if not repaired this may trigger Busulphan
cell suicide.
MISCELLANEOUS Specific DNA-site interaction Procarbazine,
interfering with DNA synthesis Mitomycin C,
and replication. Cisplatin
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1.2 Metal complexes as anticancer drugs
1.2.1 The use o f metal based compounds in cancer therapy
The use of metals for therapeutic purposes dates back to the ancient Chinese who used 
gold for medical purposes around 2500 BC, and later in the XII century to Paracelsus 
(1493-1541) who is regarded as the “father of metallotherapy” (Williams-1974 in Kopf- 
Maier, 1994). Lissauer reported in 1865 the use of an arsenical formulae (Fowler’s 
mixture) for the treatment of leukaemia. At the beginning of this century various 
treatments with metal compounds were widely used, in 1910 Erlich’s compound 606 
(arsphenamine) was used to treat syphilis, until penicillin was discovered. Gold cyanide 
was used by Koch to treat tuberculosis, antimony compounds were used against 
leishmaniasis in 1912 by Vianna and in 1929 gold compounds were being used by 
ftench physicians to treat rheumatoid arthritis (Sadler, 1991). At present some heavy 
metals are still used as therapeutic drugs against some diseases, for example silver in the 
protection of skin-bums, radioactive technetium, gadolinium, iron and magnesium 
compounds as diagnostic techniques and bismuth for the treatment of diarrhoea and 
stomach ulcers (Hnatowich, 1994; Reedijk, 1997). Moreover lithium salts as 
antidepressants, gold in arthritis treatment and platinum compounds as anticancer agents 
(Bakhtiar and Ochiai, 1999). Despite the wide use of metals as therapeutic drugs there 
is some prejudice against using metals for medical purposes because of their perceived 
reputation as apparently toxic and their possible retention since they cannot be 
metabolised by the body. For this reason the wider usage of metals for medical 
purposes depends strongly on reducing their toxicity.
Some metals are participants of biological redox reactions (e.g. copper) (Nobel et a l, 
1995) and others undergo ligand substitution with biological molecules (e.g. cisplatin) 
(Kelland, 1994). The inherent chemistry of metals determines their behaviour and the 
therapeutic prospects that they may possess. Collier and Krauss in 1931 reported that 
“The effect of a heavy metal on experimental murine cancer is not only due to the metal 
alone, but also to the structure of the compounds and the type of compound” (Keppler, 
1993). Thus the understanding of the basic chemistry of the mechanisms of 
pharmacological actions and their diverse structural and functional biological properties
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provides a wide scope for the efficient utilisation of metal compounds in cancer therapy 
(Fricker, 1994; Bakhtiar and Ochiai, 1999).
The fortuitous discovery of inhibition of cell division and antitumour activity with 
cisplatin by the biophysicist Barnett Rosenberg in the mid-1960s lead to the wide spread 
use of cisplatin against many solid tumours (Rosenberg et a l, 1965 in Fricker, 1994). 
Cisplatin is essentially used for the treatment of testicular and ovarian cancers, and has 
proved to be effective against cancer of head and neck, lung and bladder and metastatic 
breast cancer (Heim, 1993). As a result of the discovery of the antitumour activity of 
platinum-based compounds the quest for other metal-based compounds with positive 
antitumour activity and less toxic effects began.
A second generation development of cisplatin with similar anticancer effects is 
carboplatin, which was specifically developed (in the Institute of Cancer Research in the 
UK) with the aim of improving the therapeutic activity of cisplatin and reducing its 
toxicity. Carboplatin is effectively used against ovarian, germ cell, and small cell 
carcinoma of the lung and breast cancer since 1986 (Binks, 1988). Iproplatin is another 
second-generation platinum complex that has shown effective activity against small-cell 
lung cancer and ovarian carcinoma (Kelland, 1994). Moreover Kizu and collaborators 
(1999) report on a new oral platinum-derivative antitumour agent, C5-0HP, that has 
shown significant antitumour activity experimentally in a murine model. Another 
successful platinum derivative that is currently in clinical trials in humans is JM-216, it 
is an oral administered compound used for the treatment of small-cell lung cancer, 
relapsed ovarian cancer, and hormone-refractory prostate cancer (Ferrante et a l,  1999). 
In addition latest studies demonstrate that metal complexes, other than platinum and its 
derivatives, have also shown a significant potent activity against cancer. Nowadays 
some are indeed undergoing experimental and early clinical trails with positive results, 
amongst these are complexes of gallium, germanium, copper, titanium, vanadium, gold, 
rhodium, ruthenium and tin (Table 1.3) (Kopf-Maier, 1994; Kratz and Schütte, 1998).
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Chapter 1. General Introduction
1.2.2 Mechanisms o f action and resistance o f metal complexes, e.g. cisplatin 
Mechanisms of action of metal complexes
Mechanisms of action of metal complexes is determined by the type of ligand, chemical 
structure, configuration (they often contain an organic compound in planar aromatic 
structure that binds the central metal) and type of metal (Kopf-Maier, 1994). The 
nature of the ligand may determine if a compound can interact within a hydrophobic 
environment, such as membranes, charged molecules like DNA or bind with a particular 
protein (Holler, 1993). Metal complexes exhibit different mechanisms of action 
through which they interfere in cancer cell proliferation, these include DNA-adduct 
formation, site-specific DNA-strand cleavage and DNA alkylation. Amongst the most 
common metal-binding sites in DNA is the strong complex formed between nucleoside 
bases with transition-metal ions such as platinum (Pt(II)) (Bakhtiar and Ochiai, 1999). 
Studies with cisplatin have provided a major understanding of the mechanism of action 
of metal complexes and their biological targets. Cisplatin affects mainly rapidly 
proliferating cells. It is a neutral, square planar molecule containing two chlorine 
groups (‘leaving groups’) orientated in a cis configuration. Carboplatin is an analogue 
molecule of cisplatin where the two independent chloro-ligands have been replaced by 
the bidentate cyclobutane dicarboxylic acid (CBDCA) ligand of carboplatin producing a 
compound that is more resistant to water (Figure 1.1) (Kelland, 1994).
^  Cl
/
H3N Cl H3N
C is p la t in  (CDDP; cis- C a r b o p la t in  (CBDCA; cis-diammine(l,l-
diamminedichloroplatinum(n)) cyclobutane dicarboxyIato)platinum(II))
oco
/
Pt
\ oco
Figure 1.1. Cisplatin and carboplatin structures (Kelland, 1993).
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The main site of cisplatin antitumour activity is the interaction with DNA. In an 
intracellular environment cisplatin loses its chlorine atoms and it is transformed into an 
aquated reactive electrophile. This electrophile is then capable of reacting with 
nucleophilic sites on DNA, RNA or proteins. Once bound to DNA it will form stable 
bifunctional adducts consequently inhibiting transcription and blocking replication. The 
site of the most commonly known DNA adducts formed by cisplatin, is between the 
nitrogen in position 7 of adjacent deoxyguanosines (guanine N7) and platinum (Figure 
1.2) (Delmastro et al., 1997).
Figure 1.2. Most common cisplatin-induced D(GpG)-intrastrand DNA adduct (Kelland,
1994X
Recent evidence indicates that the cellular damage caused by cisplatin is mainly in the 
replication of DNA (O’Dwyer et al., 1997). In addition Jordan and Carmo-Fonseca 
(1998) report a disruption of rRNA synthesis in HeLa human cells as a result of 
cisplatin cytotoxicity, and thus blocking ribosomal transcription. Thus cisplatin 
damages the cell by targeting different cell sites, genomic DNA, RNA and protein 
(Perez, 1998). Recent evidence supports that non-genomic targets could also be a cause 
of cell damage by cisplatin. Cisplatin complexes start their attack on the cell by first 
binding to the phospholipids and proteins of the plasma membrane, thus inducing 
structural membrane changes, increasing permeability and a reduction in flexibility. 
Intracellular platinum complexes bind to cytosolic thiol groups, GSH and MT, which 
once saturated result in reduced cell protective mechanisms and thus increase 
spontaneous lipid peroxidation. Cisplatin complexes may also deactivate enzymes, 
such as those with sulphydryl groups in their active centres and therefore inflicting
12
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damage. In addition cisplatin can interact with proteins and nucleotides, such as ATP or 
GTP, interfering in their metabolic process influencing the structural and functional 
activities of the cytoskeleton by inhibition of polymerization and depolymerization 
caused by the binding. Once bound to nucleoproteins, platinum induces protein-DNA 
interactions, and it may intercalate with the double stranded DNA inhibiting synthesis 
and resulting in fatal cell damage (as mentioned above) (Wang et al., 1996). The 
pathology of the nephrotoxicity caused by cisplatin indicates substantial mitochondrial 
damage, which could be another effect that could trigger apoptotic cell death 
(Kruidering et a l, 1996). Cytotoxic injury has been related with apoptotic cell death 
induction by cisplatin (this is explained with more detail in Section 1.7.2).
The evidence that cisplatin and its derivatives, such as carboplatin and JM-216, have 
proven to be efficient anticancer compounds has opened a wide field for the research of 
other metal-based complexes with anticancer activity (Kelland, 1994). Moreover 
reports indicate that various other metal complexes exhibit effective interaction in the 
synthesis of DNA, RNA and proteins (Kdpf-Maier, 1994). In view of these positive 
reports on metal-based compounds with anticancer activity it is of most importance to 
investigate the mechanisms of new compounds.
Drug resistance to metal complexes
A major obstacle in cancer chemotherapy is the irregular response of cancer cells to 
chemotherapeutic agents, resistance. Drug resistance to chemotherapy has been most 
commonly observed in colon, pancreatic and lung cancer as well as other small-cell 
type cancers. Moreover there are other types of tumours that initially respond to 
chemotherapeutic treatment, but they stop responding and acquire resistance to therapy, 
this is the case of breast cancer and small-cell cancer of the lung (Tannock, 1992). 
Tumours consist of heterogenous cell populations of sensitive and resistant cells, 
following drug therapy most of the sensitive cells are killed and those resistant to 
therapy survive and spread. Resistant tumour cells elude the effects of a specific 
chemotherapeutic compound, specific drug resistance, or they can be cross-resistant to 
various apparently unrelated chemotherapeutic agents, multidrug resistance (Tannock,
1992).
13
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Intrinsic resistance of cancer cells, the proliferative state of the cells (cell cycle phase 
specificity), vascular access and the penetration of drugs in the tissue are some of the 
mechanisms involved in drug resistance. In addition drug resistance is a multifactorial 
process that involves the ability of tumour cells to eliminate or inactivate 
chemotherapeutic agents (D’Alessandro et ah, 1997). The cellular mechanisms of drug 
resistance can be divided, for descriptive purposes, into active and passive resistance 
(Tannock, 1992; Stewart gr a/., 1996; O’Dwyer 1997) (Table 1.4).
Table 1.4. Active and passive resistance
ACTIVE RESISTANCE PASSIVE RESISTANCE
More efficient
glycoprotein
participation)
efflux of drugs (p- 
and glutathione-pump
Deficiency in cell drug uptake (a 
decrease in transport protein activity 
and specific membrane lipids)
Increase in DNA repair enzymes Decreased or altered cofactors (tissue 
hypoxia or altered pH)
Binding to sulphydryl compounds i.e. thiol 
groups (GSH or MT) thus inactivating the 
active metabolite
Increase in drug catalytic enzymes 
(deaminases and aldehyde dehydrogenases)
Alteration in the levels of target enzymes 
and intracellular drug metabolism 
Alternative biochemical pathways of drug 
transport
Altered drug target molecule, e.g. a 
reduction of topoisomerase II activity 
as a result of a mutation-induced 
alteration may reduce enzyme activity 
or drug affinity for the cell’s 
topoisomerase II
When DNA damage occurs in normal cells, a repair mechanism is triggered, if the 
damage is irreparable the cells die before replicating. Some DNA repair mechanisms 
that have been associated with cellular resistance include DNA repair enzymes such as 
0^-alkylguanine-DNA-alkyltransferase, base excision repair and single-strand break 
repair, nucleotide excision repair system and mismatch repair mechanisms. The 
inhibition of DNA repair mechanisms are now considered as anticancer drug-targets in 
chemotherapeutic resistant tumours (Barret and Hill, 1998).
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Moreover drug-induced mutations of DNA and dysregulation of some gene pathways 
are affected in cancer cells that have developed resistance. The capacity of some cancer 
cells to resist the cytotoxic effects of chemotherapeutic drugs has been related to the 
dysregulation of cell cycle control genes, such as p53 that regulates p21, rather than the 
inherent resistance to a certain drug (Weller, 1998). The p53 tumour supressor gene can 
also function as an apoptotic mediator, it can cause an interruption (G1 phase arrest) in 
the cell cycle when DNA damage occurs, promoting cell death by apoptosis (Bellamy et 
ah, 1997). In addition inactivation of p53 function has been identified in cancer cells 
that exhibit cisplatin resistance (Gallagher et ah, 1997). In essence, p53 may enhance 
tumour chemosensitivity by promoting apoptosis via the activation of proapoptotic 
genes such as bax and the suppression of anti-apoptotic genes such as bcl-2. However, 
p53 may decrease chemosensitivity by promoting p21-mediated and independent 
growth arrest, DNA repair, differentiation, and by enhancing antiapoptotic genes such 
as bcl-x and thus participating in drug resistance (Weller, 1998).
As mentioned before cisplatin and carboplatin are effective chemotherapeutic agents for 
a wide range of tumours, however some such as colorectal and non-small-cell lung 
cancer do not respond effectively to them. Additionally some ovarian tumours which at 
first respond positively to cisplatin treatment develop resistance (acquired resistance) 
and do not respond effectively to the treatment any longer (Perez et a l, 1990). Some of 
the mechanisms for cisplatin and carboplatin resistance are a decreased intracellular 
transport of the compound and cytoplasmic detoxification through increased levels of 
thiol species (GSH or MT) and an increased repair of platinum-DNA damage (Kelland,
1993). Recently it has been suggested that enhanced capacity to tolerate cisplatin- 
induced damage also contributes to resistance, tolerance may be acquired by alterations 
in proteins that recognise cisplatin-DNA damage (mismatch repair and high-mobility 
group (HMG) family proteins) (Perez, 1998). Less formation of platinum-DNA adducts 
and enhanced removal of platinum-induced adducts from DNA are also believed to be 
involved (O’Dwyer et ah, 1997). Studies with resistant human ovarian carcinoma cells 
support that the ability to tolerate high levels of platinum bound to DNA and the 
formation of interstrand cross-links are responsible for the resistance to cisplatin 
(O’Neill e ta l,  1995).
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Studies on the interaction of cisplatin with trace metals have been performed to aid in 
the understanding of the mechanisms of cisplatin resistance. Decreased platinum and 
iron intracellular concentrations and increase in levels of copper and zinc were 
associated with cisplatin resistance. Variation of cell susceptibility to cisplatin was 
associated with a high individual variation of copper content in vitro in human ovarian 
adenocarcinoma cells (Ortega et al., 1996). It seems that the presence of 
metallothioneins (MT-I and MT-IT) may influence cisplatin resistance, supported by the 
evidence of metallothionein gene expression which could be controlled by oncogenes 
{ras and sis) in mammalian cells (Yamada-Okabe et ah, 1995).
In addition mechanisms involved in the repair or the overexpression or inactivation of 
certain genes may control tolerance to platinum-DNA damage. Studies on selected 
cisplatin resistant cell lines have provided information about genetic mechanisms 
involved in drug resistance as well as regulative mechanisms involved in drug 
resistance (O’Dwyer et al., 1997). Inactivation of p53 in a human ovarian carcinoma 
cell line (A2780) is apparently responsible for an acquired cisplatin resistance 
(Gallagher et a l, 1997).
1.3 Mechanisms of toxicity of metal complexes
1.3.1 Toxicity o f anticancer compounds
The identification of prominent toxic effects caused by chemotherapeutic agents 
contributes in the improvement of cancer therapy. Because chemotherapeutic agents 
are highly cytotoxic they exhibit various adverse effects, ranging from mild to severe, 
limiting the complete success of anticancer treatment. In addition implementation of 
modulatory schemes of dosing, clinical monitoring and immediate treatment of toxicity 
are current strategies used to avoid toxic effects caused by anticancer agents (DeGeorge, 
etal. 1998).
In general chemotherapeutic agents cause toxicity due to their specificity against cells 
that are constantly dividing, which is the reason of their susceptibility. In the body there
16
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are tissues that normally have a high proliferating rate, these include bone marrow, 
gastrointestinal (GI) mucosa, hair follicles, and the reproductive organs. Therefore 
these tissues are more likely to be affected under chemotherapy regimes. In addition, 
there are also drug-specific side effects or toxicity to different tissues of the body. The 
main toxic effects generally caused by chemotherapeutic treatment include GI toxicity 
(nausea and vomiting, oral and intestinal ulceration, diarrhoea), bone marrow 
suppression and immunosuppression (which increases the risk of opportunistic 
infections). Other toxic effects are skin reactions, alopecia, and toxicity to the hepatic, 
pulmonary, cardiac, genitourinary and central nervous tissues, in some case sterility and 
congenital malformations are likely to occur. Furthermore anticancer compounds may 
produce carcinogenic effects, becoming a source for second malignancies (Cline and 
Haskell, 1980; Tannock, 1992).
In the case of metal complexes toxicity can be exacerbated by a retention and/or 
accumulation of the metal in tissues. This can be illustrated by taking cisplatin as an 
example. The main toxic effects of cisplatin are nephrotoxicity (in majority of cases), 
severe nausea and vomiting, neurotoxicity (peripheral neuropathy) and ototoxicity 
(tinnitus/hearing loss) (Kelland, 1994). Nephrotoxicity of cisplatin is predominantly 
due to the intravenous administration of the compound, high hydrophilicity of cisplatin 
and its excretion and uptake into the tubular epithelial cells. In addition the main lesion 
identified in the kidney produced by cisplatin is acute tubular necrosis in the outer stripe 
of the medulla (Goudie et a l, 1994). Although the exact mechanisms of cisplatin- 
induced nephrotoxicity are still not well understood, it appears that iron plays a crucial 
role in mediating tissue injury through the generation of hydroxyl radicals during 
cisplatin-induced nephrotoxicity (Baliga et a l, 1998). The administration of diuretics, 
intravenous hydration and fractionated therapy schemes are routinely used to prevent 
cisplatin nephrotoxicity. Moreover reports observed with carboplatin therapy indicate 
that the main toxic effects were myelosuppression, neutropenia and thrombocytopenia, 
and anaemia (O’Dwyer et a l, 1997). Experimentally oral administration of cisplatin 
and carboplatin in rats showed significant GI toxicity by both compounds, in addition to 
a nephrotoxic effect (Binks, 1988). However a new cisplatin derivative orally 
administered compound, JM-216, has shown to present some myelosupression 
(thrombocytopenia and neutropenia) and diarrhoea, whilst no GI effects were detected
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and nephrotoxicity and neurotoxicity have been infrequently reported (Ferrante et a l,
1999).
1.3.2 Mechanisms o f  metal toxicity, generation offree radicals and reactive oxygen 
species and cell antioxidant protection
Most metals cause toxic damage to cells by interfering in specific biochemical 
processes and/or producing direct damage to the cell membrane and organelles. To 
facilitate the understanding of the toxic mechanisms of metal-based compounds in 
chemotherapy it is convenient to consider the chemical form, oxidation state and 
binding state, often referred to as spéciation, of these elements in a biological system 
(Templeton, 1998). Metals generally do not exist in a ‘free’ form in biological fluids 
and tissues they are usually bound to amino acids, peptides, proteins, phospholipids and 
other tissue constituents. Therefore their biological actions (toxic and non-toxic) and 
their disposition, including membrane transport, are determined by the availability of 
specific ligands. Metal c?i\ions {positively charged metal ions) have several available 
orbitals for bond formation with monodentate or multidentate ligands. However 
multidentate ligands form more stable complexes than their monodentate counterparts. 
The type of complex (labile or reactive) formed by a metal with a ligand determines 
the reactivity of the metal complex, e.g. copper forms low affinity complexes with 
albumin or amino acids whereas it is tightly bound to caeruloplasmin (Ballatori, 1991).
Furthermore the chemical form of a metal and its abundance in the extracellular solution 
determines its interaction with the cell membrane. The cell membrane is a fluid lipid 
and protein bilayer, where proteins have the function of enzymes, ion channel pumps, 
transport proteins and receptors. Membrane proteins are contained in the lipid bilayer 
by hydrophobic interactions as peripheral proteins, e.g. transferrin receptor and carrier 
proteins, and intrinsic proteins, e.g. ion channel proteins (Simkiss and Taylor, 1995). 
Metals can enter the cell membrane as a divalent or monovalent cation, as a neutral 
lipid-soluble complex, as an anionic complex with C l , OH , HCO3 , 0 0 3^ , or as a 
complex with an organic equivalent (such as cysteine). Moreover metals form covalent 
or non-covalent bonds with membrane proteins altering their properties or functions or 
trigger other events that could secondarily affect the structure or transport system of the
18
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cell membrane (Dawson and Ballatori, 1995). Besides the chemical form by which a 
metal may enter the cell membrane, available routes also determine this process. Metals 
can enter a cell through hydrophobic ligands/compounds in the membrane, attached to 
membrane proteins or lipids, by endocytosis of carrier proteins, permeation through ion 
channels or specific processes such as ATPases (Simkiss and Taylor, 1995). In addition 
metal membrane protein binding could result in the translocation of the metal or metal 
complex into the interior of the cell where the interaction with intracellular membranes, 
enzymes or transporters may take place (Dawson and Ballatori, 1995).
Metals usually enter the body mainly by absorption through the GI tract, however in 
some cases they can enter by skin absorption or inhalation. Once absorbed they are 
usually distributed and deposited into the tissues by blood, where they are bound to 
plasma proteins or other ligand molecules determining their tissue targeting (Goyer, 
1996). Essential elements such as iron, copper and zinc are absorbed in mammals 
across the brush border of the mucosal epithelial cells of the GI tract, where they may 
be transported across the cell and released to plasma proteins (at the other side of the 
cell). For example iron is absorbed in the form of Fe and as soluble iron complexes 
(citrate or ascorbate), it is transported ‘across’ the cell in the form of haem-iron and in 
plasma it is bound to transferrin, which transports iron to tissues. In mammals copper is 
mainly absorbed by the duodenum and in lesser degree by the stomach. Copper 
solubility is promoted by the acid environment and absorption enhanced by the small 
intestine via the brush border membranes. In plasma copper binds to albumin, amino 
acids or caeruloplasmin (Simkiss and Taylor, 1995) (this topic is extensively covered in 
Section 1.4.1).
Toxicity induced by metal ions is attributed to the reactivity of the ‘fi*ee’ metal and its 
chemical form in biological fluids. Binding to and perturbing functions of cellular 
ligands produces cell injury by an excess of trace or toxic metals. For example, due to 
shared physicochemical properties between calcium, lead and cadmium, it appears that 
lead and cadmium have the ability to replace calcium in essential proteins or lipids 
causing damaging toxic effects (Ballatori, 1991). Moreover some forms of a metal may 
be harmless, whilst other species of the same element can be toxic, or even carcinogenic 
or mutagenic. Such is the case of chromium (HI), which is an essential element in the
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body, whereas salts of chromium (VI) have been reported as highly carcinogenic (Chen 
gf a/., 1997).
Metal compounds cause cell injury due to the potential reactivity of the metal. 
Transition metals such as iron, copper, chromium, manganese, cobalt, nickel and 
vanadium contain unpaired electrons and thus can be considered as free radicals (FR). 
The ability to donate or accept electrons makes metal ions effective catalysts in 
oxidation/reduction reactions, which are used in the active site of many enzymes. 
However if  the availability is not carefully controlled they can catalyse unwanted free- 
radical reactions with oxygen capable of causing damage to biomolecules (Okada, 
1996; Halliwell and Gutteridge, 1998). In addition to transition metals, cadmium, 
mercuiy, nickel and lead can deplete glutathione and protein-bound sulphydryl groups, 
resulting in the production of reactive oxygen species (ROS) such as superoxide ion, 
hydrogen peroxide and hydroxyl radical (Stohs and Bagchi, 1995).
The detrimental effects that can be caused by transition metals can be explained taking 
copper as an example. Copper usually has two oxidation states, copper(I) (Cu(I)) and 
copper(II) (Cu(II)), allowing copper to participate in radical reactions accepting 
electrons from, and donating electrons to, the superoxide radical Oi*' in a very fast 
manner:
Cu^  ^+ O2* Cu  ^+O2 
H" + Cu+ + HO2" Cu^+ + H2O2 
O2"  + Cu+ + H2O Cu^^ +0H ' + HO2'
However in some cases copper can catalyse damaging free-radical reactions, such as the 
Fenton reaction oxidising biomolecules:
Cu'" + H2O2 -> Cu^^ + OHT + OH'
Or other free radical reactions, such as the oxidation of thiol compounds (R-SH) and 
form thiyl radicals:
RSH + Cu RS* + Cu"^  + I f  
(Halliwell and Gutteridge, 1998).
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Reports indicate that the high reactivity of Cu(II) ions in vitro may have a high damage 
potential. Copper (II) ions bound to DNA react with H2O2 and ascorbic acid generating 
hydroxyl radicals, which immediately attack DNA bases in a site-specific manner, and 
thus the availability of Cu(II) ion in vivo may also be potentially harmful (Aruoma et 
a l, 1991). A similar effect has been observed with chromium (Cr(VI)), where the 
incubation of Cr(VI) with ascorbate resulted in the production of hydroxyl radicals via a 
Cr(rV)-mediated Fenton-like reaction causing DNA double-strand breaks (Shi et a l,
1994). On the other hand vanadium, which is the metal with the highest potential for 
lipid peroxidation and has various oxidation states like chromium, is not a carcinogenic 
metal (Halliwell and Gutteridge, 1998).
Metal toxicity can be associated to oxidative tissue damage, due to the catalytic role of 
metals in the oxidative deteriorating effect to biological macromolecules (Okada, 1996). 
Lipid peroxidation, DNA damage, depletion of sulphydryl homeostasis and altered 
calcium are effects produced as a consequence from the production of ROS (Munday, 
1989; Aruoma et a l, 1991; Sarkar et a l, 1995; Hultberg et a l, 1998). Lipid 
peroxidation is a radical chain peroxidation of polyunsaturated fatty acids (such as the 
phospholipids in cell membranes) and if uncontrolled it may propagate and cause 
structural damage to the cell membrane leading to cell death (Okada, 1996). Although 
lipid peroxidation is usually associated as a primary effect of cells or tissues exposed to 
metals, the peroxidation may be a consequence of injury and glutathione depletion 
caused by the metal rather than an immediate response from metal toxicity (Halliwell 
and Gutteridge, 1998). Additionally alterations of membrane structure and 
permeability, cytoskeleton, mitochondrial damage (reducing or inhibiting its function) 
and triggering of apoptosis are perceivable cell alterations due to damage by ROS 
(Zamzami et a l, 1995). Phagocytic cells may also contribute to the generation of ROS 
in response to metal ions. Moreover studies suggest that the ability to generate ROS by 
redox cycling quinones may require metal ions, which may also enhance the production 
of tumour necrosis factor alpha (TNFa), activate protein kinase C and stress proteins 
(Stohs and Bagchi, 1995). Figure 1.3 illustrates the pathways by which reactive oxygen 
species production from intracellular and extracellular sources can damage 
biomolecules.
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Figure 1.3. Scheme of Damage to biomolecules by ROS (adapted from Stohs and
Bagchi, 1995; Okada, 1996).
During the production of ROS by metal ions antioxidants protect against cell injury, 
they delay or prevent oxidation of specific substrates (proteins, lipids, carbohydrates 
and DNA), they can be active even when present at low concentrations compared with 
the amount of oxidisable substrate (Halliwell, 1996; Okada, 1996) (Table 1.5).
Table 1.5. Mechanisms involved in the protection against free radical and ROS injury
Injury Protective mechanism
❖ ROS Superoxide dismutase and peroxidase/catalase
❖ Non-specific reduction system Glutathione and vitamin C
❖ Lipid Peroxidation Glutathione peroxidase, vitamin E and P-carotene
♦♦♦ Free radical production Transferrin, lactoferrin, ferritin, metallothionein
^  DNA cleavage DN A repair enzymes
Other antioxidants a-tocopherol (vitamin E), ascorbic acid, uric acid
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Additionally antioxidant mechanisms involve the protection by enzymes (SOD, 
peroxidases and catalases), non-specific reduction systems by small molecules (GSH 
and ascorbic acid), protection against lipid peroxidation by antioxidants (Vitamin E, 
GSH peroxidase and p-carotene), metal sequestration (metallothionein, ferritin, 
transferrin and lactoferrin), and DNA repair enzymes (Okada, 1996).
Superoxide dismutase (SOD) prevents oxidative stress by being the first enzyme to 
protect against oxygen toxicity and it can also be the source of reactive species, it 
removes the superoxide anion radical (O2’’), a potential harmful ROS and transforms it 
to hydrogen peroxide (Halliwell and Gutteridge, 1998). SOD is a highly stable enzyme, 
it is produced intracellularly and it can behave as a reductant or an oxidant at the same 
time. It is composed of two close related subunits which contain Cu^  ^and Zn^  ^(CuZn- 
SOD) and there is also a mitochondrial enzyme that contains Mn^^ (Mn-SOD) (Okada, 
1996).
Glutathione (GSH) is an abundant intracellular tripeptide of glutamate, cysteine and 
glycine and plays an important role in the protection of cells against oxidative damage 
and it is synthesised from its constituent amino acids by y-glutamyl-cysteine synthetase 
and GSH synthetase. Glutathione participates as a coenzyme, it is involved in amino 
acid transport, it maintains ascorbic acid in its reduced form, it protects against reactive 
species such as free radicals or ROS and reacts enzymatically (GSH ^'-transferase 
family) or non-enzymatically with toxic compounds to form GSH conjugates 
(Anderson, 1998). Reports on copper and zinc indicate that these metals are excreted 
into bile as a complex with GSH or by a GSH-dependent mechanism (Sugawara et a l, 
1995). Glutathione also plays an important role in regulating cellular response to stress 
as well as in the protection of cells against cytotoxins. Studies on the use of glutathione 
conjugates and derivatives for regulating cell chemosensitivity is currently being 
considered as adjuvant therapy for cancer treatment (Kauvar et a l, 1998).
Tocopherols are a group of antioxidants known to protect cells against lipid 
peroxidation caused by ROS. Vitamin E or a-tocopherol is the most important 
tocopherol found in the interior of the cell membrane. Tocopherols react with lipid 
peroxy and alkoxy radicals terminating the chain reaction of peroxidation by
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inactivating singlet oxygen species protecting the cell membrane (Halliwell and 
Gutteridge, 1998). In addition GSH and Vitamin E exhibit protective effects against 
oxidative stress in free radical mediated injury, by ascorbate/iron-induced oxidative 
stress, in rat brain synaptosomes (Morais-Cardoso et a l, 1998). Studies on cell survival 
of human fibroblasts indicate that selenium-glutathione peroxidase, catalase and CuZn- 
SOD play an important role and act in a synergistic maimer as intracellular antioxidants 
against oxidative stress (Michiels et a l, 1994).
Metallothioneins (MT) are low-molecular-weight cysteine-rich proteins that form 
complexes with metals. They contain about 30% cysteine (rich in sulphur) and are 
abundantly found in the cytosol of liver, kidney and gut cells. Metallothionein synthesis 
is induced by thiol binding metals, zinc, copper, silver, cadmium and mercury, by the 
association of the cysteine -SH group with the metal ion (Halliwell and Gutteridge, 
1998). They control the homeostasis of intracellular zinc and copper, and are involved 
in cell detoxification through the sequestration of heavy metals by storing them in a 
non-toxic form. The ability to induce the synthesis of metallothioneins is related to the 
affinity (association constant) of the metal, such is the case of Cu(T) who forms a 
stronger bond with metallothionein than Cu(II). Furthermore reports suggest that 
metallothioneins constitute the primary protective mechanism against cadmium toxicity; 
in the presence of cadmium metallothioneins are readily synthesised in the kidney 
(Klaasen et a l, 1999). Additionally metallothioneins constitute the major binding and 
storing copper proteins in the liver, they bind copper ions in a non-toxic form regulating 
its intracellular distribution and possible toxicity (Cherian, 1995).
1.3.3 Distribution, metabolism and excretion o f anticancer metal-based compounds as 
toxicity determinants
The understanding of the clinical distribution, metabolism and excretion of anticancer 
agents provides information about the therapeutic response and the potential toxic 
effects they might exhibit (Egorin, 1998). Most anticancer agents are administered 
intravenously, therefore they are rapidly distributed from plasma into extracellular and 
intracellular compartments of the body increasing the susceptibility to toxic effects 
(Ratain, 1997). However the implementation of different administration routes, dose
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schedules and treatment duration in cancer therapy trials are currently under 
investigation to improve the bioavailability, pharmacokinetic distribution, therapeutic 
activity and reduce toxicity of newly developed anticancer agents. Such is the case of 
the oral formulation of dexniguldipine-HCl, a new dihydropyrine derivative with 
antineoplastic activity, which showed a low bioavailability in the body, therefore 
therapeutic levels to the tumour site are not achieved despite the positive anticancer 
effects obtained (Goedhals et a l, 1995). Moreover metal complexes are also usually 
administered intravenously therefore some toxicity is expected, however attempts to 
improve the distribution to the site of action (tumour), reduce toxicity and facilitate 
administration are also being performed. An example could be the platinum IV 
coordination compound JM216 (satraplatin); its oral presentation facilitates 
administration and has shown less toxicity. This compound is now in phase m  trials for 
prostate cancer treatment and has shown some activity against small cell lung cancer 
and relapse of ovarian cancer (Ferrante, et a l, 1999). However in some cases the 
selection of a different route of administration does not always prove to be successful. 
Despite the positive effects observed with intraperitoneal cisplatin treatment of ovarian 
cancer no dramatic therapeutic improvements were observed by Balthasar and Fung
(1996) in the pharmacokinetic and pharmacodynamic optimisation of intraperitoneal 
chemotherapy of peritoneal tumours.
The excretion of compounds from the body may determine their toxicity. Rapid 
elimination can reduce the exposure to damage as well as the toxic effects, provided it 
has achieved the desired therapeutic effect. The two major routes of excretion of 
chemotherapeutic compounds are through renal and/or through bile; for this reason the 
kidney and the liver could be more susceptible to toxic effects of chemotherapeutic 
compounds (Ratain, 1997). Such is the case of cisplatin, which is known to be highly 
nephrotoxic (as mentioned in Section 1.3.1). Metal toxicity inferred by metal 
complexes mainly affects those organs that are involved in metal transport, such as 
intestine, liver and kidney, as well as cells with high proliferative rates. Toxic effects 
associated with metal chemotherapy compounds other than cisplatin are shown in Table 
1.6 (Kopf-Maier, 1994).
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Table 1.6. Toxicities associated with some metal chemotherapeutic agents other than
cisplatin
Compound Toxic effects
Gallium (III) nitrate Nephrotoxicity, interstitial pneumonitis, liver injury, 
diarrhoea, vomiting and haematological effects
Spirogermanium Neurotoxicity
Titanocene dichloride Nephrotoxicity, mild hepatotoxicity, GI toxicity
Ruthenium complexes Mild toxicity in liver and kidneys, and some anaemia
Copper-bleomycin and Weakness, transient blindness and some accumulation
copper-thiosemicarbazone
complexes
of copper in the pancreas
Gold complexes Adverse effects in heart and lungs
1.4 Copper metabolism
The understanding of endogenous copper metabolism may provide useful information 
to be able to elucidate on the distribution, metabolism, excretion and side effects of 
casiopeina II -  the copper-based anticancer agent which is the main theme of this thesis.
1.4.1 Absorption, distribution, metabolism and excretion o f copper
Copper is an essential metalloelement that acts as a cofactor for a number of enzymes 
and is involved with electron transport proteins in the organism. These include 
ferroxidases, cytochrome c oxidase (a terminal respiration enzyme), SOD (defence 
against ROS), metallothionein (stores excess copper and has a superoxide scavenging 
capacity) and amine oxidases (Table 1.7) (Linder and Hazegh-Azam, 1996). 
Additionally copper plays an important role in infant growth, host defence mechanisms, 
bone strength, red and white blood cell maturation, iron transport, cholesterol and 
glucose metabolism, myocardial contractility and brain development (Ohvares and 
Uauy, 1996). Most of the copper in the organism is either active or in transit, normally 
only small amounts, if any, are stored and it is usually easily excreted via bile, 
maintaining homeostatic levels (Linder and Hazegh-Azam, 1996).
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Table 1.7. Copper related proteins and enzymes
Intracellular proteins Extracellular proteins
Cytochrome c oxidase Caeruloplasmin
Superoxide Dismutase (SOD) Lysyl oxidase
Metallothionein Albumin
Dopamine-p-monooxygenase Transcuprein
Tyrosinase (catechol oxidase) Amine oxidase
a-Amidating enzyme Extracellular superoxide dismutase
Phenylalanine hydroxylase Extracellular metallothionein
Diamine oxidase Blood clotting factors V and VIII
Cartilage matrix glycoprotein Ferroxidase II
The vast majority of copper found in biological systems tends to be present in a cupric 
state (Cu(II)), however it may also be present in a cuprous state (Cu(I)). The relatively 
easy release and capture of one electron is a chemical characteristic of copper, which 
makes it useful in oxidation-reduction reactions and in free radical scavenging (as 
described in Section 1.3.2) (Linder and Hazegh-Azam, 1996).
Copper normally enters the mammalian body only via the alimentary tract. The daily 
dietary intake of copper has been estimated to be about 0.6 to 1.6 mg/day in the human 
adult. Meat, visceral organs, fish, oysters, chocolate, green vegetables and seeds are 
known to be dietary sources with high levels of copper content (Aaseth and Norseth, 
1986; Olivares and Uauy, 1996). In addition drinking water is also an important source 
of copper intake (Lonnerdal, 1996).
In mammals the major site of copper absorption (30-40% is absorbed from the diet) is 
the duodenum and some is absorbed by the stomach and the distal part of the small 
intestine (where it can be reabsorbed into the enterohepatic circulation) (Sidhu, et a l,
1995). The acid pH of the stomach enhances copper solubility contributing to the 
release of copper from diet ingredients and the further pH increase in the duodenum 
promotes copper absorption (pH 5.8) (Wapnir, 1996). Duodenum uptake of copper is 
via the brush border membranes into the intestinal mucosa where it is transferred across
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the basolateral membrane into the interstitial fluid and blood (Linder and Hazegh- 
Azam, 1996).
Once in blood copper seems to be distributed within the organism in two phases. 
During phase I copper is rapidly distributed to liver and kidney, mediated by albumin 
and transcuprein and amino acids, and in phase II copper re-emerges in plasma firmly 
bound to caeruloplasmin and is distributed into other tissues and organs (Linder et a l, 
1998). About 90% of circulating copper in plasma is firmly bound to caeruloplasmin, 
the remaining 10% is exchangeable and most of it is bound to albumin and transcuprein; 
the rest to amino acids such as histidine, threonine, or cysteine; or small peptides 
(Vargas et a l, 1994; DiDonato and Sarkar, 1997). After absorption copper bound to 
albumin and transcuprein in blood plasma is transported to the liver by portal circulation 
(Gordon et a l, 1987). Copper present in a ternary histidine-Cu(II)-albumin complex 
constitutes a readily accessible physiological pool for most tissues (Ballatori, 1991). In 
addition Lau and Sarkar, together with other groups, demonstrated that human albumin 
has a specific copper binding site, which involves histidine at its NH2-terminus (Vargas 
et a l, 1994). However it seems that the presence of albumin is not crucial for normal 
copper metabolism; studies with analbuminaemic rats showed that despite the absence 
of albumin copper levels in tissues were normal and no disturbance in copper transport 
was observed (Yu et a l, 1995). Moreover copper-binding to albumin may vary 
between different species; studies with Cu-PTSM complexes used for positron emission 
tomography revealed that Cu-67 complexes interact more strongly with human albumin 
rather than with dog albumin (Lim et a l, 1997).
Copper is transported by portal circulation into the liver where it is released from 
albumin, transcuprein or amino acids for hepatocyte uptake. Hepatic copper uptake is 
facilitated by amino acids which compete for binding sites making copper more 
available for transport, however they do not enter the hepatocyte suggesting that the 
metal crosses the basolateral plasma membrane as a free ion (Ballatori, 1991). It has 
been established that the mechanism of copper uptake by the liver involves the 
interaction of cell surface receptors, Cu(II) is reduced to Cu(I) by a membrane reductase 
and a passive transporter facilitates hepatocyte absorption, in addition sulphydryl groups 
on the membrane may facilitate the process (Simkiss and Taylor, 1995). Once 
intracellular copper is distributed into Cu-ZnSOD in cytosol and possibly
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peroxisomes, cytochrome c oxidase in mitochondria and metallothioneins in cytosol, 
nucleus and lysosomes (DiDonato and Sarkar, 1997). SOD is an intracellular 
copper/zinc enzyme that can scavenge superoxide radicals produced in oxidation 
reactions. It is present in almost all tissues in mammals (Casanova et a l, 1995). 
Metallothioneins regulate intracellular copper metabolism by the binding of sulphydryl 
groups (-SH) and cysteine to the metal, serving as storing sites in a non-toxic form 
(Halliwell and Gutteridge, 1998). Levels of SOD activity and metallothionein presence 
are known to fluctuate accordingly to the copper status in the organism (Olivares and 
Uauy, 1996; Wapnir, 1998). Intracellular copper may behave differently between cell 
types. In hepatocytes most of the distributed copper is contained in the cytosol and 
bound to macromolecules such as metallothioneins. Studies with K562 cells (an in vitro 
cell culture model) showed that two thirds of the copper content remained in organelles, 
suggesting that non-hepatic cells may have different copper sources (Linder and 
Hazegh-Azam, 1996).
Additionally an amount of the intracellular contained copper is incorporated into 
caeruloplasmin during its synthesis in the liver (Balliatori, 1991). Caeruloplasmin is the 
major non-exchangeable copper-containing protein in blood plasma and it is the source 
of most of the copper delivered into tissues in the form of Cu(I). Caeruloplasmin is 
released into plasma and through general circulation it delivers copper to other tissues, 
such as brain, bone, heart and muscle, membrane cell receptors facilitate copper release 
from caeruloplasmin into tissues by passive transport (DiDonato and Sarkar, 1997). 
Although most tissues obtain copper from a caeruloplasmin source, in some cases they 
may absorb copper from non-caeruloplasmin sources in plasma, this uptake varies 
according to the specific tissue. Low caeruloplasmin activity and the high copper 
accumulation in the liver contribute to fulminant or chronic hepatitis in Long- Evans 
Cinnamon (LEG) rats (Mori et a l, 1994). Abnormal copper accumulation in the liver of 
LEG rats has been related to an impaired copper membrane transport, although 
intracellular copper levels may not necessarily determine caeruloplasmin production in 
the liver (Nakamura et a l, 1995).
In addition to copper distribution and protein binding any copper that has not been used 
in the liver is secreted into bile for excretion (Linder et a l, 1998). Copper is mainly 
excreted via bile bound to amino acids, glutathione or non-specifically to high
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molecular-weight molecules. Intracellular GSH, has the ability of reducing Cu(II) to 
Cu(I) (Corazza et a l, 1996). The efflux of copper from the hepatocyte to the bile 
involves a glutathione-copper complex in the form of Cu(I)-GSH. In addition recent 
studies suggest that copper efflux to bile may be through lysosomal exocytosis or by the 
action of copper-transporting P-type Cu-ATPases (DiDonato and Sarkar, 1997). 
Therefore it seems that the excretion of copper is in the form of Cu(I), in contrast with 
Bingham et al. (1996) who reported that P-type Cu-ATPases-dependent transport 
system transports copper in the form of Cu(II) rather than Cu(I). Furthermore copper in 
a protein-bound form may be deposited in the bile as a result of protein catabolism and 
pinocytosis by hepatic lysosomes (Sugawara et a l, 1995; DiDonato and Sarkar, 1997). 
Bile is the body fluid with the highest concentration of copper, from which a large 
proportion is reabsorbed into the gastrointestinal tract and later distributed into the 
tissues, and the rest is excreted via faeces. A minimal amount of copper is lost via urine 
in low molecular weight forms, which is consistent with the absence or low levels of 
free copper in plasma (Linder and Hazegh-Azam, 1996). Measurements of serum or 
plasma copper, ceruloplasmin levels and erythrocyte SOD are commonly used methods 
to measure copper levels in the body, however they are not very accurate for estimating 
marginal copper (Lonnerdal, 1996; Olivares and Uauy, 1996). In addition changes in 
copper levels in the organism are usually attributed to a decrease in biliary excretion 
(Wapnir, 1998). Reports on copper levels estimate approximately I x l f  ^  mol/L in 
human blood plasma (Linder and Hazegh-Azam, 1996).
To sum up copper metabolism and transport can be described as follows. Copper 
absorbed by the GI tract binds mainly to albumin and transcuprein and it is transported 
into the liver, after hepatocyte uptake a portion of copper is incorporated into copper- 
zinc SOD, metallothionein, amino acids and cytochrome oxidase and another portion to 
caeruloplasmin in order to be distributed into tissues. A third portion is goes into bile 
circulation to be excreted via faeces. Any excess or not used copper is reabsorbed by 
the liver and excreted via faeces through bile (Figure 1.4).
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Figure 1.4. Copper absorption, transport, distribution and excretion. Values indicate 
the percentage of copper absorbed or the percentage accounted for specific tissues 
(Modified from Linder and Hazegh-Azam, 1996).
1.4.2 Defective copper metabolism related diseases - Menkes and Wilson's disease 
Menkes Disease
Menkes disease is a genetic disorder (X-linked recessive gene) of the absorption and 
transport of copper, which resembles a copper deficiency condition. It is characterised 
by a reduced activity of copper-containing proteins primarily in phase I of copper 
transport, causing an abnormal distribution of copper in tissues and cells (Schmidt et a l, 
1984; Leone et a l, 1985; Tümer and Horn, 1996). The clinical manifestations of 
Menkes disease appear before the third month of age in humans. These include growth 
retardation, hypothermia, skin and hair depigmentation, lax skin and articulations, 
tortuosity and dilatation of major arteries, varicosities of veins, osteoporosis, bone 
fractures and major alterations in mental development which lead to an early death 
(Olivares and Uauy, 1996). This condition is due to a failure of copper ion release from
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mucosal secretory cells, a process mediated by Cu-ATPases in membrane surface, and 
thus there is no available copper for tissue distribution. The gene identified for Menkes 
disease appears to encode a copper transporter of the cation transporting P-type Cu- 
ATPase subfamily (Vulpe et al, 1993). The expression of the ATP7A protein has been 
associated with Menkes disease and has shown to have some similarities with heavy 
metal binding bacterial proteins. This protein is strongly expressed in muscle, kidney, 
lung and brain; the expression in placenta and pancreas was weaker and liver showed 
only traces (Harris et a l, 1998). A variant condition of Menkes disease, known as 
occipital horn syndrome, has been attributed to a variant splice-site mutation of the 
Menkes disease gene and it is characterised by occipital exostoses (bone spurs) 
influencing intelligence and autonomic nerve fiinctions (Linder and Hazegh-Azam, 
1996; DiDonato and Sarkar, 1997). The most effective treatment for Menkes disease is 
the parenteral administration of copper-histidine (Tümer and Horn, 1996).
A homologous murine gene of Menkes disease has been identified in the mottled mutant 
mouse. A mottled pigmented coat is observed in females, whereas neurological and 
connective tissue abnormalities are manifested in affected males. A protein product of 
P-type ATPase with an 89% similarity to the ATP7A was identified in the mottled 
mutant mouse, for this reason this mouse strain can be used as a model to study Menkes 
disease and therapy (Tümer and Horn, 1996). Studies of acute copper administration to 
mottled mutant mice indicate a high sensitivity to the acute toxic or hepatotoxic effects 
of copper suggesting the implementation of alternative therapy (Shiraishi, et a l, 1991).
Wilson’s Disease
Wilson’s disease is a condition caused by a genetic malfunction of endogenous copper 
metabolism, resulting in a copper overload and poisoning. Three stages have been 
attributed to the progression of Wilson’s disease, in the first stage there is an 
accumulation of copper in hepatocyte cytosol, in the second stage cytosolic copper is 
accumulated into lysosomes bound to MT. Additionally high copper levels cause 
necrosis and the release of non-caeruloplasmic copper into circulating blood, causing 
damage to erythrocyte membrane and haemolytic anaemia. Finally in the third stage
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excess copper is distributed and accumulates in extra hepatic tissue, such as the brain, 
kidneys and cornea (DiDonato and Sarkar, 1997). Caeruloplasmin levels are not always 
affected in this condition and copper incorporation into caeruloplasmin can be normal in 
Wilson’s disease patients, although it is often characterised by low concentrations of 
caeruloplasmin in the blood. Studies on copper metabolism in Wilson’s disease suggest 
that the defective transport of copper is caused by an impaired biliary excretion from the 
liver, accounting as the main source of copper accumulation. This defective transport of 
copper into bile is due to a dysfunctional Cu-ATPase, which prevents the transport of 
copper across the canalicular membrane (Chowrimootoo et a l, 1996; Davis et a l,
1996). The genetic defect is believed to be either a mutation or a deletion of the gene 
for a P-type Cu-ATPase copper transporter of the membrane surface (Chelly and 
Monaco, 1993).
Wilson’s disease is characterised by an excessive accumulation of copper in the liver 
(and in some cases in the brain), impaired transport of copper-caeruloplasmin, and most 
important a defective biliary copper excretion (Chelly and Monaco, 1993). Clinical 
symptoms of liver dysfunction are characteristic of Wilson’s disease, these include 
jaundice, asymptomatic cirrhosis, chronic aggressive hepatitis and subacute hepatitis 
(non-A or B type). In addition to the hepatic symptoms patients in a late stage of the 
disease develop neurological symptoms such as deteriorating coordination, tremors, 
dementia, drooling, personality changes, behavioural problems and rigidity (DiDonato 
and Sarkar, 1997).
The clinical diagnosis of Wilson’s disease can be made from the measurements of urine 
copper levels (increased levels in symptomatic cases), serum alanine aminotransferase 
(elevated levels are typical in liver damage), blood caeruloplasmin (low or absent), 
appearance of Kayser-Fleischer rings in the cornea and the determination of liver 
copper concentrations (Brewer, 1995). A common therapy for Wilson’s disease is the 
use of copper-chelating agents. These include penicillamine or trientine, which are 
specific copper chelators that enhance the urinary excretion of ‘excess’ copper in blood 
plasma. However manifestation of secondary effects in blood due to the use of trientine 
or penicillamine have been reported, acquired sideroblastic anaemia was observed in 
Wilson’s disease patients treated with trientine (Perry et a l, 1996). Another potential 
treatment is tetrathiomolybdate which forms a complex with copper and a protein,
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blocking gastrointestinal absorption, and inactivating copper in a non-toxic form 
(Brewer, 1995). In addition the most recently recommended therapy is the use of zinc 
acetate for maintenance therapy in Wilson’s disease, zinc blocks the intestinal 
absorption of copper and enhances the production of hepatic metallothionein to 
sequester excess copper (Bremner and Beattie, 1995; Anderson et a l, 1998).
An animal model to study Wilson’s disease is the inbred Long-Evans Cinnamon (LEG) 
rat, a strain with a genetic impaired copper metabolism. LEG rats present increased 
liver copper accumulation, about a 40% die from fulminant hepatitis and the remaining 
60% that survive can develop chronic hepatitis and subsequently hepatic carcinoma. 
For this reason they serve as a model for studying liver damage and chronic hepatitis 
from copper accumulation and impaired biliary excretion (Mori et a l, 1994; Suzuki et 
a l, 1995). Damage to DNA by oxygen radicals generated by copper-catalysed Fenton- 
type reactions are believed to be involved in liver carcinogenesis in LEG rats (Nair et 
a l, 1996). Sugawara and collaborators (1995) report that the defective biliary copper 
excretion may be due to an impaired lysosomal exocytosis, rather than a canalicular 
membrane failure. These findings are supported by those of Nakamura and 
collaborators (1995), who report that intracellular copper did not regulate the synthesis 
and processing of caeruloplasmin in cultured LEG rat hepatocytes. In addition low 
caeruloplasmin levels are observed in most, but not all, Wilson disease patients as well 
as in LEG rats, suggesting that copper transporting ATPase encoded in the Wilson’s 
disease gene is not a crucial component of copper incorporation into the apoprotein of 
caeruloplasmin.
Glinical signs of hepatic dysfunction and progressive liver failure by copper toxicity 
have also been reported in dogs, especially in Bedlington Terriers which suffer an 
impaired copper metabolism due to an autosomal recessive defect, leading to an 
increased copper accumulation in the liver. They have also been used as a model for the 
understanding of defective copper transport and Wilson’s disease (Rolfe and Twedt, 
1995; Haywood et a l, 1996).
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1.5 Copper toxicity
1.5.1 Toxic effects o f  copper
In general the body deals with excess intake of copper by decreasing absorption and 
enhancing excretion, however copper toxicosis may occur. Different factors influence 
the susceptibility to copper toxicity, these include differences in species, age, genetics 
and the diet (Bremner, 1998). Copper toxicosis has been reported from oral ingestion of 
copper or copper salts (copper sulphate) and the use of copper containing di alysis 
equipment (Goyer, 1996). Acute cases of copper toxicity are manifested by nausea, 
vomiting, haemolysis, jaundice, haemolytic anaemia, haemoglobinuria, haematuria, and 
oliguria (Sidhu et a l, 1995). During chronic exposure there is a gradual hepatic 
accumulation of copper leading to liver damage, cirrhosis, cancer and even death (Mori 
et a l, 1994; Nair et a l, 1996; Bremner 1998), moreover reports indicate that the kidney 
is also affected by copper excess (Haywood, 1985; Giuliodori et a l, 1997).
The haemolytic toxic damage due to copper has been reported in vitro and in vivo. 
Copper sulphate salts induce erythrocyte membrane damage by the generation of 
superoxide radicals from the reduction of copper to the cuprous form by thiol membrane 
groups (Sree Kumar et a l, 1978). Sheep and dogs, particularly Bedlington Terriers, are 
highly susceptible to copper toxicity manifested by a haemolytic crisis and liver and 
kidney damage due to the copper accumulation (Gooneratne et a l, 1980; Rolfe and 
Twedt, 1995; Haywood et a l, 1996). In addition acute intravascular haemolysis 
manifested by erythrocyte damage, anisocytosis and crenation, were observed in rabbits 
after oral chronic exposure to copper sulphate-medicated food, additionally stress 
factors such as lactation, pregnancy or parturition are believed to have promoted copper 
susceptibility in this case (Cooper et a l, 1996). Studies of acute copper intoxication in 
rats administered toxic amounts of Cu-Ca EDTA intraperitoneally indicated that the rate 
of copper transfer to liver and kidney caused tissue injury rather than the high amount of 
copper, similar to a chronic copper toxicosis condition. In the same study the major 
microscopical findings in the liver were centiilobular necrosis, haemorrhages and 
degeneration, as well as haemorrhages, proximal tubules degeneration and necrosis in 
the kidney (Giuliodori et a l, 1997). Moreover chronically poisoned sheep showed
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ultrastructural liver changes, such as proliferation of hepatic lysosomes, liver necrosis, 
larger and swollen mitochondria (Gooneratne et a l, 1980).
However reports suggest that tolerance to copper overload may be developed by a rapid 
ability to mobilize and excrete copper inducing alternative defence mechanisms to 
ameliorate high levels of copper in the liver. Even though an increase in 
metallothionein synthesis and accumulation occurs as an initial response to copper 
overload when developing tolerance in the rat, apparently its reinduction is not needed 
to prevent hepatic copper toxicity during re-exposure to copper. Tolerance can be 
attributed to a rapid ability to mobilise and excrete copper and to the induction of 
alternative defence mechanisms to mitigate increased levels of copper in the liver 
(Fuentealba et a l, 1993), although increased formation of metallothionein in liver and 
kidney can also occur early in acute copper poisoning (Barceloux, 1999). Copper 
accumulation can cause the saturation of storing sites causing excess copper to be 
diffused and more likely reduced, increasing its potential of cell injury as indicated by 
studies on LEG rats where the development of chronic hepatitis or even cancer has been 
reported from a copper overload (Mori et a l, 1994; Suzuki et a l, 1995).
Transition metals have also been reported to promote the oxidation of low density 
lipoproteins (LDL). It appears that LDL can mediate oxidative damage by direct 
reduction of copper from the cupric to the cuprous form (Lynch and Frei, 1996). 
Although the mechanism by which oxidised-LDL increase the expression of adhesion 
molecules is not yet fully understood, the intracellular generation of ROS are known to 
play a major role in this process (Schreck et al, 1991). Low-density-lipoproteins 
contain small quantities of endogenous lipid peroxides, which in the presence of trace 
elements, can catalyse formation of alkoxy (RO) and peroxy (ROD) free radicals 
inducing LDL peroxidation. However the source of physiologically occurring free 
radicals is limited therefore this event may not take place in vivo, although in vitro 
studies indicate that free radical may infer cytotoxicity to cells by LDL oxidation 
(Hessler et a l, 1983; Hardwick et a l, 1996). Low density lipoprotein oxidation has 
been reported in different in vitro studies involving several endothelial, macrophages, 
lymphocytes and smooth muscle cell lines with the interaction of transition metals, such 
as iron and copper and metal-containing proteins (caeruloplasmin and transferrin) 
(Lamb and Leake, 1994; Aviram and Fuhrman, 1998). The oxidation of LDL is
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believed to play an important early step in atherogenesis, which on a long term may 
lead to atherosclerosis (Cominacini et al, 1998).
1.5.2 Prooxidant activity o f copper
Under normal conditions copper is firmly bound to protein ligands, therefore free 
copper ions and oxygen radicals are not normally present. In the cases of released free 
copper or exogenous copper this is readily bound by a variety of different ligands and 
proteins such as albumin, low molecular weight and macromolecular ligands. However, 
in some cases copper may damage cells by an enhanced production of toxic intra and 
extracellular free radicals and ROS (Vulpe et a l, 1993; Koropatnick and Leibbrandt,
1995). The toxicity of copper and copper complexes has been attributed to their ability 
to mediate OH’ and O2’ production by Fenton and Haber-Weiss mechanisms, in which 
hydrogen peroxide and thiols are required (as described in Section 1.3.2) (Bremner, 
1998).
Free radicals may be produced during intermediate steps triggered by other agents or 
directly as a result of oxidative stress. Reports suggest that lipid peroxidation may not 
be the main cause of cell injury by copper ions in isolated rat hepatocytes (Stacey and 
Klaassen, 1981). The primary targets for free cupric ions in the membranes are thiol 
groups, which are capable of reducing Cu(II) to Cu(I), upon concomitant oxidation to 
disulphides in the membrane. Copper(I) reacts with H2O2 producing hydroxyl that 
cause cell damage through mechanism of lipid peroxidation, changes in membrane 
permeability, enzyme inhibition and mitochondrial damage (Halliwell and Gutteridge, 
1998^
Evidence of the cytotoxic effects of copper particularly to erythrocytes, has been 
reported by various groups. Acute cytotoxicity caused by the induction of lipid 
peroxidation by copper(II) to immature rat blood cells and macrophages was reported 
by Chukhlovin et al. (1996). In vitro studies on red blood cells indicate that excess 
unbound copper in circulating blood enters the erythrocyte membrane and generates 
oxygen-derived free radicals and lipid peroxidation, which lead to haemolytic damage 
(Sree Kumar et a l, 1978; Rolfe and Twedt, 1995). Moreover after chronic oral dosing 
sheep with copper sulphate, a significant reduction of glucose-6-phosphate
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dehydrogenase and GSH in erythrocytes was observed, suggesting that the erythrocyte 
damage can be inferred by copper overload as well as decreased capacity of intracellular 
reducing agents (Sansinanea et a l, 1996). Thus the inhibition of glucose-6-phosphate 
dehydrogenase and GSH also contribute to haemolytic toxic damage induced by copper 
‘excess’ (Barceloux, 1999). As mentioned before GSH plays an important role in the 
prevention of cell injury by copper ions. Glutathione stabilises copper in the Cu(I) 
form, preventing a redox reaction and consequently the generation of free radicals. 
Glutathione may inhibit FR formation by copper ions in the presence of hydrogen 
peroxide, ascorbate and DNA (as described in Section 1.4.1). Common therapies to 
prevent copper accumulation and toxicity due to impaired copper metabolism are the 
use of copper chelators, penicillamine or trientine, and zinc (as mentioned in Section 
1.4.2). However in order to avoid the damaging effects of copper-induced toxicity the 
enhancement of cell detoxification mechanisms, metal exportation, inhibition and 
sequestration, can be a usefiil alternative (Dameron and Harrison, 1998).
1.6 Copper complexes
1.6.1 Biological activity o f  copper complexes
The reactivity of copper in biological systems is primarily due to its reduction and 
production of free radicals. Direct damage to DNA by copper ions has been observed in 
the presence of hydrogen peroxide due to the production of hydroxyl radicals that attack 
DNA bases in a site-specific manner (Aruoma et a l, 1991). In addition, DNA damage 
can also be caused by the catalytic reaction of NADH autoxidation to NAD*. This is 
further oxidised to NAD^ generating superoxide radicals which then produce H2O2 
reducing Cu(II) to Cu(I) (Oikawa and Kawanishi, 1996). Some copper-phenanthroline 
complexes exhibit cytotoxicity, apparently as a result of DNA-cleavage by activated 
oxygen free radicals. Cell cultures treated with phenanthroline and copper showed the 
formation of an in situ complex that binds to the DNA-strand, it is activated by reducing 
agents such as ascorbic acid or thiol in the presence of molecular oxygen or H2O2 
(Papavassiliou, 1995). In addition redox activity of copper ions promotes 1,10- 
phenanthroline intemucleosomal DNA fragmentation by hydroxyl-radical production in
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isolated rat-liver nuclei (Burkitt et a l, 1996). Other studies have proved that copper can 
accelerate DNA damage in the presence of phenylhydroquinone in calf thymus (Nagai 
et a l, 1995). Furthermore the Cu(II) ethylene diamine complex was observed to cause 
DNA damage in the presence of hydrogen peroxide probably due to the increased 
production of hydroxyl radicals (Stohs and Bagchi, 1995).
The potential of some Cu(II) complexes for SOD-like activity has been assessed in 
relation with the activity of these complexes towards O2’ radicals, in order to evaluate if 
copper complexes can mimic SOD activity and be used as cytotoxicity regulators 
(Costanzo et a l, 1993). Studies of Cu(II) complexes with macrocyclic structure ligands 
showed intraerythrocytic scavenging of oxygen free radicals, despite a limited SOD-like 
activity, promoting antioxidant activity (Bonomo et a l, 1995). In vivo studies with 
intravenously administered CuZnSOD conjugates, such as polyethylene glycol (PEG)- 
SOD, have shown to decrease ischaemia-reperfiision damage in brain or spinal cord 
injury mimicking SOD-like activity (Halliwell and Gutteridge, 1998). Other reports 
indicate that tryptophan metabolites produce H2O2 in the presence of Cu(II) causing 
DNA damage in cell cultures as well as isolated DNA (Hiraku et a/., 1995). The redox 
activity of copper can contribute to LDL damage to vascular endothelium and 
haemolytic injury from ROS generation (Halliwell and Gutteridge, 1998; Yla-Herttuala, 
1998). Copper can catalyse the production of oxygen radicals when bound to chelating 
agents, e.g. ascorbate can reduce Cu(II) to Cu(I). In addition copper (and iron) 
complexes e.g. bleomycin, adriamycin, thiosemicarbazone may exhibit redox 
properties, they may be readily reduced by thiol compounds and oxidised by iron or 
reduced iron species and produce free radicals. As a cofactor for enzymes such as 
oxidases and oxygenases, copper may catalyse the generation of ROS and lipid 
peroxidation. In addition copper has also been reported to enhance DNA strand breaks 
in the presence of hydroquinone (Stohs and Bagchi, 1995).
1.6.2 Copper complexes in medicine
Copper and its complexes have been studied for many therapeutic purposes. Nowadays 
some are used in medicine for the treatment of inflammatory disorders (Lewis, 1984), as 
a growth stimulator in farm animals (Zhou et a l, 1994), as immunomodulators in 
hypersensitivity (Kovachev et a l, 1994), contraception and arthritis (Sigman and
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Kuwabara, 1987). Sorenson (1989) reports the use of copper complexes for the 
treatment of gastrointestinal ulcers, as anticonvulsants in epileptic disease, in the 
treatment of diabetes and against bacterial infection. Radioactive copper complexes 
have been used as radiotracer models in the study of blood distribution (Mathias et ah, 
1993; Young et a l, 1994) as well as in the biodistribution of antibody fragments for 
immunotherapy of colorectal carcinoma (Anderson et a l, 1995). A number of copper 
complexes have been reported to have SOD-like activity in vitro (Costanzo et a l, 1993; 
Casanova et a l, 1995) whereas others can be used to promote SOD activity (Klotz et 
al, 1996). Copper complexes have also shown promising activity in research and 
experimentation in the cure of AIDS and mycoplasmosis (Zwart et a l, 1991; Mazumder 
et a l, 1995).
1.6.3 Copper complexes as anticancer drugs
Inspired by the potent activity of platinum as a chemotherapeutic agent numerous 
research groups have studied the antitumoural activity of other metal complexes, such is 
the case for copper and copper complexes. Copper-bipyridyl complexes and copper- 
phenanthroline complexes have been reported to be potential antitumoural agents 
(Nocentini and Berzi, 1996), the latter ones have exhibited nuclease, DNA cross- 
linking, antibacterial, antimycoplasmal, antifungal and antiviral activity (Sigman and 
Kuwabara 1987; Mazumder et al. 1995). Quinacrine, a common drug used for malaria, 
was reported to exhibit synergistic antineoplastic activity when used with copper against 
tumours in vivo (Dabancens et a l, 1994). A series of Cu(II) complexes showed 
significant cytotoxic and cytostatic activity against tumour cells in vitro, these include 
the B16 and L929 murine cells, human KB cells and non cancer human fibroblasts 
(Arena et a l, 1993). Copper(II) complexes have also been reported to increase 
radiosensitization after irradiation of cancer cells with Co^° y-rays and the formation of 
thymine-OH radical adducts (Basu Roy et a l, 1996). Non-random double strand 
cleavage of DNA by a Cu(II) complex has been reported by Detmer et a l (1996), with 
reduction of Cu(II) to Cu(I) being proposed as the mechanism of action where the 
release of O2*' generates the production of hydroxyl radicals through the Haber-Weiss 
reaction leading to the removal of hydrogen from deoxyribose and subsequently strand 
scissions occurs. Neucoprein and its copper complex facilitated the uptake of copper 
into cells; once internalised copper was reduced to Cu(I) and a subsequent generation of
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hydroxyl radicals from H2O2 was observed probably due to the formation of a redox- 
active form leading to a growth inhibition in Ehrlich tumour cells (Byrnes et a l, 1992). 
Likewise the casiopeinas series have shown promising antibacterial, cytostatic and anti­
cancer properties in vitro and in vivo (Mendoza-Diaz et a l, 1991; Ruiz-Ramirez et al, 
1991; Ruiz-Ramirez et a l, 1995).
1.7 Evaluation of the apoptotic mode of cell death induced by anticancer 
compounds
Apoptosis is a genetically mediated mechanism of cell death that can be triggered by 
several intra and extracellular factors (Kamesaki, 1998). Misregulation of apoptosis has 
been associated in degenerative conditions, such as vascular disease, AIDS and cancer 
development (Thompson et a l, 1992; Allen et a l, 1998). A number of oncogenes and 
tumour supressor genes, c-myc, p53, Bax, Bcl-2, are known to be involved in this cell 
death process. Chemical agents, radiation or changes in cell environment are 
extracellular factors that can also trigger apoptotic cell death. In addition to interfering 
with the cell cycle of proliferating cells chemotherapeutic agents may trigger apoptosis 
and inhibit cancer development (Hannun, 1997). In cancer apoptosis is a negative 
growth-regulating process that can vary with tumour type and can be used as a predictor 
of radiosensitivity or clinical response to chemotherapy (Staunton and Gaffriey, 1998). 
Thus the regulating of this process by chemotherapeutic agents provides a powerful tool 
against cancer (Lyons and Clarke, 1997).
1.7.1 Apoptosis as a mechanism o f cell death
It is well known that the mechanism of cell death involves either apoptosis or necrosis. 
Apoptosis differs from necrosis (degenerative cell death) by its morphology, 
biochemistry and incidence. The apoptotic process or programmed cell death can be 
described as a dismantling of the cell into its various components in an orderly sequence 
of events which leads to the cell being ‘removed’ by phagocytosis by neighbouring cells 
(Staunton and Gaffriey, 1998). Necrosis is characterised by the loss of osmotic 
regulation and organelle swelling leading to cell lysis. The involvement of
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neighbouring cells and an inflammatory process usually accompany necrosis 
(Kamesaki, 1998). Some of the key morphological and biochemical changes that 
differentiate apoptosis from necrosis are shown in Table 1.8. In the apoptotic process a 
number of initiators and promoters are involved, and their effects on cells are frequently 
cell-type dependent. Additionally cell type differences in the proteases involved in 
apoptotic cell death by antitumour agents have also been observed, providing a 
possibility for the use of chemotherapeutic agents to selectively induce and suppress 
apoptotic cell death (Lotem and Sachs, 1996). Morphologically the process of 
apoptosis is characterised by nuclear condensation, nuclear fragmentation, and finally 
phagocytosis by neighbouring cells. Subsequently avoiding cell content release into the 
extracellular space and thus preventing an inflammatory response and lysis by 
neighbouring cells (Martin, 1997; Green and Reed, 1998).
All cells (normal or cancerous) are equipped to die by apoptosis, however the cell- 
specific differences in susceptibility and different routes determine the end process 
(Toft and Arends, 1997). The apoptotic process can be triggered by intrinsic, calcium 
deregulation signalling or ceramide mediation, and extrinsic cellular factors, cell surface 
death receptors or growth factor removal (Trump and Berezesky, 1996; Kamesaki, 
1998).
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Table 1.8, Differential characteristics between apoptosis and necrosis (Adapted from
Toft and Arends, 1997).
APOPTOSIS NECROSIS
Key moroholoffical changes
Affects single cells Affects groups of cells
Membrane surface blebbing without Damaged membrane and loss of integrity
integrity loss allowing uncontrolled fluid and ionic
fluxes
Cells shrinkage and detachment Cell swelling
Formation of apoptotic bodies Cell lysis
Phagocytosis by adjacent normal cells Phagocytosis by macrophages
and macrophages
Reduction of nuclear size with Aggregation of nuclear chromatin and
chromatin condensation and disintegration
nucleolus disintegration
No inflammatory response Acute inflammatory reaction
Biochemical alterations
Induced by physiological stimuli and As a result of cell injury, non-
genetically regulated by oncogenes physiological perturbation of the cellular
and oncosuppressor genes environment
Regulated process involving No evidence of a signalling pathway
signalling pathways involved
Calcium signalling stimuli and Uncontrolled calcium influx with
activation of caspases activation of proteases, nucleases and
phospholipases
Characteristic DNA Random DNA disintegration and
oligonucleosomal fragmentation digestion
Requires energy production from the No energy requirement, failure of ATP
cell production and generation of ROS
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Direct signalling of cell surface death receptors, the two best characterised are 
CD95/Fas/Apol and TNF-Rl, can initiate apoptotic cell death (Schmitt et a l, 1999). 
CD95 is activated by a ligand from the TNF gene superfamily, CD95ligand (CD95L). 
CD95L once bound to CD95 clusters a receptor cell death domain which binds to the 
Fas-associated death domain (FADD) that binds to an analogous domain of caspase -8  
and -10 (Ashkenazi and Dixit, 1998). These caspases activate the “executioner 
caspases” -3, -6  and -7  downstream the caspase cascade (Allen et a l, 1998).
Alternatively to the death receptor apoptotic trigger, irreparable damage to DNA by 
cytotoxic agents, ionizing radiation, growth factor withdrawal or oxidants may also 
trigger the activation of the same “executioner caspases” through mitochondria 
regulation. These post-mitochondrial events are regulated by members of the Bcl-2 
protein family and result in the release of cytochrome c, which induces ATP or ATP- 
dependent formation of caspase -9  and Apaf-1 (Allen et a l, 1998; Green and Kroemer, 
1998; Salvesen, 1999).
The “executioner caspases” -3, -6  and -7  cleave and inactivate proteins that are 
required in the maintenance of cell homeostasis as well as activate endonucleases that 
promote a nuclear disassembly of chromatin, and finalise in DNA chromosomal 
fragmentation (Sakahira et a l, 1998). However apoptotic cell death does not always 
involve the activation of caspases, although they are fundamental factors of an effective 
apoptotic cell removal. Cell shrinkage and membrane blebbing together with the 
progress of apoptotic cell death in the presence of Z-VAD-FMK (a caspase inhibitor) 
account for an independent-caspase apoptotic cell death (Borner and Monney, 1999).
Furthermore proto-oncogenes such as c-Myc and the p53 tumour supressor gene, have 
been shown to be involved in apoptotic regulation (Hale et a l, 1996; Staunton and 
Gaffriey, 1998; Weller, 1998). Following chemotherapy treatment (cisplatin and 
etoposide) wild-type p53 has been observed to increase, resulting in G1 arrest and 
apoptosis induction. Additionally other intracellular factors contribute in apoptotic 
mediation in soriie cells, such is the. case of sphingomyelin/ ceramide, which increases 
during apoptosis by chemotherapeutic agents (Kamesaki, 1998).
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1.7.2 Apoptosis in cancer therapy
Chemotherapy-induced apoptosis involves several mechanisms. It is a negatively 
growth-regulated process where the type of cancer cells treated and the compounds used 
may influence the process. However the involvement of the CD95L system (Hueber, et 
a l, 1998), p53-signalling and gene induction pathways (Burger et a l, 1998), Bcl-2- 
family proteins participation (Luo et a l, 1999) and the sphingomyelin/ceramide 
pathway (Kamesaki, 1998) using several chemotherapeutic agents to induce apoptosis 
have been observed. In addition cytochrome c release by mitochondria (Zhuang and 
Cohen, 1998) and caspases cascade involvement (Barge et a l, 1997; Kayeka et a l, 
1998) in the apoptotic process have also been identified independently of the 
chemotherapeutic agent used. Other aspects of whether apoptosis influences tumour 
resistance to chemotherapy or the possibility of selectively inducing apoptosis in tumour 
cells is still under investigation (Martin, 1997; Luo e/ a l, 1999). The exposure of cells 
to chemotherapeutic agents results in damage to critical cell components, such as DNA 
or microtubules. The cell recognises the severity of the damage and assesses whether to 
slow growth and repair the damage or undergo apoptosis (Hannun, 1997). Recent 
evidence indicates that the mitochondrial pathway of caspase activation plays a central 
role in cell death induced by chemotherapeutic agents. Activation of “executioner 
caspases” -3 , -7  and - 6, and also caspase -9 , -2  and in some cases - 8  have been 
identified in chemotherapy induced apoptosis. Additionally evidence that drug-induced 
apoptosis in some cases is mediated by the death receptor CD95/Fas signalling pathway 
has been reported (Schmitt er a l, 1999).
Most of the chemotherapeutic compounds used in cancer act on dividing cells, as they 
are more sensitive than non-dividing cells. Chemotherapeutic agents that actively 
induce apoptosis in different cancer cell types are listed in Table 1.9. Barge et a l
(1997) report that the involvement of caspases in apoptosis induced by actinomycin D 
in myeloid leukaemia cells is mediated by a crm-A-insensitive mechanism. Activation 
of serine and ICE-like proteases may be closely related in etoposide induced human 
leukaemia HL-60 cells (Yoshida et a l, 1996). Etoposide has also been shown to play 
an important role in the modulation of apoptosis signalling in lymphoma cells 
(Sebestyén et a l,  1997). Vinblastine, paclitaxel, etoposide and cisplatin are involved in 
apoptosis modulation by B c1-xl, which acts as a primary checkpoint that can delay or
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block the apoptotic signals that precede DNA damage in response to chemotherapy and 
prevents activation of the protease cascade (Schmitt et a l, 1998). Furthermore a 
variation of the ratio of death repressors and death promoters in the Bcl-2 family 
determines the sensitivity of cells to apoptotic stimuli. No expression of the death 
repressor Bcl-2, or death promoters Bcl-xg and Bax were observed in apoptotic cell 
death of hepatoblastoma HepG2 cells induced with taxol and doxorubicin, however one 
cell repressor, B c1-X l, and two cell death promoters, Bak and Bad were expressed (Luo 
et a l, 1999). The authors suggest that the variation in expression patterns of the Bcl-2 
family proteins induced by anticancer agents in liver cells may be associated with 
chemoresistance. Additionally new specifically targeted compounds are being tested, 
Kayeka and collaborators (1998) propose the novel anticancer compound, cytotrienin A, 
kills promyelocytic leukaemia HL-60 cells by apoptosis through the signalling of p36 
MBP kinase pathway.
Table 1.9. Chemotherapeutic agents associated with the apoptotic induction in different 
cancer cell types (Collins et a l, 1991; Costa et a l, 1997; Henkels and Turchi, 1997; 
Sebestyén et a l, 1997; Burger et a l, 1998; Kamesaki, 1998; Schmitt et a l, 1998)
Chemotherapeutic agents Cancer cell types
5 ’fluoro-deoxyuridine Dexamethasone Adenocarcinomas
5’-fiuorouracil Doxorubicin Breast carcinoma
5-Azacytadine Etoposide Colon carcinoma
Actinomycin D Hydroxyurea Leukaemia
Adriamycin m-AhdSA Lymphoma
Ara-C Melphalan Malignant glioma
BCNU Methothrexate Ovarian carcinoma
Bleomycin Nitrogen mustard Prostate cancer
Camptothecin Paclitaxel Seminoma
Chlorambucil Taxol Testicular germ cell tumour
Cisplatin and analogues Vinblastine
Cycloheximide Vincristine
Cyclophosphamide VM26
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Apart from its well known interaction with the DNA of proliferating cells, cisplatin and 
its analogues are now known to also induce apoptotic cell death (O’Neill et ah, 1996, 
Ormerod et a l, 1994). In some cases these agents may interfere in the cell cycle, 
causing a slow down in the S-phase transit (Ormerod et a l, 1996). Cisplatin treatment 
has also been proven to induce apoptosis through activation of p53 in human ovarian 
carcinoma cells (Jones et a l, 1998a). However evidence of apoptotic induction by 
cisplatin independently from the p53 pathway was shown in testicular germ cell tumour 
(Burger et a l, 1998), thus the role of p53 in induction of apoptosis with 
chemotherapeutic agents is currently under investigation by various groups. Likewise 
in view of the evidence confirming that chemotherapeutic agents kill cells by apoptosis 
(Huschtscha et a l, 1995; Barge et a l, 1997; Kamesaki, 1998) a possibility for the 
search of new compounds that could specifically trigger apoptosis has been opened.
1.8 Casiopeinas® - Review of the copper-phenanthroline complexes
1.8.1 Synthesis, characterisation and development o f copper-phenanthroline 
compounds
Inspired by the successful application of metal coordinated compounds for 
chemotherapy and in the light of copper’s range of biological activities, and also the 
ability of the body to handle excess copper levels. Dr Lena Ruiz-Ramirez and 
collaborators developed a number of copper-coordinated complexes at the Faculty of 
Chemistry, National University of Mexico (UNAM). A generic name, Casiopeinas®, 
was given to this group of compounds, whose main characteristics are a copper centre in 
the form of copper(II), two nitrogens from a chelator i.e. bipyridine or phenanthroline, 
and an aminoacid (Table 1.10) (Ruiz-Azuara et a l, 1994).
This group of compounds was synthesised considering parameters such as the nature of 
the metal, the oxidation, co-ordination states, the ligands and their chelating capacity as 
well as the hydrophilic or hydrophobic properties. The chemical properties of the 
complexes may determine their use according to their solubility, electrochemical 
potency, membrane transport capacity and stability (Gracia-Mora et a l, 1995).
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Table 1.10. Casiopeinas complexes and ligands (Tovar-Tovar et a l, 1998).
CASIOPEINAS (N-N) donors (0 -0 ) donors (O-N) donors
I 4,7-diphenyl-1,10- 
phenanthroline
-valine
-glycine
-serine
n 4,7-dimethyI-l,10-
phenanthroline
-glycine
-serine
-valine
n iF 4,7-diphenyl-1,10- (acetylacetonate)
m H phenanthroline (salicylaldéhyde)
DIE 4,7-dimethyl-1,10- (acetylacetonate)
m e phenanthroline (salicylaldéhyde)
m B
m A
1,10-phenanthroline (acetylacetonate)
(salicylaldéhyde)
m D 2 ,2 ’-bipyridine (acetylacetonate)
m j (salicylaldéhyde)
m i
m o
4,4 ’ dymethyl-2,2 ’ -bipyridine (acetylacetonate)
(salicylaldéhyde)
V 3,4,7,8-trimethyl-1,10- 
phenanthroline
-glycine
v m 1,10-phenanthroline -glycine
The main mechanisms of action of this group of copper-based compounds were 
predicted to involve active membrane transport mechanisms and DNA interaction. 
These compounds were characterised by basic analytical methods of UV-V, X-ray 
diffraction, IR and RPE (Ruiz-Azuara et a l, 1994). Studies on the chemical properties 
of casiopeinas indicate that they should not be administered orally due to their 
dissociation at low pH conditions, such as within the stomach. Subsequently the best 
administration route has been suggested to be intravenously because of casiopeinas’ 
stability in water or in a pH higher than 6 (Ferrer-Sueta et a l, 1994).
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In view of the above, casiopeina II has been selected as a starting point for toxicity 
evaluation because of its potential cytostatic activity (Ruiz-Ramirez et a l, 1993d). 
Casiopeina II (MW 408.7) contains a 4,7-dimethyl-1,10-phenanthroline and glycine 
bound to a copper centre in a planar structure [Cu (4,7-dimethyl-1,10- 
phenanthroline)(glycine)N03] (Ruiz-Ramirez, 1993b) (Figure 1.5).
”  4,7-dimethyl-1,10-Phenanthroline ”  
H X CH
n o :
Cu
GLYCINE
Figure 1.5. Structure of casiopeina II [Cu(4,7-dimethyl-1,10-phenanthroline)(glycine) 
NO3] (MW. 408.7).
1.8.2 Assessment o f the anticancer activity o f casiopeinas
Working on the premise that copper is an endogenous essential element, casiopeinas 
were designed with the aim of finding a more effective and less toxic chemotherapeutic 
agent against cancer, with a wider spectrum for resistant tumours, and to be used with 
other chemotherapeutic agents. In addition the ligands in casiopeinas’ structure may 
interchange with biological molecules, due to their positive charge and two bidentate 
ligands that lead to a cis position. The leaving groups have a specific range of liability 
and the non-exchanging ligands are strongly linked in the molecule (Gracia-Mora et a l , 
1995).
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These compounds have shown compatible cytotoxic activity in vitro and in vivo (as 
mentioned in section 1.5.1) against the following murine and human cancer cell lines 
(Ruiz-Ramirez et a l, 1993a; Gomez-Ruiz, 1994; Gracia Mora et a l, 1994):
• L1210 - Murine Leukaemia • LW 1-Lewis Lung Tumour
• S180 - Murine Sarcoma • Calo - Human Ovarian Carcinoma
• P33 8 -M urine Lymphoid Leukaemia • InBl -  Breast Cancer Cell Line
• B16 -  Melanotic Melanoma
The in vitro activity of casiopeina I, II and m  in Calo cells was reported to have a 
similar dose-response curve as mytomicin-C, a commonly used chemotherapeutic agent 
(Ruiz-Ramirez et a l, 1995). Casiopeinas II and m  induced point mutations in 
genotoxicity studies in the Drosophyla wing spot system (SMART) (used as an 
indicator of genetic status) in a dose response mode (Ruiz-Ramirez et a l, 1995). The 
activity in Drosophyla melanogaster may imply an interaction between casiopeinas and 
DNA. Agarose gel electrophoresis studies on the interaction of casiopeinas I, II and IH 
with DNA were performed. Casiopeinas with more hydrophobic ligands, i.e. casiopeina 
I, showed stronger interaction with linear DNA than those of less hydrophobic ligands 
i.e. casiopeina H, which interacts stronger with supercoiled DNA, and casiopeina m  
showed a weak DNA interaction (Ruiz-Ramirez et a l, 1993d; Ruiz-Ramirez et a l, 
1994b).
The in vivo antitumour activity of casiopeinas against inoculated L1210 and S I80 
tumoural cell lines in mice was reported to show a 16 to 200% increase in life span 
(relative to untreated tumour control group) although no complete tumour erradication 
was observed (Ruiz-Ramirez et al., 1991). Treatment of cats infected with Feline Viral 
Leukaemia resulted in a reduction in leukocyte blood count and an increase in their life 
expectancy. Moreover using casiopeinas as an adjuvant therapy after tumour removal 
surgery in dogs with osteosarcoma and leimyosarcoma resulted in an increase in life 
expectancy and no tumour recurrence was observed (Ruiz-Ramirez et a l, 1994a).
Similar to other antineoplastic compounds casiopeinas exhibit some acute cytotoxicity, 
which may be caused by the inherent activity of casiopeina-like complexes. Reports on
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the survival and increase in life span of mice treated 'with casiopeinas (even though they 
exhibited certain toxicity) encouraged further research into the toxicity of casiopeinas 
(Garcia et a l, 1991). Preliminary toxicity clinical studies in vivo suggest that the 
administration route and scheme are determinants of acute toxicity of these compounds. 
Dogs administered with a single bolus (6.43 mg/kg) of casiopeina I exhibited acute 
toxic effects, such as respiratory insufficiency due to pulmonary oedema, whereas with 
an intravenous continuous administration (drop to drop) no apparent toxic effects were 
observed (Gomez-Duque et a l, 1994).
Genotoxicity studies with casiopeina I, H and m  were performed in Salmonella 
typhimurium and Escherichia coli, where no significant damage to DNA with 
casiopeinas I and in  was observed whereas casiopeina U did infer certain DNA 
cleavage. It has been suggested that copper-phenanthroline ring may be responsible for 
this activity. It appears that casiopeinas’ toxicity could be due to the activity of the 
complex determined by the organic groups present in the compound rather than by the' 
metal only (Cano and Breha, 1996).
Pathophysiological studies in mice with casiopeina I indicate that when administered 
intraperitoneally the main effects were on the circulatory system, the main lesion was 
congestion in lung, kidneys and spleen. However the toxic effects observed in these 
experiments were evaluated as moderate and reversible, with toxic lesions disappearing 
when the treatment was suspended (Tinoco-Mendez et a l, 1996).
Studies on the toxicity of casiopeinas have been performed to determine the acute lethal 
doses in mice:
Casiopeina Administration
route
, LD50
mg/kg b/w
Mice
I Intraperitoneal 17.2 C57BL/6J
II Intraperitoneal 8.8 GDI
II Intravenous 16.7 NIK
m Intraperitoneal 14.6 GDI
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Preliminary toxicity studies with casiopeinas suggest that the administration route of 
casiopeina II may influence the toxicity, the LD50 was 2-fold higher when administered 
intravenously rather than intraperitonealy suggesting a higher tolerance (Gracia-Mora et 
a l, 1994). The main lesions found in tissues after casiopeina II administration in mice 
indicate an immediate toxicity of haematological origin (Quiroz-Rocha et a l, 1996).
Preliminary blood pharmacokinetics after intravenous administrations of casiopeina II 
to dogs indicated a half-life in blood of of 22 hours. This data is based on copper 
analysis and assumes no dissociation of casiopeina II, which implies a slow elimination 
rate and no retention of copper in the blood extracellular volume compartment (De 
Vizcaya-Ruiz et a l, 1996). This data is consistent with that found in this study in the 
rat (see Chapter 2).
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1.9 Aims
Evaluation of the toxic effects of casiopeinas
In the light of the successful application of metal coordinated complexes in medicine, 
particularly as anticancer drugs (Kratz and Schütte, 1998), and in the search for more 
effective, less toxic and wider spectrum chemotherapeutic agents a group of copper- 
coordinated complexes, Casiopeinas ®, were developed and synthesised at the Faculty 
of Chemistry, National University of Mexico (UNAM). Some members of this series of 
compounds have been shown to have effective anticancer activity in vitro and in vivo, 
the study of their toxicity and in vivo fate may provide useful information about their 
mechanisms of action and further clinical use. Due to the positive anticancer activity 
shown by casiopeina 11 [Cu(4 ,7-dimethyl-l,10-phenanthroline)(glycine)NO3] it was 
selected as the most appropriate member of the family to study the toxicity and in vivo 
fate of this group of compounds (Ruiz-Ramirez et al., 1993a; Gomez-Ruiz, 1994).
The main purpose of this project is to study the in vivo fate, metabolism, distribution, 
excretion and toxicity of casiopeina II (Ruiz-Ramirez et a l, 1993d) at therapeutic doses 
in the rat. Of particular interest are the fate of the complex and whether its stability or 
dissociation plays a role in the toxicity, whether endogenous copper levels are perturbed 
and to evaluate the nature and extent of its toxic side effects. It is hoped to obtain a 
labelled phenanthroline casiopeina II in order to evaluate its in vivo stability, 
distribution, metabolism and excretion. It is important to establish an appropriate dose, 
which reflects a therapeutic dose for studying the toxicity as well as allowing the 
detection of casiopeina Il-derived copper (by Atomic Absorption Spectrometry). In 
view of the acute copper toxicity to blood cells and chronic copper tissue injury it is 
anticipated that haematology screening and tissue histopathology may be particularly 
relevant for assessing casiopeina II toxicity. Once better understood approaches to 
ameliorate or reduce the toxicity caused by casiopeina II will be examined with the aim 
of improving the therapeutic use of this compound. It is also proposed to evaluate the 
drug-induced mode of cell death in two cancer cell lines. Human Ovarian Carcinoma 
CH 1 and Murine Leukaemia L1210.
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CHAPTER 2. DISTRIBUTION. METABOLISM 
AND EXCRETION OF THE NOVEL COPPER- 
BASED COMPOUND CASIOPEINA II IN THE RAT
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2.1 INTRODUCTION
In order to evaluate the biological activity and toxic effects of a metal complex it is 
important to consider the in vivo disposition, i.e. distribution, metabolism and excretion, 
of the components of the compound, the metal and the ligand. The study of the 
pharmacodynamics and pharmacokinetics of metal complexes provides information on 
plasma and/or tissue concentration of its components as well as their fate in a specific 
time period (Baud, 1998). Toxicokinetic studies can also provide useful information for 
comparative evaluation between animal and human cases and for predicting/evaluating 
about the starting doses for further use in human clinical trials (Horii, 1998).
Currently most antitumour metal complexes are administered intravenously and their 
metabolism, disposition and excretion vary according to the chemical form at which 
they are present and the ligand they are bound with, thus determining their toxic effect. 
Metal complexes have hydrolysable, exchangeable groups which may react with 
organic and inorganic anions or serum proteins (Kratz, 1993). An example of this is the 
case of carboplatin, whose reduced toxicity seems to be due to a lower binding rate of 
its bidentate ligand to macromolecules such as plasma proteins or kidney cells (Kratz, 
1993). In addition there are other metal complexes that remain inert when administered 
intravenously, such as the paramagnetic resonance imaging agent [Gadolinium (III) 
DTPA]'^ (diethylenetriaminepentacetic acid), which has one vacant coordination site for 
H2O to exhibit its paramagnetic activity, and is rapidly excreted through the kidneys 
into urine without interacting with any other molecule (Sadler, 1991; Swan et a l, 1999). 
Moreover other metal complexes have a slow acting therapeutic activity, such as the 
gold antirheumatic agent, aurofin, for whom delays of several weeks or even months 
have been reported before any beneficial effects are observed. This could be due to a 
delay in the achievements of steady-state concentrations for an effective therapeutic 
activity to occur (Tett, 1993).
Considering that casiopeina II has a copper centre and that the complex may dissociate, 
it is helpful to consider the homeostatic distribution of copper in the body. Dietary 
copper is mainly absorbed through the gastrointestinal tract (stomach and duodenum) in 
the form of Cu(I). After absorption it is transported through portal blood into the liver 
loosely bound to albumin, transcuprein or amino acids. Copper is deposited into the
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liver, where it is used as a cofactor of several enzymes and proteins (as described in 
Chapter 1, Section 1.4.1), after being used remaining copper released into the 
circulation is firmly bound to caeruloplasmin in plasma as Cu(II) and transported to 
other tissues. In the body copper is usually stored in liver and bone bound to 
metallothionein, although it is not an effective metallothionein inducer when compared 
with zinc and cadmium (Cherian, 1995). In the liver a third portion of copper can be 
excreted via bile to faeces, as well as any circulating copper which is reabsorbed into 
liver. Small amounts of copper may also be reabsorbed from biliary excretion. Copper 
when in ‘excess’ forms a complex with albumin, which can be potentially toxic. 
Additionally accumulation of excess copper may cause haemolytic anaemia due to its 
redox potential, which may cause oxidative stress to erythrocytes and result in severe 
haemolysis (Barceloux, 1999).
Previous studies indicate that casiopeina II complex remains stable in water (Ferrer et 
a l, 1994) and it is better solubilized in a 5% glucose solution (Romero et a l, 1998), 
thus it can be inferred that it will remain stable in vivo. In order to study the disposition 
(distribution and metabolism), excretion and to determine whether casiopeina II ([Cu 
(4,7-dimethyl-1,10-phenanthroline) (glycine) NO3]) dissociates in vivo, the fate of two 
components of casiopeina II were measured in body fluids, tissues and faeces in the rat. 
The phenanthroline ligand of casiopeina II complex was labelled in the two methyl- 
groups with radioactive tritium. The two components measured were the copper centre 
and the tritium-labelled phenanthroline ligand (^H).
2.2 MATERIALS AND METHODS
2.2.1 Animal Husbandry
Male Wistar/Albino (W/A) rats of approximately 250 g supplied by Bantin and 
Kingman were kept under standard conditions of temperature 20 ± 3°C, humidity 50 ± 
10%, and light from 07:00 to 19:00 hours through out each experiment. After an 
adaptation and acclimatisation period they were randomly allocated into groups of 4
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maximum and housed in standard plastic cages. Each animal was carefully examined to 
note their health and activity, and was then identified with an accession number on the 
tail for further sample reference. Tap water and Pelleted Rodent Diet No. 1 Standard 
Maintenance Diet (SDS Ltd, Essex) were given ad libitum. For urine and faeces 
analysis animals were transferred to 19 cm^ stainless steel metabolic cages (Arrowmight 
Biosciences, U.K.) previously decontaminated with 10 % HCl and MilliQ water.
2.2.2 Casiopeina II, 4,7-dimethyl-1,10-phenanthroline and ^H-casiopeina II 
administration
Casiopeina II
Casiopeina II [Cu(4 ,7-dimethyl-l,10-phenanthroline)(glycine)NO3] was synthesised and 
supplied by Dr Lena Ruiz-Ramirez (UNAM, Mexico). Treatment consisted of a single 
intravenous injection at a dose of 5 mg/kg via tail vein at a rate of 1 ml/minute, whilst 
the animal was restrained in a plastic cylinder with both sides temporarily sealed. A 5 
mg/kg dose represents a third of the LD50 dose in mice (Quiroz-Rocha et a l, 1994), it 
was selected as an intermediate dose between a high therapeutic dose and that which 
would allow the detection of casiopeina Il-derived copper above endogenous levels. 
Casiopeina II was dissolved in 5% sterile glucose solution at a concentration of 2.5 
mg/ml (5 mg/kg) and a volume of 0.5 ml of casiopeina II solution was administered for 
every 250 g of body weight. After injection, each animal was returned immediately to 
either a plastic cage or a metabolic cage according to the protocol.
4,7-Dimethyl-1,10-Phenanthroline 
The 4,7-dimethyl-1,10-phenanthroline was purchased ftrom (Aldrich,UK) and dissolved 
in pure ethanol and subsequently glucose 5% was added to obtain a 5% ethanolic/ 
glucose solution at a concentration of 0.636 mg/ml. Due to the low solubility of 4,7- 
dimethyl-1,10-phenanthroline in glucose solution it was dissolved to half the molarity of 
a casiopeina II solution. In order to obtain a casiopeina II equimolar dose twice the 
volume of phenanthroline was administered intravenously.
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Synthesis of ^ H-casiopeina II 
The 4,7-dimethyl-1,10-phenanthroline ligand of casiopeina II complex was tritium 
labelled on the two-methyl groups, by Prof. J. Jones and Mrs. L. Carroll in the 
Chemistry Department at the University of Surrey. The ^H-casiopeina II complex was 
synthesised as described by Rivero-Miiller (1999) and was sent to Dr L. Ruiz-Ramirez 
(UNAM, Mexico) to confirm its purity by IR analysis. The specific activity of ^H- 
casiopeina II was 2.625 mCi/g (1.07 mCi/mmol). The ^H-casiopeina II complex was 
administered intravenously as described above for the non-labelled casiopeina n. The 
distribution of activity refers to the activity of the radioactive tritium labelled 
methyl-groups in 4,7-dimethyl-1,10-phenanthroline.
2.2.3 Experimental design for in vivo copper and phenanthroline distribution and 
excretion in blood after intravenous administration o f casiopeina II
To investigate the distribution of copper in blood 6 male W/A rats were intravenously 
injected with casiopeina II and copper was measured in blood collected firom tail vein at 
20, 40 and 60 minutes, and 2, 4, 8, 24, 48 and 96 hours. At the same time points copper 
was measured in a second group of 6 animals intravenously injected with an equivalent 
concentration of the 4,7-dimethyl-1,10-phenanthroline (as described above). This was 
performed with the purpose of investigating if phenanthroline would alter the 
endogenous copper content. Copper was measured in blood collected fi'om tail vein 
firom both groups at the time points described above and the variations in blood copper 
distribution after casiopeina II and phenanthroline administration compared. The results 
of copper values are expressed as a mean of n = 6 + S.D.
2.2.4 Experimental design for in vivo copper and tritium-labelled phenanthroline 
distribution and excretion in body fluids, faeces and tissues after intravenous 
administration o f casiopeina II
To establish the in vivo and copper fate of casiopeina H, the complex was 
administered intravenously to groups of 4 W/A rats which were terminated at 0, 2, 8, 
12, 24 and 48 hours after casiopeina II administration and copper and tritium were 
measured. Copper and tritium values were determined in the following body fluids: 
whole blood, plasma, urine and bile. Faeces, tissues including liver, kidneys, spleen and 
heart, together with liver and kidneys pellet and cytosol were also analysed to determine
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their copper content and tritium distribution. The results of copper and tritium values 
are expressed as a mean of n = 4 ± S.D.
2.2.5 Sample collection, storage and autopsy procedure
■ Blood and plasma
After anaesthesia by intraperitoneal administration of Sagatal (Pentobarbitone Sodium 
60 mg/ml, Rhone Mérieux) at a dose of 0.1 ml/100 g of body weight, blood was 
collected from the inferior vena cava into metal-free heparinised blood tubes for copper 
and tritium analysis. Blood aliquots were then taken for copper and tritium analysis and 
samples were centrifuged at 750 g  for 10 minutes in JB6 centrifuge to obtain plasma. 
Both whole blood and plasma were stored at 4°C until analysis.
■ Urine
Animals were placed into stainless steel metabolic cages for 6 , 12 and 24 hours for 
urine collection (for the 48 hour group, urine was collected in the 24 hour period prior 
to autopsy). Urine was collected into metal-free plastic universal bottles and 
centrifuged at 750 g  for 15 minutes in a JB6 centrifuge in order to remove particles 
before copper and creatinine analysis. Urine samples were stored at 4°C until analysis.
■ Bile duct cannulation
Male W/A rats were anaesthetised with Sagatal as described above, and the bile duct 
exposed by a mid-line abdominal incision. The bile duct was then cannulated with a 0.8 
mm of internal diameter polyethylene tubing through a transversal incision in the wall 
of the vessel. The cannula was maintained in position by fixation with two ligatures. 
Once the bile duct was fixed, the abdominal cavity was fastened using surgical staples 
to prevent dehydration. During the collection time the abdominal organs were kept 
moisturised regularly by slowly pouring drops into the abdominal cavity from a side of 
the incision of 0.9% saline solution with damped cotton. The animals were kept alive 
under anaesthesia by the intraperitoneal administration of 0.1 ml of Sagatal every 30 
minutes and kept warm on a heated pad to minichanges in bile flow and composition.
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Approximately 0.5 ml of bile was collected every 30 minutes for a 5-hour period in 
sterile eppendorf tubes and stored at 4°C until analysis.
■ Faeces
Animals were placed into metabolic cages as described previously for urine collection. 
Faeces were collected into clean polythene bags and stored at -20®C before digesting 
with acid.
■ Tissues
Liver, kidneys, spleen and heart were excised at autopsy, weighed and rinsed with 
MilliQ water. All tissues were stored in clean polythene bags and stored at -20®C 
before digesting with acid. The four tissues analysed were selected due to their high 
copper content and in the case of the spleen also due to a weight increase observed after 
casiopeina II administration.
2.2.6 Digestion procedure o f  tissue andfaecal samples for trace element analyses 
The digestion assay was performed in a Techator Digestor System (Perstop Analytical 
Ltd).
■ Heating Block, Digestion system 12
■ Autostep 1012 temperature controller
• Reagents
Concentrated nitric acid (69% Analar) 20 % %  (BDH)
Concentrated nitric acid (69% Analar) 1% %  (BDH)
Concentrated perchloric acid (70% Aristar) 10 % %  (BDH)
RO/DI (Reverse Osmosis/Deionised) water
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• Digestion procedure
A 0.5 g portion of each sample (tissue or faeces) was placed into a glass digestion tube 
(previously soaked in 10% HCl RO/DI water overnight and rinsed thoroughly with 
RO/DI water) with 7.0 ml of RO/DI water and 2.0 ml of nitric acid. Digestion tubes 
were then placed into the heating-block (HB) that was heated up to 150°C for 30 
minutes. Tubes were removed from the HB and allowed to cool down, before adding 
1.0 ml of perchloric acid and placing them back into the HB for a 3-stage heating period 
of 30 minutes at 150°C, 15 minutes at 200°C and 15 minutes 250°C. Once the digestion 
was completed the tubes were removed and allowed to cool, before adding 5 ml of a 1% 
nitric acid solution to dissolve the residues. The solution was transferred into plastic 
tubes and made up with 1% nitric acid to a 10 ml volume and was ready to be analysed 
by AAS.
2.2.7 Measurement o f  copper by flame atomic absorption spectrometry (AAS) in body 
fluids, whole blood, plasma, red blood cells, urine and bile
• Reagents
Cupric chloride standard 1 mg/ml (BDH)
solution (“SpectrosoL”) (15.7mmol/L)
RO/DI (Reverse Osmosis/Deionised) water 
Quality Control Samples: Standard values:
Nycomed High 30 pmol/L (Nycomed Pharmaceutical, Norway)
Biotrol-33plus 6.3-9.4 pmol/L (Alpha Labs, France)
Randox 12.4 pmol/L (Randox Labs, Ltd, UK)
• Procedure
Copper was measured by AAS in whole blood, plasma, red blood cells, urine and bile 
following the dilution of samples in RO/DI (Reverse Osmosis/Deionised) water. 
Samples were diluted to ensure that their copper content was within 
detection/measurement range. Once measured the ‘unknown’ samples were compared 
with a standard curve previously prepared and measured to obtain copper concentration.
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The copper standard curve values were verified using quality control samples, nycomed, 
biotrol and randox, with known copper concentrations.
Copper was analysed by AAS with a SP 9 Atomic Absorption Spectrophotometer 
(PYEUNICAM, now THERMOUNICAM, UK), with the following settings:
Wavelength 324.7 nm
Slit width 320 pm
Lamp current 5 mA
PM voltage 530 V
Chart speed 20 mm / min
Chart range 20 mV
The working standard curve was prepared by adding 637 pi of the ‘SpectrosoL’ stock 
standard (15.7 mM) into an acid washed 100 ml volumetric flask and topping up with 
RO/DI water, to obtain a concentration of 0.1 mmol/L. Subsequently the standard curve 
was prepared as follows:
Concentration
(pmol/L)
Volume of working standard 
(ml)
Volume of RO/DI water 
(ml)
0 0 10.0
5 0.5 9.5
10 1.0 9.0
20 21 ) 8.0
30 3.0 7.0
40 4.0 6.0
A 0.5 ml volume of the standards, quality control or samples was diluted with 2 ml of 
RO/DI water (1:5) and mixed, however dilution factors varied according to the different 
copper content of the specific samples (Table 2.1). Once diluted they were measured by 
AAS and the peak absorbance recorded with a PM 8251 single pen-recorder (PHILIPS).
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Table 2.1. Sample dilutions for measuring copper concentration
Sample Dilution factor
Whole blood 1 in 10
Plasma 1 in 5
Red blood cells 1 in 5
Urine I in 10
Bile 1 in 10
To calculate copper levels the peaks of copper values were measured in mm and a 
calibration curve of the standards against peak absorbance was drawn using Excel 5.0. 
With the use of linear regression analysis the absorbances of test samples were derived 
from the curve equation to obtain the copper concentrations in pmol/L.
120
y = 2.4863X - 2.6772100
R = 0.9938
40
pmol/L
EXAMPLE: Blood sample 23 mm (23+2.6772)/2.4863 = 10.3274 pmol/L of
copper.
Finally the pmol/L concentration was converted into pg/ml by using the following 
equation in each test sample:
10.3274//WO/ / L*63.54
ÎÔÔÔ = 0.6562//g / ml
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2.2.8 Measurement o f  copper by AAS analysis in tissues andfaeces 
• Procedure
Tissue digests were analysed as described in 2.2.6, with liver, spleen and heart no 
dilution of the digests was necessary. However with kidney and faeces samples further 
dilutions of 1:5 and 1:10 respectively were performed (Table 2.2). A 0.5 ml volume of 
the standards was diluted with 2 ml of RO/DI water (1:5) and mixed. The standard 
curve for tissues and faeces copper determination was adapted as follows:
Concentration
(pg/ml)
Volume of working standard 
(ml)
Volume of RO/DI water 
(ml)
0 0 10.0
&318 0.5 9.5
&637 1.0 9.0
1.592 2.5 7.5
3.185 5.0 5.0
To calculate the copper levels a calibration curve of the standards was drawn using 
Excel 5.0, and a similar calculation procedure was used (see section 2.2.7). The peak 
absorbances of the test samples measured in mm were plotted into the standard curve to 
obtain the final copper concentrations in pg/ml. Values were calculated according to 
the dilution factor that had been performed.
Table 2,2. Dilution factors of tissue digests
Tissue Dilution factor Formula Result
Liver No dilution Divide by 5 pg of copper per ml
Kidneys 1 in 5 None pg of copper per ml
Spleen No dilution Divide by 5 pg of copper per ml
Heart No dilution Divide by 5 pg of copper per ml
Faeces linlO Multiply by 2 pg of copper per ml
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To obtain the final copper concentration in pg/g of tissue or pg/total tissue the following 
calculations were performed in each test sample.
g  =
pg  / m/*10
WDS
pg l TT^ pg  / g* TTW 
WDS
Where WDS means weight of digested sample, TT means total tissue and TTW means 
total tissue weight.
Copper levels in body fluids, tissues and faeces of control W/A 250 g rats were 
determined as by AAS and such values account for the endogenous copper content 
(Table 2.3).
Table 2.3. Endogenous copper levels of body fluids, tissues and faeces of W/A rats 
measured by AAS. Each value represents a mean of n = 4 ± S.D.
Body fluid pg of copper / ml Tissue pg of copper / g
Whole blood 1.03 + 0.02 Liver 44.45 ± 7.5
Plasma 0.93 ± 0.06 Kidneys 25.03 ± 3.9
Red blood cells 0.27 0.03 Spleen 6.01 + 1.7
Bile 0.94 ± 0.01 Heart 4.28 + 1.2
pg/pmol creatinine pg of copper/ g
Urine* 0.17 + 0.01 Faeces* 13.78 ±2.12
Representative of 24 hours excretion
An estimated normal copper consumption of a 250 g W/A rat in the diet (B&K 
Universal Limited, UK) was 420 pg, and assuming a 50% absorption (Linder and 
Hazegh-Azam, 1996) the real intake of copper was approximately 210 pg and the faecal 
excretion measured was about 192 pg in a 24-hour period.
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2.2.9 Detection o f tritium in body fluids, faeces, and tissues by scintillation counting
• Reagents
Scintillation cocktail (SAFEFLOUR) (Packard Instrument Co.)
SOLVABLE (Packard Instrument Co.)
hydrogen peroxide (BDH)
EDTA-di-sodium (Sigma)
• Procedure
Tritium activity was measured in blood, plasma, RBC, bile, urine, tissues and faeces by 
liquid scintillation counting using a Wallac Counter 1410 as described in Rivero-Müller 
(1999). Briefly, plasma, urine, bile and cytosols (50 to 100 pi) were poured in 
scintillation vials with 4 ml of scintillation cocktail (SAFEFLOUR). Tissue, pellets and 
faeces homogenates were digested with SOLVABLE and 300 pi were bleached with the 
addition of 150 pi of 30% hydrogen peroxide and incubated for 1 hour in a 50°C 
waterbath. Samples were cooled down and 4 ml of SAFEFLOUR was added to each 
tube. A volume of 50 pi of blood or lysed red blood cells (RBC) were digested with 
250 pi of SOLVABLE and 100 pi of hydrogen peroxide in scintillation vials and 
incubated for 1 hour at 55°C in a waterbath. A volume of 100 pi of 0.1 M EDTA-di- 
sodium was added to each sample as well as 100 pi of 30% hydrogen peroxide and
incubated for another hour at 55°C. The last step was repeated 4 times capping the
tubes and allowing occasional ventilation. Vials were allowed to cool down at room
temperature and 4 ml of SAFEFLOUR was added to each sample before analysis.
2.2.10 Caeruloplasm in assay
The method used for caeruloplasmin determination is based on the enzymatic activity of 
caeruloplasmin which is able to oxidase o-Dianisidine as a substrate and analysed as a 
rate reaction as described in Schosinsky et al (1974).
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2.3 RESULTS
2.3.1 Copper and phenanthr aline distribution in blood
After intravenous administration of casiopeina II to a group of 6 male W/A rats copper 
reached its maximum concentration in blood within the first 20 minutes, a 3-fold 
increase over endogenous copper levels in blood being observed. After reaching its 
maximum peak there was a steady decline, when almost control levels were reached, at 
96 hours (Figure 2.1). An equivalent intravenous dose of the ligand alone, 4,7- 
dimethyl-1,10-phenanthroline, did not affect the blood copper values over the same time 
period.
6  -r
5 - — Phenanthrollne 
—6— Casiopeina I I*a
3 -4
64 72 80 88
TIME (hours)
Figure 2.1. Time course of copper levels after casiopeina 11 and 4,7-dimethyl-1,10- 
phenanthroline ligand administration over a 96-hour period. Each time point is a mean 
of n = 6 ± S.D.
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2.3.2 Casiopeina II distribution in blood, plasma and red blood cells
The disposition and excretion of the two components of casiopeina II, copper and 
(iabelled ligand), were measured in body fluids (whole blood, plasma, red blood cells, 
urine and bile), tissues (liver, kidney, spleen and heart) and faeces after intravenous 
administration of the labelled casiopeina II.
Copper and distribution in whole blood reached the highest concentration during the 
first hour after injection (Figure 2.2). Tritium then declined in the second hour and 
between 6 and 12 hours, finally reaching an activity some 4-fold lower than the peak at 
48 hours, whilst copper values showed a steady exponential elimination cur\'e. Copper 
values during the first hour after administration are not shown in Figure 2.2, however 
from Figure 2.1 a peak at 20 minutes can be observed followed by a decrease. The 
decline of blood copper in whole blood was consistent with the previous experiment, 
showed in Figure 2.1.
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Figure 2.2. Distribution with time of H and copper in whole blood after intravenous 
administration of ^H-casiopeina II in the rat. Each value represents a mean of n = 4 ± 
S.D.
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Plasma distribution of after casiopeina II injection showed a similar trend as in 
whole blood, an early peak in the first hour followed by approximately 1.5-fold decline 
in the second hour followed by a steady slow elimination until 48 hours (Figure 2.3). 
Copper plasma distribution showed a significant continuous increase after injection, 
reaching an approximately 2-fold higher concentration than the control value at 48 
hours (Figure 2.3). Copper and were also measured in the red blood cell (RBC) 
component of blood, where a rapid uptake of copper and was observed during the 
first 2 hours after injection. Tritium declined rapidly from 2 to 12 hours and slowly 
afterwards until the end time point at 48 hours. Copper had a minor decrease of 1.5- 
fold from 6 to 24 hours and little change to the end of the time course showing a typical 
elimination curve (Figure 2.4). Tritium is more easily and rapidly eliminated from RBC 
than copper which appears to be slower. At the end time point no increase in total 
blood copper levels were observed after casiopeina II administration, whilst there is an 
increase in plasma copper levels. These increase in plasma copper levels corresponds to 
an increase in caeruloplasmin activity after administration (Figure 2.5), where an 
increase from 24 to 48 hours is observed (Rivero-Müller, 1999).
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Figure 2.3. Time course of copper and tritium in plasma after intravenous 
administration of ^ H-casiopeina II. Each value represents a mean of n = 4 ± S.D.
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RED BLOOD CELLS
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Figure 2.4. Distribution of H and copper in red blood cells (RBC) after the 
intravenous administration of ^H-casiopeina II. Each time point is a mean of n = 4 ± 
S.D.
Time (hours)
Figure 2.5. Caeruloplasmin (Cp) time course in plasma after intravenous^ 
administration of casiopeina II. Each time point represents a mean of n = 4 ± S.D. 
Caeruloplasmin is expressed as international units per litre (Schosinsky el a i, 1974).
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2.3.3 Disposition o f casiopeina II in tissues
Most of the and copper from casiopeina II was distributed into liver or kidney after 
administration. Figure 2.6 shows an early uptake and elimination of by the liver 
after injection, suggesting a mimic of the liver vascularity. In contrast copper showed a 
slow steady uptake and retention until the end time point at 48 hours. An increase 
above endogenous levels, 3-fold, with no obvious down trend at the end time point is 
observed. A predominance of copper in the cytosolic fraction was observed, which 
suggests that copper can be bound to metallothioneins that are indeed induced and reach 
a maximum peak at 48 hours (Rivero-Muller, 1999).
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Figure 2.6. Time course of H and copper in the liver. Each time point is a mean of n 
= 4±S.D.
Kidney uptake of H and copper showed a similar trend to the one in liver (Figure 2.7). 
Tritium rapid uptake and excretion mimics the kidney vascularity, after reaching a 
maximum concentration a dramatic decline at 6 hours was observed. Tritium 2-hour 
value could be lower considering the large error, and then the distribution would be 
consistent with the vascular change observed in the liver. The excretion of tritium 
observed in the first 6 hours after injection corresponds with tritium values found in
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urine (see below). A steady uptake and retention of copper into the kidney after 
injection was observed during the 48-hour time course (Figure 2.7).
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Figure 2.7. Distribution in time of H and copper in the kidney. Each value represents a 
mean of n = 4 ± S.D.
Tritium in kidney cytosol showed a peak 2 hours after administration, which 
disappeared almost completely at 6 hours suggesting that was excreted via urine. 
The highest concentration of in the kidney pellet was observed during the first hour 
after administration, followed by an almost total excretion for the next 5 hours until the 
end of the time course. Similar to the liver, copper was localised mainly in the cytosolic 
fraction of the kidney rather than in the pellet. A significant increase of copper in 
cytosol was observed at 12 hours and continued up to the end time point. Copper 
concentrations in the pellet did not show variations throughout the whole of the time 
course (Figure 2.8). Tritium and copper time course distribution in cytosol is consistent 
with the time course of and copper in the kidney.
Tritium levels in the spleen reached a high peak during the first hour after 
administration of casiopeina 11 followed by a slow decrease until 24 hours, the increase 
at 48 hours cannot be explained. Spleen tritium distribution in time is similar to the
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tritium changes observed in whole blood, an early uptake and elimination. Copper 
concentrations increased after injection reaching a maximum peak at 12 hours, and from 
there a continuous decline up to 48 hours was observed (Figure 2.9). The increase of 
copper during the first 12 hours could be from the uptake of damaged erythrocytes due 
to the filtrating role of the spleen, followed by a decrease suggesting no more damage to 
erythrocytes.
Tritium and copper in heart showed a similar trend as in liver and kidney after injection. 
An early uptake and elimination of tritium resembles the organ vascularity distribution. 
A high uptake of copper can be observed during the first hour after injection, followed 
by retention judged by the increase of copper above endogenous levels (Figure 2.10). 
The retention of copper in the muscle suggests that the skeletal muscle could also 
represent an important site for copper storage.
KIDNEY CYTOSOL AND PELLET
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Figure 2.8. Time course of and copper in kidney cytosol and pellet. Each time point 
is a mean of n = 4 ± S.D.
73
Chapter 2. Distribution, metabolism and excretion of casiopeina II
SPLEEN
2 0 0 0 0  -r
- Tritium
1 6 0 0 0  -■ -  16Copper
p  1 2 0 0 0  - I -  12
t :-CL.
8 0 0 0
4 0 0 0  4 -  4
3 0
TIME (hours)
Figure 2.9. Distribution in time of H and copper in the spleen. Each time point 
represents a mean of n = 4 ± S.D.
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Figure 2.10. Time course of H and copper in the heart. Each value represents a mean 
ofn  = 4±S.D.
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2.5.4 Excretion o f casiopeina II
Excretion of and copper via urine after casiopeina II administration is presented in 
Figure 2.11, The first urine collection was at 6 hours, when a high activity of tritium 
was found in urine, followed by a continuous decline to almost no tritium at 48 hours. 
Copper excretion via urine did not show any significant variation after the injection of 
casiopeina H. Copper is usually excreted via bile except in cases of the treatment of 
Wilson’s disease where a copper chelator is used to remove excess copper ftom the 
body and it is excreted via urine (Brewer, 1995).
Bile was collected from the bile duct after cannulation for 5 hours, data of and 
copper concentrations in bile for this period are presented in Figure 2.12. Tritium 
reached its highest peak in bile 60 minutes after casiopeina 11 administration followed 
by a continuous decrease for the next 4 hours, when a 2.7-fold decrease was observed. 
Copper reached its maximum peak in bile excretion 30 minutes after injection, followed 
by a decline until the last collection at 5 hours (300 minutes), where an 8-fold lower 
concentration was observed. A 30-minute discrepancy between copper and tritium 
excretion via bile can be observed suggesting a dissociation of both components of 
casiopeina 11. Copper is eliminated through the normal excretion route and tritium is 
excreted via both urine and bile routes.
Excretion of copper and via faeces is presented in Figure 2.13. Tritium reached a 
maximum peak of excretion via faeces 24 hours after administration of casiopeina n  
and decreased in the following 24 hours. Copper excretion via faeces showed small 
variations with no significant difference. The levels of copper in faeces are the result of 
non-absorbed copper from the diet plus that excreted through bile. Copper and tritium 
excretion via faeces showed different curves of elimination, suggesting the dissociation 
of casiopeina 11 complex.
At the end time point most of the tritium injected was excreted via urine and faeces 
whereas the amount of copper excreted was minimal suggesting the dissociation of both 
components of casiopeina 11.
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Figure 2.11. Time course of tritium and copper excretion via urine. Each time point 
represents a mean of n = 4 ± S.D. The time points represent time intervals from 0-6, 0- 
12, 0-24 and 24-48 hours respectively. Copper levels are given in pg of copper /pmol 
of creatinine to correct for changes in urine concentration.
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Figure 2.12. Time course of tritium and copper elimination in bile collected over a 
period of 5 hours. Each time point is a mean of n = 4 ± S.D.
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Figure 2.13. Time course of tritium and copper excretion via faeces. Each time point 
is the cumulative value in time, except for the last time point, which represents the 
amount of copper from 24 to 48 hours. Each value represent a mean of n = 4 ± S.D.
2.3.5 Copper and tritium recovery
Table 2.4 shows the estimated recovery in percentage of copper attributable to 
casiopeina II administration from blood, tissues, urine and faeces. In the first 1, 2 and 6 
hours after administration an approximately 50 to 80 % of the total copper dose was 
recovered from blood and tissue content. Additionally most of the copper recovered in 
the first 12 hours after injection was distributed in tissues and blood. After 24 and 48 
hours some 20 to 25% of the copper equivalent to that administered as casiopeina II was 
excreted in faeces while none was present in urine. The tissue content however was 
above 50% suggesting retention. Figure 2.14 shows the distribution of copper in time 
expressed as percentage of the total copper recovered in the different compartments 
measured, blood, urine, tissues and faeces. During the first 12 hours after injection 
copper is mainly distributed in blood and tissues, some excretion via faeces is observed 
after 24 hours. Most of copper recovered was distributed in tissues over the whole of 
the time course.
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Table 2.4. Percentage of copper recovery from body compartments. Each value 
represents a percentage in each of the compartments (blood, urine, tissues or faeces) of 
the copper recovered from the total copper administered with casiopeina II (194.254 
pg). Bold - highest amount recovered at the specific time point. Underlined - highest 
level of the specific compartment.
TIME 1 2 6 12 24 48
BLOOD * 13.92 10.42 11.35 9.29 6.73 6.09
TISSUES ^ 40.90 41.39 67.79 67.59 51.56 62.92
URINE* — — 0.02 0.21 0 0
FAECES * — — 0 0 22.62 25.55
TOTAL 54.90 51.80 79.15 77.08 80.94 94.56
Approximately 10 m l o f  blood per 250 g rat; tissues include liver, kidney, spleen and heart; 
in total volum e excreted.
Copper BLOOD □ TISSUES 
URINE □  FAECES
6 12 24
TIME (hours)
4 8
Figure 2.14. Distribution in time of the copper, equivalent to that administered as 
casiopeina II, in the different compartments measured. Values are expressed as 
percentage of the total copper recovered.
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Table 2.5 shows the percentage of tritium recovered in blood, tissues, urine and faeces 
after casiopeina II administration. Blood and tissues data indicate that tritium was 
rapidly distributed through the body, approximately 40 to 45% of tritium was recovered 
from blood and tissues 2 hours after injection. During 6 and 12 hours some 20 to 30% 
of tritium was recovered, mainly distributed in the blood and tissues compartments, 
however a 15% is excreted via urine and faeces. From 24 to 48 hours 60 to 80% of the 
tritium dose was recovered, mainly from urine and faeces excretion.
Figure 2.15 represents the distribution in time expressed in percentage of the total 
tritium recovered in the different compartments measured. During the first two hours 
after injection most of the tritium recovered was distributed between blood and tissues, 
approximately a 35 to 40% in blood and 60 to 65% in tissues. After 6 hours about a 
36% of tritium was excreted via urine and faeces, and at 12 hours almost a 50% was 
excreted. After 24 hours approximately 50 to 70% of tritium recovered was contained 
in urine and faeces.
Table 2.5. Percentage of tritium recovery fi'om body compartments. Each value 
represents a percentage of tritium recovered in blood, tissues, urine and faeces from the 
total tritium administered as casiopeina II (3,039 kBq). Bold - highest amount 
recovered at a specific time point. Underlined - the highest level of the specific 
compartment.
TIME 1 2 6 12 24 48
BLOOD * 17.73 12.98 11.44 5.59 6.07 3.98
TISSUES < 28.03 25.41 12.37 7.47 5.78 4.08
URINE^ — — 9.11 7.88 17.68 18.94
FAECES ^ — — 4.67 4.49 31.23 55.90
TOTAL 45.76 38.39 37.59 25.43 60.76 82.89
* Approxim ately 10 ml o f  blood per 250 g rat; < tissues include liver, kidney, spleen and heart; 
X  in total volum e excreted.
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Figure 2.15. Distribution in time of the tritium from casiopeina II administration in the 
different compartments measured, results are expressed in percentage of the total tritium 
recovered.
2.4 DISCUSSION
The time course of blood copper after casiopeina II intravenous administration suggests 
a fairly rapid but complex distribution and elimination of copper contained in blood. 
Additionally the administration of 4,7-Dimethyl-1,10-phenanthroline did not have any 
effect on in situ copper blood levels suggesting that the variations observed over the 96 
hours after casiopeina II administration can be attributed to casiopeina Il-derived 
copper. However casiopeina II could possibly mobilise endogenous copper so the 
excess and redistribution of copper may not be “absolutely” attributed just to the 
casiopeina Il-derived copper.
As a general observation the rapid uptake of and copper by tissues would suggest 
that after intravenous administration of casiopeina II the complex is distributed in the 
first 2 hours into tissues, liver, kidney, spleen and heart through general circulation. 
Copper concentrations per total tissue were higher in liver > kidneys > heart > spleen 
and in liver > kidneys > spleen > heart. The distribution of activity refers to the
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activity of the radioactive tritium labelled methyl-groups in 4,7-Dimethyl-1,10- 
phenanthroline. Although casiopeina II as a complex appears to be rapidly distributed 
to tissues by blood, it seems that the elimination of its components varies. Copper and 
levels in blood and plasma indicate that at early stages the complex is associated 
with red cells, however after 6 hours tritium is distributed into tissues whereas copper 
remains contained in blood for longer. The increase in plasma copper levels 
corresponds to increased caeruloplasmin activity after casiopeina II administration 
(Rivero-Muller, 1999). Both components of the coniplex appear to be eliminated at 
different rates, most of the being rapidly distributed into tissues and excreted via 
urine while copper remains in tissues during the first 12 hours after administration 
suggesting some dissociation of the complex.
Liver, kidney, spleen and heart showed a rapid uptake and release of tritium in the first 
6 to 12 hours, however the elimination of tritium fi'om spleen was slower. Most of the 
tritium in the liver was eliminated during the first 12 hours after casiopeina II 
administration, which corresponds with a rapid elimination via bile and a high excretion 
in faeces 24 hours after injection. In the kidney tritium was eliminated 6 hours after 
injection via urine, when it began to increase and reached its maximum peak of 
elimination at 24 hours.
Copper derived ftom casiopeina II administration was rapidly taken up into tissues 
(liver, kidney, spleen and heart). During the first 2 hours after injection high levels of 
copper were detected in the liver and maintained throughout the whole of the time 
course. The copper increase in liver at 48 hours could be attributed to a promotion of 
caeruloplasmin synthesis and further tissue distribution, metallothionein induction 
resulting in copper storage and increase in glutathione-bound copper for bile excretion. 
The increase of caeruloplasmin activity in plasma corresponds to increased hepatic 
uptake of copper being incorporated for redistribution to other tissues or possibly for 
further excretion via bile (Dijkstra et a l, 1996). In the kidney copper uptake occurred 
mainly after 12 hours of injection and its subsequent retention corresponds with the lack 
of copper excretion via urine. The observation that copper in liver and kidney was 
mainly found in the cytosolic ftaction, strongly suggests that copper is bound to 
cytosolic proteins such as metallothioneins (Young et a l, 1994; Klaassen et a l, 1999). 
The high increase of copper in the spleen 12 hours after administration of casiopeina II
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suggests that together with the normal copper disposition to tissues copper could be 
inferring damage to blood cells, particularly erythrocytes (as described in Chapter 3, 
Section 3.3.1). This increase of copper concentration at 12 hours may be due to an 
uptake of damaged blood cells by the spleen. After reaching its highest concentrations 
in the spleen copper levels return to endogenous levels, probably because there is no 
further damage to erythrocyte and thus no further uptake by the spleen. After injection 
of casiopeina II copper is rapidly distributed to the different tissues where it 
accumulates, as observed when copper sulphate is administrated intravenously and 
further distributed in liver, kidney and heart (Gregus and Klaassen, 1986). Studies on 
copper administered intravenously suggest that in addition to the copper destined for 
redistribution to other tissues by caeruloplasmin it is mainly excreted via the 
hepatobiliary system, once in the liver it forms a complex with glutathione and is 
eliminated into bile (Dijkstra et a l, 1996). After casiopeina II administration most of 
the copper was retained in tissues, however a small amount of the ‘excess’ copper from 
casiopeina II was excreted via bile and later through faeces following the normal 
elimination route for copper.
After 24 hours of the intravenous administration of ^ H-casiopeina II approximately 60% 
of the total dose of tritium injected was recovered. During the first two hours tritium 
was distributed mainly in blood and tissues in a 1:1.5 ratio respectively. After 12 hours 
most of the total dose was eliminated via urine and faeces and by 48 hours almost 83% 
ftrom the total was eliminated. Copper had a similar rapid distribution into tissues 
through blood circulation during the first 12 hours. However in contrast with tritium, 
copper was mainly retained in tissues and only about 25% of the copper injected with 
casiopeina II was eliminated via faeces after 24 hours. The excretion of both 
components differed, tritium being excreted via urine and faeces whilst copper only by 
faeces but to a lower extent. Furthermore the ‘extra’ copper from casiopeina II injection 
was excreted to bile more rapidly than tritium, suggesting that it followed the normal 
route of copper excretion, whilst tritium had a delay and was also found to be excreted 
through urine. This observation is also consistent with the dissociation of casiopeina II 
suggesting that despite its apparent chemical stability the in vivo conditions with 
numerous competing ligands and pH gradients results in some dissociation of this 
copper complex.
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On the assumption that the copper measured is attributable to casiopeina II 
administration and that the activity represents the intact 4,7-Dimethyl-1,10- 
phenanthroline component, it can be concluded that casiopeina II complex does 
dissociate in vivo after intravenous administration. In addition tritium was excreted via 
urine and faeces whereas a small amount of copper was excreted via faeces. However 
tissue copper retention and the relatively effective elimination of tritium indicate a 
dissociation of the complex in vivo. A redistribution of the ‘excess’ copper in the body 
is suggested by the slow excretion via faeces and the high retention in tissues, most of 
the ‘excess’ copper may be excreted further without affecting the normal copper 
homeostasis (Harada et a l, 1993).
Due to the administration route and the susceptibility of red blood cells to copper 
damage casiopeina II is clearly cytotoxic to erythrocytes (Sree Kumar et a l, 1978; 
Cooper et a l, 1996). Casiopeina II complex dissociates between 12 and 24 hours after 
administration, maybe as a result of its own reactivity with biomolecules, and whilst the 
ligand is possibly metabolised and eliminated ftrom the body the copper is integrated 
into the normal copper homeostatic metabolism and may be excreted via faeces at a 
much slower rate (Young et a l, 1994; Barceloux, 1999). The phenanthrollne ligand 
fi'om casiopeina II could possibly be metabolised via cytochrome P450, by the CYPlAl 
isoform which usually is involved in the metabolism of planar molecules, resulting in 
either an hydroxylation of the methyl groups or an oxidation forming an epoxide in C5 
and C6 (Figure 2.16) (loannides and Parke, 1990). The first hydroxylated metabolite 
could be further conjugated by glucuronyltransferase or sulfotransferase and then 
excreted via bile. On the other hand the epoxide metabolite, may either be metabolised 
by epoxide hydrolase forming double OH groups which would be conjugated as 
previously described or it could be conjugated with glutathione and excreted via bile. 
The most likely metabolic pathway is the formation of an epoxide metabolite because of 
the aromatic chemical structure of phenanthrollne that resembles anthracycline, which is 
epoxidated and conjugated with glutathione. Thus the high ^H-phenanthroline activity 
detected in bile 1 hour after administration, and the activity observed in urine, could be 
attributed to possible epoxidation of phenanthrollne. Additionally the possible 
enterohepatic recirculation could explain the delayed ^H excretion in bile compared 
with that of copper.
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CH. HO-HX
CH,
4,7-dimethyl-l,10-phenanthroline
Glutathione transferase
HX
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Epoxide hydrolase
CH.-OH
CH. H X CH
Excretion via bile
Conjugation
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Sulphate
Figure 2.16. Proposed hypothetical scheme of phenanthrollne ligand metabolism via 
the cytochrome P450 pathway. The scheme is based on known/possible metabolism of 
phenanthrollne and its derivatives.
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CHAPTER 3. HAEMATOLOGICAL EFFECTS OF 
CASIOPEINA II TREATMENT IN THE RAT
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3.1 INTRODUCTION
The treatment for cancer involves aggressive measures that usually imply some toxic 
side effects. For this reason it is recommended and indeed recognised that new 
anticancer agents should be tested for potential toxic effects (DeGeorge et a l, 1998). 
When administered intravenously, chemotherapeutic agents may cause toxic effects 
mainly in blood and its components (Tannock, 1992). In cancer therapy with cytotoxic 
agents bone marrow and haematological response to chemotherapy is used as a 
parameter of toxicity in order to assess the development of the patient towards recovery 
(De Vita, 1997 ).
Intravenously administered agents may infer a primary effect to blood and its 
components. The major components of blood are red cells or erythrocytes (non­
nucleated cells), white cells or leukocytes (nucleated cells), which include lymphocytes, 
monocytes, neutrophils and eosinophils, and platelets, plasma and proteins (Sanderson 
and Phillips, 1981; Smith et a l, 1994). The major haematopoietic organ in adult 
mammals is the bone marrow where pluripotential stem cells, undergo a series of cell 
divisions and differentiation steps to produce three main cell lines, erythroid, 
granulocytic and monocytic, and megakaryocitic. These later differentiate into red 
cells, white cells and platelets respectively (Hoffbrand and Pettit, 1998). The bone 
marrow, spleen, lymph nodes and thymus are important active haematopoietic organs 
during infancy and childhood in humans, and in adults the bone marrow has the major 
haematopoietic function (Weiss, 1983 ). However different to other species, the spleen 
plays an important haematopoietic role in the young and adult rat (Rosse, 1987). Rat 
erythrocytes are smaller than their human homologues and have a life span of 50 days. 
Young rats have a higher reticulocyte count than older rats, with some nucleated red 
cells sometimes being found in the peripheral circulation (under seven weeks of age) 
(Benirschke era/., 1978).
Metal chemotherapeutics exhibit a range of toxic effects as described in Chapter 1 
Section 1.3.1. Considering that casiopeina II has a copper centre, it is important to 
consider the general and particularly blood toxicity of copper. Reports on the toxicity 
of copper indicate that the acute response to unbound copper, present in blood, is
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haemolytic anaemia (Goyer, 1996; Linder and Hazegh-Azam, 1996). It appears that 
oxidative stress on erythrocytes by copper is the main cause of the increase of red cell 
destruction giving rise to haemolytic anaemia (Hochstein et a l, 1980; Kumar et a l, 
1983; Rolfe and Twedt, 1995).
Preliminary toxicity studies with casiopeina U in mice indicate that the main adverse 
effects were of haematological origin (Quiroz-Rocha et a l, 1996). For this reason in 
this study a further evaluation of toxic side effects associated with casiopeina U were 
investigated. Effects on the haematological parameters, recovery post-administration, 
dose scheme and different age groups response after the intravenous administration 
were studied. In addition the use of two copper chelators, penicillamine and trientine, in 
order to ameliorate the effects caused by casiopeina E-copper ‘excess’ were 
investigated. In the condition of Wilson’s disease the most common therapies against 
copper toxicity due to an increase in copper accumulation are the use of copper 
chelators (as described in Chapter 1 Section 1.4.2). These agents have demonstrated to 
reduce the effects of copper overload and toxicity, moreover, due to their copper 
chelating activity, they have also been successfully used in Long-Bvans Cinnamon 
(EEC) rats to prevent hepatic damage and liver tumours caused by excess copper 
(Togashi et a l, 1992; Sone et a l, 1996).
Furthermore due to the acute haemolytic toxic effects associated with copper overload 
and some evidence of haematological effect of casiopeina E the use of an erythropoietic 
promoter was studied. Therapy with subcutaneous recombinant erythropoietin, a 
hormone secreted in the kidney that stimulates the final differentiation of red blood cells 
from precursor cells, is a common practice to promote erythropoiesis and ameliorate 
the adverse effects of chemotherapeutic agents when they affect blood and its 
components (Griffin, 1997).
In the presence of transition metal ions or metal complexes (casiopeinas, chromium (IV) 
or iron) ascorbic acid can exert pro-oxidant properties in vitro, promoting free radicals 
damage to DNA, lipids and proteins or can inactivate protection enzymes such as 
catalase (Da Cruz Fresco and Kortenkamp 1994; Halliwell, 1996; Rivero-Muller et al, 
1998). Other reports indicate that ascorbic acid can also exert antioxidant effects in 
vitro, it can reduce ROS avoiding damage to biomolecules as dehydroascorbate (DHA)
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and therefore an antioxidant activity m vivo is feasible, however not enough evidence of 
this effect has been reported (Halliwell and Gutteridge, 1998).
3.2 MATERIALS AND METHODS
3.2.1 Animal Husbandry
Male Wistar/Albino (W/A) rats of 9 to 10 weeks of age and weighing 300-400 g 
supplied by Bantin and Kingman were used through out these experiments. Tap water 
and Pelleted Rodent Diet No. 1 Standard Maintenance Diet (SDS Ltd, Witham, Essex) 
were provided ad libitum. They were kept under standard conditions of temperature 20 
± 3°C, humidity 50 ± 10%, and light from 07:00 to 19:00 hours. After an adaptation 
period they were randomly allocated into groups of 5 maximum and housed in plastic 
cages. Each animal was carefully examined to note their health and activity, and was 
then identified with an accession number on the tail for further sample reference. 
Animals of 6 to 7 weeks of age and weighing 250 g were used for the experiment 
designed to compare two different age groups.
3.2.2 Experimental design for haematology screen and prevention
To evaluate the haematological effects following the administration of casiopeina II 
12-hour and 5-day time points were chosen. Furthermore in order to follow up the 
progression of the haematological lesion a 15-day time point was established.
A dose scheme of 1,3 and 5 mg/kg of casiopeina II treatment was used to evaluate the 
effect on haematology as a response to the administration for 12 hours. In addition the 
haematological response to casiopeina II in two different age groups at 5 days was also 
evaluated.
A pretreatment with penicillamine and trientine (copper chelators) was used to avoid the 
presence of ‘free copper’, if any, in circulation and ameliorate the haematological effect 
of casiopeina II. Erythropoietin (promoter of erythropoiesis) was used to ameliorate the 
haematological effect of casiopeina II, and this group was supplemented with iron to
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avoid anaemia due to the enhancement of erythropoiesis. Pretreatment with ascorbic 
acid, which had been observed to intensify DNA damage in vitro, was tested in vivo to 
observe the effect after administration of casiopeina n. Control animals were kept 
under the same conditions and period of time as treated animals.
Casiopeina II administration
Casiopeina II [Cu(4,7-dimethyl-l,10-phenanthroline)(glycine)NO3] was synthesised and 
supplied by Dr Lena Ruiz-Ramirez (UNAM, Mexico). Casiopeina II was dissolved in 
5% sterile glucose solution at a concentration of 2.5 mg/ml. Treatment consisted of a 
single intravenous injection at a dose of 5 mg/kg via tail vein at a rate of 1 ml/minute, 
whilst the rat was held in a cylindrical plastic restrainer. A volume of 0.5 ml of 
casiopeina II solution was administered for every 250 g of body weight. After injection, 
each animal was returned immediately to the corresponding plastic cage.
Treatment schedule:
Compound Concentration Dose Administration
route
Casiopeina II 2.5 mg/ml 5 mg/kg (0.6 
ml/300g rat)
Single intravenous 
injection
Pretreatment schedule:
Penicillamine, trientine, erythropoietin and ascorbic acid administration
• Compounds used:
Penicillamine D 
Trientine
Erythropoietin (EPREX) epoietin a  1000 lU / 0.5ml 
Iron (SYTRON)
Ascorbate
(Aldrich Chemicals Ltd, U.K.) 
(Aldrich Chemicals Ltd, U.K.)
(Janssen-Cilag, UK) 
(Link Pharmaceuticals Ltd, U.K.)
(Sigma, U K.)
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Compound Concentration Dose Duration Administration
route
Penicillamine D 50 mg/ml (Togashi 200 mg/kg 9 days Oral gavage
Trientine
Erythropoietin
+
Iron
et a l, 1992)
1.5 mg/L (1500 
ppm)
(Sone et a l, 1996) 
lOOOUI/0.5 ml
5.5 mg/ml
Ascorbate 40 mg/ml
(*Daily approximate water consumption
37.5
pg/day*
7 units/ 
3 X week 
0.25 
ml/day* 
1 g/day* 
25 ml)
2 weeks Drinking water
2 weeks Subcutaneous 
injection 
2 weeks Drinking water
2 weeks Drinking water
3.2.3 Autopsy procedure and sample collection
After weighing each animal, they were anaesthetised with Sagatal (Pentobarbitone 
Sodium 60 mg/ml, Rhone Mérieux) by an intraperitoneal injection at a dose of 0.1 
ml/100 g of body weight. Once under anaesthesia blood was collected from the inferior 
vena cava into 2.5 ml plastic tubes with EDTA (TEKLAB) and carefully mixed in a 
rotary mixer until analysis. Slices of liver, kidney, spleen and heart were removed and 
fixed in 10% neutral buffered formalin for at least a week before being processed for 
histopathology (Chapter 4, section 4.2.2).
3.2.4 Blood cell counts
A count of red and white blood cells per unit volume of whole blood was performed 
using an automated Coulter Counter model ZM (Coulter Electronics, Ltd, U.K.). The 
result of this test is expressed in number of cells per unit volume.
• Reagents 
ISOTON II ® (Azide-fteee balanced 
electrolyte solution)
(Coulter Electronics Ltd, 
England)
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‘Zap-Oglobin’® (red blood cell lysing (Coulter Electronics Ltd,
reagent) England)
• Procedure
To count red cells 40 pi of whole blood was diluted into 20 ml of ISOTON II (Dilution 
1), and 100 pi of this dilution was added to another 20 ml of ISOTON II (Dilution 2) to 
obtain a 1:100,000 dilution. To count white cells 6 drops of Zap-Oglobin were added to 
dilution 1 (1:500) to lyse red cells and remain with white cells only. The manometer 
volume in the Coulter counter was of 500 pi and the orifice tube aperture diameter was 
of 100 pi.
Settings for the Coulter Counter:
Red Blood Cells White Blood Cells
Current (I) 500 100
Full-scale (mA) 1 10
Polarity + +
Lower threshold (TL) 10 12
Upper threshold (TU) 99.9 99.9
Attenuation (A) 1 2
Alarm threshold (MA) OFF OFF
Preset gain 2 2
Cell counts were scored for each sample at least twice and corrected to a final 
concentration of 1x10^  ^ for red cells and 1x10^ for white cells, according to the 
corresponding dilution factors.
3.2.5 Determination o f  Packed Cell VolumefPCV) or Haematocrit
Packed Cell Volume or haematocrit is a measure of the total volume of erythrocytes, 
relative to the total volume of whole blood in a sample. The results are expressed in 
volume units cL/L.
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• Procedure
Capillary tubes of 75 mm long and 1 mm of internal diameter were filled with a small 
volume of whole blood of each test sample, leaving approximately 15 mm unfilled. 
Capillary tubes were then sealed with CRITOSEAL® and spun down in a CAMLAB 
ALC 4223 centrifuge for 5 minutes. The length of the column of red blood cells was 
measured with a micro-haematocrit reader (MSE-Measuring and Scientific Equipment 
Ltd, U.K.) in relation to the length of the column of the total volume in the capillary 
tube.
3.2.6 Determination o f  Haemoglobin
Haemoglobin was determined by the Cyanmethaemoglobin Method (Dacie and Lewis, 
1995). Erythrocytes are lysed and haemoglobin (Hb) is released into a potassium 
cyanide and potassium ferrî cyanide solution (Drabkin’s reagent). Haemoglobin is then 
converted into a more stable substance, cyanmethaemoglobin (HiCN), and its 
absorbance is measured by spectrophotometry. The result is expressed as g/dl.
• Reagents
Drabkin’s cyanide-ferricyanide solution (Sigma)
Cyanmethaemoglobin standard 57.2 mg/100 ml (BDH-Merck Ltd)
• Procedure
A 20 pi volume of blood was diluted in 4 ml of Drabkin’s reagent, any excess of blood 
was carefully wiped off the pipette tip. Samples were thoroughly mixed and incubated 
at room temperature for 10 minutes. Subsequently the absorbance of the solutions was 
measured in a UVIKON 860 spectrophotometer, Kontron Instruments at a wavelength 
of 540 nm. A cyanmethaemoglobin standard and blank of Drabkin’s reagent were also 
measured to obtain a constant value for haemoglobin calculation in g/dl.
Calculation:
rrr  ^ absorbonce o f  blood sample , ,  ^Hb{g / dl) = ------      — ---------—  X 11.5
absorbance o f  the std
Where std equals standard.
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3.2.7 Reticulocyte determination
Reticulocytes are precursor forms of erythrocytes and can be distinguished by using a 
Brilliant Cresyl Blue solution.
• Reagents
Brilliant Cresyl Blue 1% (Raymond A. Lamb, U.K.)
Citrate-saline solution (freshly prepared and filtered):
Tri-sodium citrate (NagCeHsOT.ZHzO) (BDH)
Sodium Chloride (NaCl) (BDH)
• Procedure
Citrate-saline solution was prepared by mixing 1 part 3% w/v aqueous trisodium citrate 
with 4 parts of 0.9% w/v sodium chloride.
In LP3 tubes 3 drops of brilliant cresyl blue solution were incubated at 37°C for 1-2 
minutes. Subsequently 3 drops of fi*eshly mixed EDTA of blood were added, gently 
mixed with the colorant and incubated for 20 minutes at 37°C. After incubation and a 
gentle remix, one drop of the mixture was spread on a clean and previously identified 
glass slide as a film and quickly dried with a hair drier (dried films can be kept 
indefinitely) and later analysed by light microscopy.
Using a graticule microscope eye piece, reticulocytes were counted using a light 
microscope with xlOO oil-immersion objective in 20 consecutive fields and red blood 
cells (RBC) in 4 of the 20 fields (5"^ . 10*, 15* and 20*). The calculation of 
reticulocytes was determined as follows:
total number o f  reticulocytes counted
% reticulocytes = ---------------------     x 100
estimate o f  total number o f  RBC
Calculation of the total number of RBC:
No. RBC in sample fields x total No. fields scanned 
No. sample fields counted
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Finally by using the Total Red Blood Cell count, the Absolute Reticulocyte count was 
calculated.
3.2.8 Preparation o f  bloodfilms
Using previously identified clean glass slides a blood smear was performed with a drop 
from each sample. Slides were quickly dried with a hair drier and then fixed in 
methanol for 10 minutes. After fixation slides were left to diy before staining with May- 
Grunwald/Giemsa staining method (fixed films can be kept indefinitely before staining).
3.2.9 Leukocyte differentiation and erythrocyte morphology evaluation by May- 
Grunwald/Giemsa staining method
Using the May-Grunwald/Giemsa (GIBMSA) staining method leukocyte differentiation 
and erythrocyte morphology was performed by light microscopy. The different white 
cells (neutrophils, lymphocytes, monocytes, and eosinophils) were scored using a Hagar 
International HE 120 differential leukocyte counter, and the total white cell counted was 
corrected for normoblast if  necessary. Red cell morphology was analysed to determine 
any changes in size, shape and colour.
• Reagents
Sorensen’s Phosphate Buffer (0.066M stock solution):
(A) Naz HPO4 (9.46 g/L) -  30 ml + (B) KH2PO4 (9.07 g/L) -  70 ml diluted
up to 1 litre of distilled water.
May-Grunwald stock solution (BDH.)
Giemsa stock solution (BDH)
Distilled water
• Procedure
Fixed film samples were transferred to May-Grunwald stain, freshly diluted with a 1:1 
7v of buffered distilled water for 5 minutes. After draining, the slides were transferred 
to the Giemsa stain, freshly diluted with 9 volumes of buffered distilled water for 10 
minutes. Finally slides were transferred to buffered distilled water and washed rapidly 
in 2 changes allowing differentiation for approximately 2 minutes in the second change
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before a quick rinse in a third change. Slides were drained and let to dry until 
examination by light microscopy at XlOO oil-immersion objective to carefully evaluate 
the appearance of red and white blood cells.
The results of all the haematological parameters measured are expressed as the mean of 
n = 5 ± S.D. Data was analysed with Student’s unpaired t test, where P < 0.05 was 
considered significant.
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3.3 RESULTS
3.3.1 Haematological toxic effects after casiopeina II administration
Values of haematological parameters of treated animals were compared with those from 
control groups kept under the same conditions. The experiments to evaluate the 
haematological effect of casiopeina II treatment were performed in triplicate. Values of 
control groups found were similar with reference values found in Sanderson and 
Phillips (1981) and Smith et a l (1994) for the different haematological parameters 
measured.
The major haematological effect of the intravenous administration of casiopeina II at a 
dose of 5 mg/kg resulted in a considerable reduction of haemoglobin concentration 
(Hb), red blood cell count (RBC) and packed cell volume (PCV) as shown in Table 3.1. 
After 12 hours of administration a slight decrease was detected, however the most 
significant and considerable reduction was observed 5 days after the administration. 
Following the haematological effect up to 15 days, values of Hb, RBC and PCV were 
found to be similar to those in the controls.
Abnormalities in red cell morphology were observed following the administration of 
casiopeina II. The early effects observed at 12 hours, were severe changes in the 
morphology of erythrocytes when compared to those in the controls (Figure 3.1). A 
severe anisocytosis and poikilocytosis, with the presence of echinocytes (‘burr cells’) 
and spherostomatocytes (‘spherocytes’) was observed (Figure 3.2). Five days after 
casiopeina II administration a marked polychromasia in red cells was detected together 
with a mild anisocytosis and poikilocytosis. In addition presence of normoblasts, 
immature red blood cells that are not normally found in circulating blood, were detected 
5 days after the administration (Figure 3.3). Following the changes in red cell 
morphology up to 15 days after dosing a slight polychromasia was still observed, 
however erythrocyte morphology was similar to that from controls (Figure 3.4).
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Table 3.1. Peripheral blood haematology (Hb, RBC, PCV) of control and casiopeina II 
treated W/A rats. Haematological parameters were evaluated at three different time 
points after administration (12 hours, 5 and 15 days). * P < 0.05. Abbreviations: Hb = 
Haemoglobin; RBC = Red Blood Cells; PCV = Packed Cell Volume. Results are 
means ± SD for n = 5.
Hb(g/dl) RBC (10^^/L) PCV(cL/L)
REFERENCE
VALUE
(Sanderson and 
Phillips, 1981)
13.6-16.2 6.57-8.00 37.7-46.0
CONTROL Experiment 1 17.2 ±1.1 7.8 ±0.3 44.4 ±2.3
Experiment 2 15.1 ± 0.5 8.3 ±0.3 45.0 ±1.9
Experiment 3 15.0 ±0.7 7.9 ±0.3 45.4 ±1.8
12 HOURS Experiment 1 17.1 ± 1.7 7.6 ±0.7 44.4 ±4.8
Experiment 2 15.1 ±1.2 8.2 ± 0.4 44.2 ± 3.5
Experiment 3 12.8 ±0.8* 6.7 ±0.5* 37.2 ±3.4*
5 DAYS Experiment 1 13.9 ±1.6* 5.5 ±0.6* 38.2 ±2.2*
Experiment 2 8.9 ±1.2* 4.1 ± 0.8* 28.5 ±2.4*
Experiment 3 9.6 ±1.8* 5.3 ± 0.5* 33.2 ±3.6*
CONTROL Experiment 3 14.5 ±0.1 8.3 ± 0.2 46.0 ±0.7
15 DAYS Experiment 3 14.5 ±0.9 6.2 ±0.8* 46.0 ±0.7
97
Chapter 3. Haematological Effects
Erythrocyte morphology in rat peripheral blood (GIEMSA stained, overall 
magnification xl050)
Figure 3.1. N orm al erythrocytes from  a control rat.
Figure 3.2. Erythrocyte m orp h ology  12 hours after in travenous adm inistration  o f  
ca sio p e in a  II. S evere a n iso cy to s is  and p o ik ilo cy to s is , presence o f  sp h erostom atocy tes  
( ‘sp h ero cy tes’) and ech in o cy tes  ( ‘burr c e l ls ’) can be observed .
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m
Figure 3.3. C hanges in erythrocyte m orp h ology  5 days after in travenous adm inistration  
o f  casio p e in a  II. M arked p o lych rom asia , m ild  a n iso cy to sis  and p o ik ilo c y to s is , presen ce  
o f  norm oblasts (im m ature erythrocyte) can be observed .
Figure 3.4. R ed ce ll m orp h ology  15 days after intravenous adm inistration  o f  
casio p e in a  II. A  sligh t p o lych rom asia  in red c e lls  can be observed.
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A sum m ary o f  w h ite  ce ll d ifferentiation  after the adm inistration o f  ca sio p e in a  II is 
sh ow n  in T ab le 3.2 . V alu es from  the control groups vary b etw een  exp erim en ts, 
h ow ever they are all in accordance w ith norm al va lu es found in Sanderson and P h illips  
(1 9 8 1 )  and Sm ith et al. (1 9 9 4 ). D ata reveals a sign ifican t increase in w h ite  b lood  ce ll 
count (W B C ), i.e. leu k o cy to sis , 12 hours after the adm inistration  o f  ca sio p e in a  II. 
L eu k ocytosis  persisted  5 days after adm inistration  o f  ca sio p ein a  II, but recovered  by 15 
days w h en  the w h ite  ce ll count dropped to sim ilar va lu es to th ose  ob served  for the  
control groups. F igure 3 .5  illustrates the d ifferent w hite  ce ll types, neutrophil, 
lym p h ocyte , m o n o cy tes  and eo sin o p h ils  in rat peripheral b lood.
%
Figure 3.5. Rat peripheral b lood  stained w ith  G IE M SA  and ob served  under light 
m icroscop y  at xlOO. C ontrol sam p le, norm al erythrocytes, neutrophil and lym p h ocyte  
(top ), m on ocyte  (right b ottom ) and eosin op h il (le ft bottom ) can be observed .
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The leukocytosis was characterised by a marked increased in neutrophil ratio 
(neutrophilia) 12 hours after the administration of casiopeina II. At 5 days a reduction 
in the neutrophil count was observed, although it remained higher than the one from the 
controls. After 15 days the values detected showed that the neutrophil count dropped 
down to control values. A marked increase in lymphocytes (lymphocytosis) was 
observed 5 days after the administration of casiopeina II. No significant changes in 
lymphocyte count were observed 12 hours after the administration and at 15 days values 
are similar to the ones from the controls. Figure 3.6 illustrates neutrophil and 
lymphocyte differences after the administration of casiopeina II.
lymphocytes 
—o  ■ neutrophils
10 1
up p e r  lim it o f  c o n tro l10 VL
low er lim it o f  c w t r o l
'  _WPP%Llimit o f ^ Q t r Q ( ^
-  — -  -  — -  -  —— -  —  -  —  C D -  
low er lim it o f  c o n tro l
Control 12 hours 5 days 15 days
Figure 3.6. Mean neutrophil and lymphocyte count changes in time after intravenous 
administration of casiopeina II (data from Experiment 3). Each time point represents 
the mean of n = 5 ± S.D.
As with the lymphocyte count, monocyte values were found to have a considerable 
increase 5 days after the administration of casiopeina II. At 12 hours no significant 
change was detected and at 15 days values are within normal range. No significant 
changes were detected in the eosinophil count post administration of casiopeina II.
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Some increase in reticulocyte levels, erythrocyte precursors, was observed 12 hours 
after the administration of casiopeina II. However a major and more significant 
increase in absolute reticulocyte count was observed 5 days after the administration of 
casiopeina II together with an increase in spleen weight and size, when compared with 
the absolute reticulocyte count and spleen weight from controls (Figure 3.7). At 15 
days the reticulocyte count and spleen weight from treated animals recovered to normal 
values. Figures 3.8, 3.9, 3.10 and 3.11 show the increase in reticulocyte count after the 
administration of casiopeina II in peripheral blood stained with 1% Brilliant Cresyl 
Blue.
□  Spleen weight 
2 T  ■  Absolute Reticulocytes
1.6 4-
1.2 -  
0.8 - -  
0.4 -  
0 É
Control 12 hours 5 days 15 days
T  2 
1.6 
-  1.2 
- -  0.8 
0.4 
0
io^Vl
Figure 3.7. Absolute reticulocyte count and spleen weight of control and after the 
administration of casiopeina II at 12 hours, 5 days and 15 days. Each time point is the 
mean of n = 5 ± S.D. * = P < 0.05.
Between a 3 to 11% of normoblasts were observed 5 days after the administration of 
casiopeina II (Figure 3.3). The presence of normoblasts together with the increase in 
absolute reticulocyte count and spleen weight is suggestive of an effective 
erythropoiesis.
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Rat peripheral blood, 1% brilliant cresyl blue stain (overall magnification xH)50)
Figure 3 .8 . N orm al red ce lls  and reticu locy tes sta in ed  w ith 1% brilliant cresy l blue.
Figure 3 .9 . S ligh t increase in reticu locytes 12 hours after the adm inistration  o f  
casio p ein a  11.
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F ig u r e  3 .1 0 . M arked increase in reticu locyte  num bers, a lm ost all c e lls  are reticu locy tes  
after 5 days o f  adm inistration  o f  ca sio p ein a  II.
F ig u r e  3 .1 1 . A fter 15 days o f  adm inistration  o f  casiop e in a  II so m e reticu lo cy tes  are 
observed.
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A considerable and significant body weight loss was observed after the intravenous 
administration of casiopeina II reaching a nadir at 4 days. Recovery in weight gain can 
be observed in the following 15 days, however animals treated with casiopeina II gained 
less weight than controls (Figure 3.12).
400 1- - A  - 5 DAYS TREATEDCONTROL
380 - - -15 DAYS TREATED- o  - CONTROL
360 -
—6
340 -
320 --
- o -
300 -
280 -
260
DAYS
F igu re  3.12. Effect on weight gain after intravenous administration of casiopeina II in 
rats. The data presented corresponds to Experiment 3. Each time point represents the 
mean of n = 5 ± S.D.
The above data shows evidence of an haematotoxicity associated to the intravenous 
administration of 5 mg/kg casiopeina II to W/A rats. Reduction of Hb, PCV and RBC, 
accompanied by an increase in leukocyte numbers and a responsive augment of spleen 
weight and reticulocytes levels, as well as the presence of normoblasts in peripheral 
blood were observed. The haematotoxic damage detected mainly by the reduction in 
haematological parameters from casiopeina 11 administration appears to take place 
during the first 12 hours after injection, and consequently aggravates 5 days post 
administration. The haematological effect induced by casiopeina II appears to show 
some recovery 15 days after administration.
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3.3.2 Dose response haematological effect associated to casiopeina II intravenous 
administration
The most significant haematological damage due to casiopeina II intravenous 
administration was observed 5 days after injection, however evidence of the 
haematological effect inferred by casiopeina II is also observed at the earlier 12-hour 
time point. Casiopeina II was administered intravenously in an increasing dose scheme 
of 1, 3 and 5 mg/kg for 12 hours in order to evaluate the early haemolytical effect 
according to the dose administered.
Haemoglobin concentration, RBC and PCV were significantly reduced after the 
administration of casiopeina II at the highest dose of 5 mg/kg. With 3 mg/kg of 
casiopeina II a significant reduction in PCV was also observed, however Hb and RBC 
appear to have no significant changes. Additionally with 1 mg/kg of casiopeina II no 
significant changes were detected (Figure 3.13). The response in white blood cell count 
to a dose scheme after 12 hours of casiopeina II administration, resulted in a significant 
leukocytosis with the 5 mg/kg dose of casiopeina II when compared to WBC from 
controls. A slight but insignificant increase in WBC was observed with 3 mg/kg of 
casiopeina II (Figure 3.14).
Absolute reticulocyte count and spleen weight after the administration of 1, 3 and 5 
mg/kg of casiopeina II at 12 hours revealed a marked increase in absolute reticulocyte 
count and spleen weight with the highest dose of 5 mg/kg (Figure 3.15).
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Figure 3.13. Haematological response to dose scheme of 1, 3 and 5 mg/kg of 
casiopeina II for 12 hours in the rat. * = P < 0.05. Each time point is the mean of n = 5 
±S.D.
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W hite Blood Cell Count
lOVL
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Figure 3.14. Response of WBC 12 hours after casiopeina II administration. * = P < 
0.05. Each time point representsthe mean of n = 5 ± S.D.
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Figure 3.15. Response of absolute reticulocyte count and spleen weight after the 
administration of 1, 3 and 5 mg/kg of casiopeina II at 12 hours. Each time point is the 
mean of n = 5 ± S.D. * = P < 0.05.
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3.3.3 Effect o f  age in casiopeina 11-induced haematotoxicity
Intravenous administration of casiopeina I I 5 days post-administration produced a minor 
haematological effect in 6-week old rats (‘young’) of 250 g of body weight, in contrast 
with the significant (P<0.05) effect on haematological values that have already been 
described for 10-week old rats (‘old’) in section 3.3.1. The haematological effects 5 
days after the administration of casiopeina II described in this section refer to values of 
‘young’ rats against the values obtained for ‘old’ rats. Although 10-week old rats are 
not necessarily old, for technical reasons they were called ‘old’ due to the fact that they 
were chosen of this age because they would have had already reached a steady plateau 
of reticulocyte levels. In contrast with 6-week old rats ‘young’ which still have a high 
reserve of reticulocytes (Benirschke et a l, 1978).
A slight and insignificant reduction was observed in Hb levels after the administration 
of casiopeina II when compared to young controls (Figure 3.16). Moreover no 
significant changes were observed in PCV values 5 days after the administration of 
casiopeina II in young animals, instead of a reduction, a slight increase was observed in 
casiopeina II treated group. A similar trend in RBC was observed 5 days after the 
administration of casiopeina H, a slight, insignificant increase detected in the treated 
group when compared to the control group (Figure 3.16). A minor increase in 
leukocyte values in young treated animals 5 days after the administration of casiopeina 
II was observed, when compared to control ‘young’ rats (Figure 3.17). Absolute 
reticulocyte count measured 5 days after the administration of casiopeina II in young 
treated rats showed a very slight increase from the ‘young’ control rats, compared to the 
major increase found in the absolute reticulocyte count observed in ‘old’ rats (Figure 
3.18).
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F igu re  3.16. Haemoglobin concentration, PCV and RBC from rats of two different age 
groups after 5 days of casiopeina II administration. The three parameters show minor 
changes in young animals compared with the effect in blood haematology of old 
animals.
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Figure 3.17. White blood cell count in young and old rats, control and 5 days after the 
administration of casiopeina II. A slight increase in WBC was observed in young 
animals when compared to the significant increase observed for old animals.
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Figure 3.18. Absolute reticulocyte count in young and old rats, control and 5 days after 
the administration of casiopeina II. A slight increase in reticulocytes in young animals 
was observed and was not significant in contrast with the marked increase observed for 
old animals.
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3.3.4 Amelioration o f  casiopeina 11-induced haematotoxicity
To ameliorate the haematotoxic effect of casiopeina II a pretreatment with penicillamine 
and trientine was administered. Additionally the effect of erythropoietin pretreatment 
and ascorbic acid before casiopeina II administration were also evaluated (as described 
in Section 3.2.2). Table 3.3 shows the different agents tested with casiopeina II 
treatment.
Table 3.3. Agents tested to evaluate the haematotoxic effect of casiopeina n.
Compound Pretreatment Casiopeina II treatment
Penicillamine D (PENICILL.) 9 days 12 hours
Trientine (TRIEN) 15 days 24 hours
Erythropoietin (EPO) 15 days 24 hours
Ascorbate (As A) 15 days 24 hours
Pretreatment with two different copper chelators, penicillamine and trientine, was tested 
with the intention of ameliorating the haematological effects caused by the intravenous 
administration of casiopeina II at 12 and 24 hours time points respectively. In general 
penicillamine pretreatment had no significant improvement on haematological 
parameters after casiopeina II treatment except in the case of RBC, when a considerable 
and significant increase was observed, suggesting some potential amelioration with the 
use of penicillamine. In contrast Hb, PCV and absolute reticulocyte count showed no 
difference with penicillamine pretreatment after casiopeina It administration. A marked 
leukocytosis was observed after the administration of casiopeina II with and without 
penicillamine pretreatment (Figure 3.19). Although some improvement of the effect on 
RBC was observed, PCV, Hb, reticulocyte levels and WBC showed no evidence that 
the haematotoxic effect of casiopeina II was avoided with penicillamine pretreatment.
Pretreatment with trientine had no significant improvement in the haematological effect 
post-administration of casiopeina It. Reduction of Hb, RBC and PCV was detected 
with and without trientine pretreatment as well as a marked leukocytosis (Figure 3.20).
113
Chapter 3. Haematological Effects
No improvement of the effect in absolute reticulocyte count after casiopeina II 
administration was observed with trientine pretreatment. Additionally a higher 
reticulocyte count was observed Avith trientine pretreament. However more than a 
higher increase with trientine pretreatment and casiopeina II a lower reticulocyte 
response in the casiopeina II group was detected.
Enhancement of eiythropoiesis by erythropoietin pretreatment resulted in a significant 
improvement of all the haematological effects after the administration of casiopeina II. 
Haemoglobin concentration, RBC and PCV after casiopeina II administration showed a 
marked increase with erythropoietin pretreatment when compared to the marked 
reduction in haematological parameters caused by casiopeina II administration. 
Additionally pretreatment with erythropoietin only, also revealed a significant increase 
in the haematological parameters (Figure 3.21). Furthermore a considerable 
leukocytosis was observed with and ^vithout erythropoietin treatment with a marked 
neutrophilia in the casiopeina II treatment group, which was not significant in the 
erythropoietin pretreatment group (Figure 3.22). When compared to casiopeina II 
treated group without erythropoietin pretreatment the absolute reticulocyte count 
showed a considerable increase in reticulocyte levels after casiopeina II administration 
in the erythropoietin pretreatment group (Figure 3.23).
Ascorbic acid pretreatment had no significant effect on the haematological response to 
casiopeina II treatment, however some improvement in RBC was detected with ascorbic 
acid pretreatment after casiopeina II administration. A marked leukocytosis was 
observed after casiopeina II treatment in the presence and absence of ascorbic acid. 
Absolute reticulocyte counts showed no changes with and without ascorbic acid 
pretreatment (Figure 3.24). Therefore although some improvement in RBC was 
detected after administration in the presence of ascorbic acid the haematotoxic effect 
induced by casiopeina II treatment was still observed.
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Figure 3.19. Effects o f penicillamine pretreatment on haematological parameters 12
hours after the administration of casiopeina II. Each time point is the mean of n = 5 ±
S.D. * = P<0.05  CONT vs. CII. ** P = <0.05 CII vs. CII+PENICILLAMINE.
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Figure 3.20. Effect of trientine pretreatment on haematological parameters 24 hours
after administration of casiopeina II. Each time point represents the mean o f n = 5 ±
S.D.
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Figure 3.21. Haematological effect after casiopeina II administration in rats with 
erythropoietin and iron pretreament. * = P < 0.05 CONT vs. CII. ** P = <0.05 CII vs. 
CII+EPO. Each time point is the mean of n = 5 ± S.D.
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Figure 3.22. White blood cell count after the administration of casiopeina II with and 
without erythropoietin pretreatment. * = P < 0.05 CONT vs. CII. ** P = <0.05 CII vs. 
CII+EPO. Each time point represents the mean of n = 5 ± S.D.
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Figure 3.23. Absolute reticulocytes count after casiopeina II administration in rats with 
and without erythropoietin and iron pretreament. * = P < 0.05 CONT vs. CII. ** P = 
<0.05 CII vs. CII+EPO. Each time point is the mean of n = 5 ± S.D.
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Figure 3.24. Effect of ascorbic acid pretreatment on haematological parameters after
24 hours of the administration of casiopeina II. Each time point is the mean of n = 5 ±
S.D. * = P < 0.05 CONT vs. CII. **P  = <0.05 CII vs. CII+AsA.
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3.4 DISCUSSION
Data presented in this chapter generally leads to the conclusion that the major toxic 
effect on haematology from the intravenous administration of casiopeina II was 
haemolytic anaemia in the rat (10-week old rats). This was manifested as a reduction in 
haemoglobin concentration, red blood cell coimt and packed cell volume, which were 
significantly lower when compared to those from controls (Figure 3.25). Moreover a 
severe leukocytosis and neutrophilia were also associated with the toxic effect after the 
administration of casiopeina II, which have been reported as characteristic features that 
accompany haemolytic anaemia (Williams et a l, 1983). Appreciable changes in red 
cell morphology reveal an early damage to red blood cells after the administration of 
casiopeina II, the presence of burr cells and spherocytes in peripheral blood 12 hours 
after administration indicate severe haemolysis (Williams et a l,  1983). The haemolytic 
anaemia caused by the administration of casiopeina II can be attributed to direct 
erythrocyte oxidative damage by casiopeina II or its copper component, due to the 
ability of copper to oxidise proteins and lipids through ROS production from the 
reduction of Cu(II) to Cu(I). The toxic haemolytic effect observed with casiopeina II 
correlates with reports which indicate that copper can exert damage to membranes or 
macromolecules due to its reduction-oxidation activity and that erythrocytes are a main 
target of copper-induce^damage (Sree Kumar et a l, 1978; Sansinanea et a l, 1996; 
Bremner, 1998). In addition acute haemolytic toxicity and tissue hemorrhage and 
necrosis from copper excess has been reported in rabbits, dogs and rats, a similar acute 
haematotoxicity was observed in rats treated with casiopeina II (Rolfe and Twedt, 1995; 
Cooper et a l, 1996; Giuliodori et a l, 1997).
The major increase observed in absolute reticulocyte levels together with the presence 
of normoblasts in peripheral blood 5 days after casiopeina II administration, indicate an 
effective erythropoiesis in 10-week old rats (Figure 3.25). Reduction in haemoglobin 
concentration and changes in urine colour (data not shown) of animals treated with 
casiopeina II confirm the breakdown of erythrocytes (Hoffbrand and Pettit, 1998). 
Damaged erythrocytes are processed by the reticulo-endothelial system (RES) of the 
spleen, thus accounting for the increase in spleen weight and size. The rise in spleen 
weight and the increase in reticulocyte production correlates with the erythropoietic role
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of the spleen in the rat (Weiss, 1983 ; Rosse, 1987). Increase in spleen weight and size 
has been reported as a response to an haemolytic toxicity from oral and intraperitoneal 
administration of a Cu(II)-levamisole complex in rats (Kovachev et a l,  1994).
Consequent to the administration of casiopeina II a 7% reduction in body weight was 
observed 4 days after administration when compared to the control, but increased over 
the following 15 days indicating recovery. This improvement correlates with the 
recovery observed in haematological parameters, haemoglobin concentration, RBC and 
PCV at 15 days, suggesting that casiopeina II induced an acute haematotoxic effect with 
no delayed or permanent toxic effect being produced.
] Absolute Reticulocytes 
•PCV cL/L 
-RBC 10 12/L
] Spleen weight 
-Hb g/dl
T  3
cL/L
g/d l 25 - -  1.5
12 hoursControl 5 days 15 days
Figure 3.25. Summary of peripheral blood haematological parameters (Hb, PCV, 
RBC) and erythropoietic indicators (spleen weight and reticulocyte levels) after 
casiopeina II administration.
The haemolytic damage in a dose response mode correlates with the dose scheme of 
administration of casiopeina II. The haematotoxic damage 12 hours after administration 
was observed with 5 mg/kg of casiopeina II, a reduced haemolytic damage was 
observed with a 3 mg/kg dose and apparently no effect with I mg/kg of casiopeina II. 
Thus the lack of haemolytic damage with the lowest dose (1 mg/kg) suggests that this 
dose could represent a no observed adverse effect level (NOEL) dose. A 1 mg/kg dose
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of casiopeina II administered in a repeated dose scheme could be used to evaluate a 
long-term toxicity of casiopeina II (or any other member of the casiopeinas series). 
Perhaps the toxic effect would not be an acute haematotoxic effect, however it could 
still affect haematological parameters as well as resembling a chronic copper overload 
in tissues.
No significant haemolytic toxic effect from casiopeina II administration was observed 
in young (6-week old) rats whereas older (10-week old) rats presented a severe 
haemolytic damage. This difference could be attributed to the turnover of erythrocyte 
life span. In older rats more erythrocytes could be reaching an older stage, thus being 
more susceptible to damage whereas in younger rats erythrocytes would be in an earlier 
stage of their life span an thus stronger and less susceptible to damage (Benirschke, 
1978). Additionally the high reticulocyte count observed in control young rats is also 
due to the short life span of the erythrocyte in the rat.
Some improvement in RBC was detected with penicillamine pretreament against the 
haemolytic effects caused by casiopeina II administration, however no significant 
improvement of the overall haematotoxic damage was observed with the copper 
chelators, penicillamine or trientine. This could be explained by the fact that these two 
copper chelators remove abnormal copper accumulated from the liver and facilitate its 
excretion via urine, whereas the attributable haematotoxicity caused by casiopeina II- 
copper occurs promptly in circulating erythrocytes (Togashi et a l, 1992; Sone et a l, 
1996).
In the practice the use of erythropoietin treatment has been proposed to improve the 
overall condition of cancer patients during cancer therapy as well as to ameliorate an 
anaemic condition caused by chemotherapeutic agents (Abels, 1993). The promotion of 
red blood cells by erythropoietin contributed to ameliorate the overall toxicity from 
casiopeina II although some haemolysis still occurred. The stimulation of red blood cell 
reserves with erythropoietin pretreament before casiopeina II administration resulted in 
some improvement in haemoglobin concentration, RBC and PCV. The increase in red 
blood cell reserves could be an equivalent condition to the ‘young ra f, where 
erythrocytes are in an earlier stage of their life span and are less susceptible to injury.
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No significant, pro- or anti- oxidant, effect in the overall haematological damage from 
casiopeina II treatment was observed with ascorbic acid pretreament, although a slight 
increase in RBC was detected. If casiopeina Il-attributable copper ions came into 
contact with ascorbic acid some pro-oxidant effects could occur, however the 
presumambly dominating antioxidant effects of ascorbic acid in vivo could mask the 
pro-oxidant effects, a scenario that has been proposed for intracellular low-molecular- 
mass iron ‘pools’ (Halliwell and Gutteridge, 1998).
In view of the above it is concluded that the major toxic effect observed after 
casiopeina II administration is haemolytic anaemia, due to casiopeina II or its copper 
component probably by the generation of ROS, in W/A rats. The recovery observed in 
haematological parameters 15 days after administration indicates an acute toxic effect 
caused by casiopeina II, however the effect does not last and later results in an adaptive 
responsive erythropoiesis. Some amelioration of the toxic effect was achieved with the 
use of erythropoietin and older rats appear to be more susceptible to the toxic effect 
from casiopeina II.
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CHAPTER 4. PATHOPHYSIOLOGY OF ADVERSE 
EFFECTS OF THE SPTÆEN ASSOCIATED WITH 
THE INTRAVENOUS ADMINISTRATION OF 
CASIOPEINA II IN THE RAT
124
Chapter 4. Pathophysiology o f the spleen
4.1 INTRODUCTION
In mammals the spleen is a reticuloendothelial organ that functions essentially as a filter 
for blood cells, infectious agents, particles and blood macromolecules (Moghimi, 1995). 
In humans the spleen also participates in immunological processes by storing T and B 
lymphocytes (Weiss, 1983 ). In some animal species, such as the rat, the spleen has a 
normal haematopoietic function and serves as a reservoir of blood cells that may be 
recruited as a response to an increased demand (Rosse, 1987).
The spleen has a unique vascular structure constituted by white pulp and red pulp. The 
white pulp is mainly formed by the aggregation of lymphocytes surrounding arterioles, 
called peripheral periarteriolar lymphoid sheath (PALS), and a marginal zone with 
marginal sinuses and germinal centres. Additionally to lymphocytes other cells such as 
histiocytic cells, macrophages and monocytes, and dendritic cells are also present within 
the white pulp (Greaves, 1990). The red pulp constitutes most of the splenic volume, 
being composed of splenic sinuses, thin walled large blood vessels which contain 
erythrocytes, lined by the splenic cords, cellular tissue composed of macrophages and 
endothelial cells which facilitate the disposal of damaged or aged red cells (Weiss, 
1983 ). Through the passage of blood between the splenic cords and back into 
circulation the removal of erratic or unwanted cells and intracellular inclusions takes 
place (Rosse, 1987). Moreover during haematopoiesis the red pulp expands in response 
to an increased demand for red blood cells (Greaves, 1990).
Slight morphological changes in the spleen can be manifested from the effects of drugs 
or chemicals on the haematopoietic and lymphoid system, and the measurement of 
splenic weight in rodents can serve as a guidance for treatment-related response to 
xenobiotics (Greaves, 1990). Compounds that have a direct effect on red blood cells 
enhance the production of erythropoietic cells in the spleen. Reports on the toxicity of 
the byproducts from the herbicide dichloroaniline, tetrachloroazobenzene and 
tetrachloroazoxybenzene, caused responsive anaemia as one of the major toxic effects in 
rats; as a response to erythrocyte damage there was an increase in haematopoietic cell 
proliferation in the spleen (Van Birgelen et a l, 1999a; Van Birgelen et a l, 1999b). 
Haematotoxicity and increase in spleen weight were observed as a response to the 
subchronic exposure to gamma-cyclodextrin in rats, cyclodextrins are cyclic
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oligosaccharides commonly used in food, pharmaceutical preparations and cosmetic 
products due to its high solubility and stability (Donaubauer et a l, 1998).
In conjunction with the observations described in Chapter 3 of the haematotoxic 
response to casiopeina II it was considered important to look specifically at the 
pathophysiological effects in the spleen, together with the fact that the spleen plays a 
major haematological role in the rat.
4.2 MATERIALS AND METHODS
4.2.1 Experimental design, casiopeina II administration, autopsy and sample 
collection
At autopsy spleens were collected for histopathology at 12-hour, 5 days and 15-days 
post casiopeina II administration to assess spleen response in an acute and at long-term 
points, as well as the progression of the effect. In addition tissues from rats of two age 
groups, ‘young’ (6-week old) and ‘old’ (10 week old) were also evaluated at 5 days, 
which represents the peak of the lesion in the spleen. Benirschke and collaborators 
(1978) report old age in Wistar/Albino rats at 108 weeks old. However for technical 
reasons in this study 10-week old rats have been chosen as ‘old’ due to the fact that 
reticulocyte levels have reached a steady plateau at this age even though 10-week old 
rats are note necessarily ‘old’. In contrast with 6-week old rats which still have a high 
reserve of reticulocytes. Animal husbandry and casiopeina II administration were 
performed as described in Chapter 3 Section 3.2.1 and 3.2.2.
Under anaesthesia as described in Chapter 3 Section 3.2.3 tissues (liver, kidney, spleen 
and heart) from each animal were removed and slices were cut and fixed in 10% neutral 
buffered formalin for at least a week before being processed for wax embedding.
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4.2.2 Light Microscopy 
■ Specimen preparation
Tissues were embedded in paraffin wax by cutting a slice of 2-3 mm thick from each 
one and placed into a previously identified embedding cassette. The cassettes were 
placed into a metal tissue basket, which was then fitted to the Histokinett automatic 
tissue processor (British American Optical Co. Ltd, Slough, England). In the 
Histokinett tissues were transferred automatically from one beaker of reagent to the 
next. The process of dehydration, clearing and wax impregnation was performed as 
follows:
Beaker Process Content TIME (hours)
1 Fixation 10% formalin 1
2 Dehydration 70% alcohol 1
3 Dehydration 80% alcohol IV2
4 Dehydration 90% alcohol 1%
5 Dehydration 100% alcohol 2
6 Dehydration 100% alcohol 2
7 Dehydration 100% alcohol 2
8 Clearing Toluene 1
9 Clearing Toluene 1%
10 Clearing Toluene 214
Wax bath 1 Wax impregnation Molten paraffin wax 60°C 3
Wax bath 2 Wax impregnation Molten paraffin wax 60°C 3
Once the process was completed, the tissue sample cassettes were embedded with 
paraffin in an appropriate sized metal mould using a Tissue-TEK 11 embedding centre. 
After embedding wax blocks were mounted in a Rotary Microtome (R. Jung Rotary 
Microtome, West Germany) and sections of 5pm from each block were cut. Sections 
were then floated in a water bath with distilled water and mounted in clean glass slides 
to let dry on a hot plate at 55°C for 1 to 3 hours. The sections were either immediately 
stained or stored in a dust free dry environment for further staining.
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■ Haematoxilyn and Eosin (H/E) staining 
Procedure
Sections were dewaxed, dehydrated, and stained with the conventional 
Haematoxylin/Eosin method as in Culling (1974). After mounting sections with DPX 
in glass slides they were examined and photographed under light microscopy.
■ Toluidine Blue staining 
Procedure
Sections from epoxy resin were cut for light microscopy and stained with toluidine blue 
as described in Lewis and Knight, 1977.
4.2.3 Electron Microscopy (EM)
■ Specimen preparation
Reagents
Glutaraldehyde EM 
Sodium Cacodylate buffer 
((CH3)2AsO2Na.3H20)
Osmium tetraoxide 
Alcohol (Ethanol)
Propylene Oxide
TAAB Embedding Resin Kit ®
Uranyl Acetate
Lead Nitrate and trisodium citrate
25 % stock fixation buffer 
0.2 M stock
4 % stock 
100, 90, 75, 50 and 25%
(TAAB)
(TAAB)
(BDH) 
(BDH) 
(Fischer Scientific) 
(TAAB)
2%
3%
Procedure
The spleen from each test individual was excised and cut into 1-2 mm pieces vvdth a
scalpel blade and fixed in 4% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) and
stored in a 5 ml screw capped glass vial. Spleen samples were fixed for 2 to 4 hours
128
Chapter 4. Pathophysiology o f the spleen
minimum at room temperature. After fixation the samples were washed several times 
with cacodylate buffer 0.1 M (pH 7.4) over a period of 1 hour. The solution was then 
decanted off and the samples were counter fixed with 2% osmic acid in 0.1 M 
cacodylate (pH 7.4) at room temperature in a fume cupboard for 1 to 2 hours. The 
samples were then dehydrated through the alcohol series: 2 changes of 10 minutes in 
each alcohol at a concentration of 25%, 50%, 75%, 90% and 100% (absolute ethanol) 
7v.
After the dehydration process the samples were put into 2 changes of 10 minutes each in 
a 1:1 mixture of propylene oxide and absolute ethanol solution and 2 changes of 10 
minutes each in propylene oxide. Tissues were then covered with a mixture of 1:1 
propylene oxide and TAAB Embedding Resin® for 20 minutes minimum. Small 
blocks (2-3) of tissue were then transferred to resin filled capsules, and left at room 
temperature for 4 hours. The samples were polymerised in resin for 24 hours at 60 
degrees centigrade before sectioning.
Sections of 80 nm were cut using an OmUg ultramicrotome (C. Ceichert, Austria), 
mounted in a copper grid and placed in a numbered grid box ready to be counterstained. 
The sections were counterstained with 2% uranyl acetate and 3% lead citrate. Sections 
were observed and photographed using a Philips 400T transmission microscope.
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4.3 RESULTS
4.3.1 Pathophysiological effects o f  casiopeina II on the spleen
The pathophysiological response of the spleen after the intravenous administration of 
casiopeina II was evaluated at 12 hours, 5 days and 15 days after injection. Firstly the 
spleen weights of untreated and treated animals were compared, as an indicative 
response of the spleen to haematotoxicity. Subsequently the histopathology of spleen 
was evaluated together with fine morphology using electron microscopy to assess 
changes after casiopeina II treatment. In addition the same pathophysiological 
parameters in the spleen were evaluated in ‘young’ (6 weeks) and ‘old’ (10 weeks) rats. 
Additionally because there was not any significant pathology observed in the kidney 
and liver, these organs were not processed for fine morphology by electron microscopy 
and are not shovm.
Over the period of 0 to 15 days, after intravenous administration of casiopeina II the 
only significant change in the spleen weight was observed at 5 days (Figure 4.1).
2 - r
1.6 —
1.2 -
0.8 -
0.4
Spleen weight
Control 12 hours 5 days 15 days
Figure 4.1. Spleen weights from untreated and 12 hour, 5 days and 15 days after 
casiopeina II treatment. Results are means of ± SD for n = 5 animals per group, ** 
P<0.005.
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No significant difference in spleen weights of ‘young rats’ (6 weeks old) was observed 
5 days after casiopeina II administration compared with a 1.5-2.0-fold increase in spleen 
weight of ‘old rats’ (10 week old) (Figure 4.2).
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□  CONTROL 
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Spleen weight
young rat old rat
Figure 4.2. Spleen weights of ‘young rats’ (6 weeks old) and ‘old rats’ (10 weeks old) 
5 days after the intravenous administration of casiopeina II. Results are means of ± SD 
for n = 5 animals per group, ** P<0.005.
The normal histopathology, with normal white pulp - red pulp ratio of the spleen is 
illustrated in Figure 4.3. Splenic sinuses and cords from the red pulp surrounding the 
white pulp and the marginal zone. Erythrocytes, some endothelial cells and 
lymphocytes mainly compose the red pulp of the spleen (Figure 4.4). The toluidine 
blue stained spleen section shows a clear view of the red pulp cellularity from a control 
rat where erythrocytes are contained within splenic sinuses and cords, as well as the 
presence of a few lymphocytes (Figure 4.5). Electron microscopy of the spleen from a 
control rat can be observed in Figure 4.6, where different shape erythrocytes are 
contained in a splenic sinus. Some cells seem to be in passage through the endothelial 
cell cords and lymphocytes.
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Figure 4.3. L ow  pow er m agn ifica tion  o t a sp leen  section  from  an untreated rat. P icture  
illustrates the n onnal red pulp (R P ) and w h ite  pulp (W P ) ratio, an artery (A )  surrounded  
by the periarteriolar lym p h oid  sheath and m arginal zo n e  (M Z ) (H /E , overall 
m agn ifica tion  X 42).
. u
Figure 4.4. H igh pow er H /E  stained  sp leen  section  from a control rat. R ed  pulp  
organisation  and structure can be ob served  (overall m agn ifica tion  X 4 2 0 ).
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Figure 4.5. T olu id in e b lue stained  sp leen  section  from an untreated rat. Picture  
illustrates m ain ly  the erythrocyte (E ) content o f  the red pulp, so m e ly m p h o cy tes  (L ) and  
en d oth elia l c e lls  (E C ) (overall m agn ifica tion  o f  X I 0 50).
%
Figure 4.6. E lectron sp leen  m icrograph from the red pulp o f  an untreated rat. D ifferent 
shape erythrocytes (E ), en dothelia l c e lls  (E C ) and ly m p h ocytes (L ) can be o b served  
(overall m agnification  of 9.26K.).
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A reduction in the white pulp -  red pulp ratio was observed 12 hours after casiopeina II 
administration, when compared to a control sample. Figure 4.7 illustrated some 
depletion of the marginal zone and reduction of the white pulp. Red pulp enlargement 
is mainly due to a significant increase in erythrocyte content, also the presence of some 
lymphocytes and reduction of the white pulp and marginal zone is observed (Figure 
4.8). In a high power view a loss of cellularity in the red pulp mainly from a marked 
increase in erythrocyte content is observed, enlargement in size and stain variation of 
the erythrocytes are suggestive of cell damage. Some endothelial cells from the splenic 
cord and enlarged macrophages are also observed (Figure 4.9). These features were 
confirmed with electron microscopy (Figure 4.10) where a difference in erythrocyte 
density can be noted, suggesting erythrocyte damage and accumulation in the spleen. In 
addition Figure 4.10 also shows engulfed damaged cell detritus by a macrophage and 
some endothelial cells.
The infiltration of dark coloured nucleated cells 5 days after casiopeina n  
administration in the red pulp is illustrated in Figure 4.11, which correlates with the 
significant increase in spleen weight. In addition some reduction of the marginal zone 
and the white pulp can also be observed. Moreover there was loss of red pulp 
organisation 5 days after casiopeina II administration, no splenic sinuses and cords can 
be recognised due to the presence of lymphocytes, endothelial cells and macrophages 
(Figure 4.12). An accumulation of iron deposits amongst lymphocytes in the red pulp 
can be observed, probably due to a release from broken erythrocytes (Figure 4.13). An 
apparent loss of cellularity in the red pulp and the presence of endothelial cells, 
lymphocytes, macrophages and some damaged erythrocytes can be confirmed with 
toluidine blue staining of a spleen section (Figure 4.14). Five days after administration 
of casiopeina II erythrocytes of varying electron density are still present. In addition to 
the erythrocytes in the red pulp, electron microscopy also revealed the presence of 
lymphocytes (Figure 4.15).
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Figure 4.7. Low power spleen section taken 12 hours after the administration o f casiopeina II. 
Picture illustiates a marked increase of eiythrocytes in the red pulp (RP), depletion of the 
marginal zone (MZ) and the white pulp (WP) can be observed. Splenic sinuses seem contracted 
and splenic cords thickened when compared with Figure 4.3 (H/E, overall magnification X42).
■M
Figure 4.8. Higher magnification o f H/E stained spleen section taken 12 hours after the 
administration of casiopeina 11. Clear evidence o f eiythrocyte accumulation in the red pulp can 
be observed. In addition there is a clear reduction o f the white pulp and marginal zones (overall 
magnification X210).
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Figure 4.9. Toluidine blue stained spleen section taken 12 hours after the administration o f 
casiopeina 11. Picture illustrates damaged erythrocytes (E) in the red pulp, endothelial cells 
(EC) and histiocytic cells (H), containing eiythrocyte detritus, can be observed (overall 
magnification of X I050).
Figure 4.10. Election micrograph from the red pulp o f the spleen taken 12 hours after the 
administration of casiopeina II. Endothelial cells (EC) and different dense colour damaged 
eiythrocytes (E) can be observed (overall magnification of X9.26K). Arrow shows engulfed 
eiythrocytes and endothelial cells.
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r ^ r \ \ \ r i = ^ v  1T1 r \ f  Q  C T ' ï l / a o t l  Q O iFigure 4.11. Low power magnification o f a spleen section taken 5 days after the administration 
of casiopeina II. An infiltration o f dark coloured cells (mainly lymphocytes) in the red pulp 
(RP) are present, additionally certain depletion o f white pulp (WP) and marginal zone (MZ) can 
also be obseiwed (H/E, overall magnification X42).
%
Figure 4.12. Red pulp from a spleen section taken 5 days after the administration o f casiopeina 
II. Infiltration o f lymphocytes, histiocytic and endothelial cells in the red pulp can be observed 
(H/E, overall magnification X420).
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J
Figure 4.13. High power view o f the red pulp from a spleen section taken 5 days after the 
administration o f casiopeina II. Picture shows cellularity loss o f the red pulp, damaged 
erythrocytes (E), lymphocytes (L), histoicytic cells (H), nucleated immature red cells (IRC) and 
iron accumulation (Fe) (right bottom quadrant) (H/E, overall magnification X I050).
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Figure 4.14. Toluidine blue stained spleen section taken 5 days after the administration o f 
casiopeina II. Picture illustrates different dense colour damaged eiythrocytes (E) and 
lymphocytes (L) in the red pulp, as well as some endothelial (EC) and histiocytic (H) cells with 
iiTegulai- vacuoles (overall magnification of X 1050).
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Figure 4.15. Electron m icrograph from  the red pulp  o f  the sp leen  taken 5 days after the  
adm inistration  o f  casio p ein a  II. D en se  co lou red  c e lls  dam aged  erythrocytes (E ) and  
ly m p h ocytes (L ) can be ob served  (overa ll m agn ifica tion  o f  X 9 .2 6 K ).
A t 5 days post ca sio p e in a  II adm inistration  in ‘y o u n g ’ rats (6 -w e e k s  o ld ) the sp leen  
h istop ath o logy  w as evaluated . For com p arison  the norm al sp leen  structure o f  a control 
‘y o u n g ’ rat is illustrated m Figures 4 .1 6  and 4 .1 7 . A fter casiopeina II treatm ent so m e  
lym p h ocytes can be ob served  in the sp leen  red pulp, h ow ever  there is no a lteration  in  
w h ite  pulp -  red pulp ratio (F igure 4 .1 8 )  in contrast w ith  the m arked e ffe c t  in the sp leen  
sec tio n  o f  an ‘o ld ’ rat (F igure 4 .1 1 ). Furtherm ore under a h igher p o w er  norm al red pulp  
organisation  w ith  no loss o f  cellu larity  and the presen ce o f  a lo w  num bers o f  
lym p h ocytes, en dothelia l c e lls  and m acrophages in the red pulp is ev id en t (F igure 4 .1 9 ).
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Figure 4.16. Low power magnification o f a spleen section fi'om a conti'ol ‘young’ rat at 5 days 
post casiopeina 11 administiation. Normal red pulp (RP) and white pulp (WP) ratio and 
marginal zone (MZ) can be observed (H/E, oyerall magnification X42).
Figure 4.17. High power H/E stained spleen section from a control ‘young’ rat. Picture 
illustrates the red pulp containing erythrocytes, endothelial cells and some lymphocytes (oyerall 
magnification X420).
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Figure 4.18. Low power inagnification o f a spleen section from a ‘young’ rat taken 5 days after 
the administration o f casiopeina II. Picture illustrates white pulp (WP) and red pulp (RP) ratio, 
and marginal zone (MZ). Some dark coloured cells in the red pulp can be obseryed when 
compared to the control (H/E, oyerall magnification X42).
IB
.
Figure 4.19. Higher magnification o f the red pulp from a ‘young’ rat spleen section taken 5 
days after the administration o f casiopeina II. Some infiltration o f lymphocytes, histiocytic and 
endothelial cells in the red pulp can be observed (H/E, oyerall magnification X420).
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To further investigate the progression of the effect of casiopeina II spleen sections of 
‘old’ rats were examined 15 days after administration. Figure 4.20 shows recovery of 
the white pulp -  red pulp ratio and the marginal zone surrounding the white pulp. In 
addition splenic cords and sinuses containing erythrocytes can be observed in the red 
pulp. However at a higher power some infiltration of lymphocytes, endothelial cells 
and macrophages in the red pulp can be distinguished (Figure 4.21). The detail of 
section stained with toluidine blue shows recovery of the red pulp cellularity and the 
presence of some endothelial cells and lymphocytes (Figure 4.22). Electron microscopy 
of the red pulp from a spleen section taken at this time point revealed the normal 
appearance of erythrocytes, endothelial and reticular cells, and lymphocytes suggesting 
some recovery of the spleen morphology. However some cell debris is observed, 
probably as part of a macrophage indicating the damage and lysis of cells (Figure 4.23).
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MZ-
F ig u r e  4 .2 0 . L ow  p ow er sp leen  section  taken 15 days after the adm inistration  o f  
casiop ein a  II. Certain recovery  o f  the red pulp (R P ) and w h ite  pulp (W P ) ratio can  be  
observed , as w e ll as a recovery  o f  sp len ic  s in u ses, cords and m arginal zo n e  (M Z ) (H /E , 
overall m agn ification  X 42).
U M  *
F ig u r e  4 .2 1 . H igher m agn ifica tion  o f  the red pulp from  sp leen  section  taken after 15 
days o f  the adm inistration  o f  casiop e in a  II. S o m e ly m p h ocytes, en d oth elia l and  
h istio cy tic  c e lls  in the red pulp can be ob served  (H /E , overall m agn ifica tion  X 4 2 0 ).
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Figure 4.22. Toluidine blue stained spleen section taken 15 days after the administiation o f 
casiopeina 11. Although a recovery o f cellularity is observed some damaged erythrocytes (E) 
and lymphocytes (L) are still present in the red pulp. Endothelial (EC) and histiocytic (H) cells 
with inegulai- vacuoles are also present but in lesser amount (overall magnification o f X I050).
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Figure 4.23. Electron micrograph from the red pulp of the spleen taken 15 days after the 
administration of casiopeina 11. Dense coloured cells represent damaged erythrocytes (E), 
endothelial cells (EC) and lymphocytes (L) can be observed (overall magnification o f X9.26K).
144
Chapter 4. Pathophysiology of the spleen
4.4 DISCUSSION
The above results suggest a pathophysiological effect of the spleen associated with the 
intravenous administration of 5 mg/kg casiopeina 11. Usually spleen lesions are 
manifested as changes in size and cellularity of the spleen zones, for this reason to 
detect changes in the spleen cellularity a careful comparison with tissues from untreated 
animals is required (Gopinath et a l, 1987). The major effect in the spleen associated 
with casiopeina n  administration after 12 hours was a dramatic increase of erythrocyte 
content in the red pulp when compared to a control sample. In addition the effect 
extended to some reduction of the white pulp and marginal zone, consequently affecting 
the white pulp -  red pulp ratio. In rodents enlargement of the spleen can be related to 
an increase in damaged red blood cell removal and the presence of intracellular 
inclusions (Rosse, 1987). After 5 days of injection the significant increase in spleen 
weight and lymphocyte infiltration in the red pulp suggests an extensive removal of 
unwanted damaged red blood cells. Moreover the infiltration of dark nucleated cells in 
the red pulp suggest that some immature red blood cells may also be present due to the 
initiation of a haematopoietic process as a response to casiopeina 11 administration, as 
well the presence of iron accumulation (Figure 4.13). The peak of pathophysiological 
changes observed 5 days post administration of casiopeina 11 is a normal splenic 
functional response to an increased haematopoietic demand due to the acute 
haematotoxic damage rather than a time adverse effect. Evidence of damaged or broken 
erythrocytes in cells from the reticuloendothelial system (RES), engulfinent of 
erythrocyte fragments by histiocytic cells in the spleen was observed. In the light of the 
lesion observed in the spleen, it was considered that some changes might also have been 
apparent in the RES of the liver, however no evident changes were observed when 
assessed by histopathology.
Following the progression of spleen changes 15 days after administration recovery of 
spleen pathophysiology was observed, white pulp -  red pulp ratio was restored as well 
as red pulp cellularity. No significant pathophysiological changes in the spleen of 
‘young’ rats were observed 5 days after the administration of casiopeina 11, which 
correlate with the haematological data obtained previously in Section 3.3.3 in Chapter 3. 
No haematotoxic effect in ‘young’ rats was observed after casiopeina 11 administration, 
and no splenic response. In ‘young’ rats the erythrocyte structure is stronger and their
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reticulocyte levels are higher, which in fact are indicative of a greater red blood cell 
reserve and thus they are able to handle the haematotoxic damage caused by casiopeina 
II administration.
Changes in splenic pathophysiology associated with casiopeina II administration are in 
accord with reports that indicate that following administration of drugs or chemicals 
variations in circulation, extramedullary haematopoiesis, accumulation of macrophages, 
connective tissue and pigment (mainly iron) may occur in the spleen red pulp (Greaves, 
1990). As observed with the Cu(ll) levamisole complex, where after oral 
administration to W/A rats an increase in spleen index was used as a responsive 
parameter for toxicity, similar to the response observed with casiopeina n  treatment 
effect (Kovachev et a l, 1994).
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CHAPTER 5. MODE OF CELL DEATH INDUCED 
WITH CASIOPEINA II IN TWO CANCER CELL
LINES
147
Chapter 5. Mode of cell death
5.1 INTRODUCTION
In the last decade it has been discovered that most chemotherapeutic agents can kill 
cancer cells by apoptosis, however the exact mechanism by which they do so is still a 
matter of controversy (Kamesaki, 1998). It appears that they may induce apoptosis by 
interacting with specific cell targets such as cell surface death receptors 
(CD95/Fas/Apol and TNF-Rl) (Weis et ah, 1995) and/or via intracellular 
mitochondrial pathway resulting in the release of cytochrome c and caspase activation 
(Green and Kroemer, 1998). Moreover signal transduction due to DNA damage may 
also induce apoptotic cell death and thus inhibit cancer growth (Hannun, 1997). A vast 
number of chemotherapeutic agents have shown to kill cancer cell by apoptosis (as 
described in Chapter 1, Section 1.7.2). In particular the metal compound cisplatin has 
shown to induce apoptotic cell death in different cancer cell lines such as human 
ovarian carcinoma, testicular germ cell tumour and murine leukaemia (Ormerod et ah, 
1996; Burger et ah, 1998; Jones et ah, 1998b). Intrinsic genetic cell mechanisms and 
extracellular signalling from surrounding microenvironment determine the mode of cell 
death in a cell population, together with its susceptibility to injury by hypoxia or 
cytotoxic treatment, and thus the ability of the anticancer agents to kill cancer cells will 
be compounded by these factors (Toft and Arends, 1997).
Apoptotic cell death is regulated by intrinsic genetic modulators that can activate or 
inhibit the cell cycle amongst these are the p53 tumour supressor gene, Bcl-2 protein 
family and the retinoblastoma protein (Rb) (Allen et a/., 1998; Burger et a l, 1998; 
Weller, 1998). These genetic modulators can have positive or negative regulatory 
effects on cell cycle progression, which consequently determines an induction or 
inhibition of the apoptotic process. Cyclin dependent kinases (CDKs), E2F-1 and c- 
Myc are positive regulators of the cell cycle and effective promoters of apoptosis 
whereas Rb, p53 and p21 are negative cell cycle regulators and whilst Rb inhibits 
apoptosis p53 can promote apoptotic death. Some of these oncogenes and gene 
products involved in the apoptotic process are listed in Table 5.1. However p53 at the 
same time that it is involved in apoptotic induction it can also promote p21 cell cycle 
arrest activity, however the exact role of p21 cell cycle arrest and its consequent role in 
apoptosis is at present unclear (Fotedar et a l, 1997; Allen et a l, 1998; Weller, 1998).
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Table 5.1. Oncogenes and tumour supressor gene products involved in apoptosis 
(Allen et a l, 1998; Staunton and Gaffiiey, 1998; Weller 1998)
Initiators and inducers Inhibitors
c-Myc Bcl-xs Bcl-2 c-Abl
p53 Bak B c1-xl  R b
Bad Bax
E2F-1 CDKs Mcl-l
During the cell cycle the cell prepares itself for duplication, following cell division the 
cell commences its growth in the Gi phase and prepares itself for DNA synthesis. DNA 
replication occurs during the S phase, followed by chromatin alignment to enter mitosis 
and cell growth in the G2 phase, finally the chromosomes segregate in mitosis in phase 
M. Once completed the two daughter cells will re-enter the cycle or remain quiescent in 
Go. Cell injury causes an arrest in the cell cycle, the damage is evaluated in specific cell 
cycle checkpoints before entering the mitotic phase, and it appears that in some cases it 
is then when the apoptotic process may be triggered (Fotedar et a l, 1997). Recent 
reports indicate that chemotherapy-induced cell injury by cross-linking agents, such as 
cisplatin, can produce an accumulation of cells in the G2 phase. With higher 
concentrations there is evidence of an S phase arrest and if the drug concentration 
increases the cells can exhibit a Gi block, with an apparent presence of a ‘subGT peak 
before entering the Gi phase (Ormerod et a l, 1994; Souhami, 1996). These lesions can 
lead to a G2 arrest and the failure to overcome this block in the G2 phase by cisplatin 
treatment appears to lead to cells to die by apoptosis (Ormerod et a l, 1996). The 
interaction of chemotherapeutic agents in the cell cycle may result in an inability of the 
cell to complete the cell cycle and consequently die, indeed through the apoptotic 
pathway.
However some solid tumours are intrinsically resistant to chemotherapy, may be unable 
to undergo apoptosis and may subsequently be resistant to chemotherapeutic cell death. 
This has been explained by the malfunction of mechanisms of cell-damage repair, gene 
mutations such as in the p53 gene, as well as the over expression of the Bcl-2 gene 
family (Hannun, 1997). For this reason the discovery of new chemotherapeutic agents,
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that alone or in combination with therapeutical schemes which induce cell death in 
resistant tumours, has become a challenging objective in the battle against cancer.
As previously described in Chapter 1 Section 1.7, amongst the major effects identified 
when cells undergo apoptosis are the radical modifications in morphology or integrity. 
Some of the main morphological features of apoptosis are cell shrinkage, chromatin 
condensation, membrane blebbing, nuclear condensation and cell segmentation. An 
early marker of apoptosis is the translocation of Phosphatidylserine (PS). 
Phosphatidylserine is a membrane lipid normally found in the inner surface of the 
plasma membrane. During apoptosis PS suffers a translocation to the outer surface of 
the plasma membrane, due to the activation of an inside-out side PS-translocase or an 
aminophospholipid scramblase. A convenient method to identify this early event in the 
apoptotic process is the use of a PS-binding protein, annexin V, which may be tested by 
flow cytometry or fluorescence microscopy (Martin, 1997). A key event of the 
apoptotic process is the activation of the caspases, which cleave cellular substrates 
leading to distinct intracellular events identified as morphological apoptotic hallmarks. 
This process is associated with nuclear fragmentation and the cleavage of genomic 
DNA into high molecular weight fragments followed by cleavage of oligonucleosomal 
DNA fragments and condensation of nuclear organelles (Allen et a l, 1998; Kuida et a l, 
1998).
Recent evidence supports that excess or deficiency of trace elements may influence, 
specifically or non-specifically, the apoptotic process. Some trace elements are known 
to incite cell injury in toxic concentrations resulting in apoptotic death, such as Mn or 
Ga, whereas others may inhibit the apoptotic process, such as Zn (Koudrine, 1998). 
Reports indicate that Zn prevents apoptosis by interfering upstream events in the 
caspase cascade, particularly caspase 3, restraining the activation of nuclear 
endonucleases (Perry et a l, 1997). Moreover the heat shock protein, HSP70, which has 
been shown to prevent ROS-induced DNA damage, lipid peroxidation and protect 
mitochondria integrity, was overexpressed in the presence of Zn and prevented 
apoptotic cell death (Wong et a l, 1996). Free radicals and ROS are cytotoxic causing 
cell injury and death (as described in Chapter 1 Section 1.3.2). Additionally free 
radicals and ROS have also been reported to be effective inducers of apoptotic cell 
death by free radical-induced DNA damage in neuronal ischemic apoptosis (Shaikh et
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a l, 1998) or as products of chemotherapeutic agents injury mechanisms, such as 
cisplatin or etoposide (Uslu and Bonavida, 1995). Furthermore the generation of ROS 
by different agents such as chemotherapeutics or an impaired antioxidant cell defence 
mechanism may lead to cell death by apoptosis. Subsequently surviving L1210 cells, 
resistant to oxidative stress, presented increased expression of Bcl-2 as part of the 
natural defence mechanism against free radical and apoptosis, corroborating the 
participation of free radicals as apoptotic regulators (Zimowska et a l, 1997). Apoptosis 
was induced in PC 12 neuronal cells by SOD inhibition due to free radical induction 
suggests that free-radical-mediated cell injury requires antioxidant promotion (Troy and 
Shelanski, 1994).
Research on the direct or indirect role of copper in cellular processes and cell injury 
suggests that copper complexes may trigger apoptosis, which is supported by reports on 
the induction of intemucleosomal DNA cleavage as a result of free radical generation 
(Koudrine, 1998). Moreover although thiol compounds in general act as antioxidants, 
some may be toxic to cells and thus induce apoptosis in the presence of Cu^^ by the 
Fenton reaction (Held et a l, 1996).
Murine leukaemia (LI210) and human ovarian carcinoma (CHI) have been reported to 
undergo apoptosis after exposure to cisplatin (Ormerod et a l, 1994 and 1996). In the 
present study, we have examined the mode of cell death in resistant and sensitive 
cisplatin strains of these two cancer cell lines, after treatment with casiopeina II. These 
studies have focused on the effects of casiopeina II in L1210 and CHI cells by 
determining the concentrations at which casiopeina n  induces apoptosis, assessment of 
cell and nuclear morphology, involvement of caspases, DNA fragmentation and cell 
cycle analysis.
5.2 MATERIALS AND METHODS
5.2.1 Cytotoxic drugs 
• Reagents
Casiopeina II 1 mM (UNAM, Mexico)
Glucose solution 5% (BDH)
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Cisplatin 1 mM (Johnson Matthey Technology Centre, UK)
Sodium chloride solution 15 mM (BDH)
• Procedure
Casiopeina n  synthesised and supplied by Dr Lena Ruiz-Ramirez (UNAM, Mexico) 
was dissolved in 5% sterile glucose solution. A stock solution of 1 mM of casiopeina II 
was prepared from which lower concentration dilutions were made up as needed.
Cisplatin was supplied by Johnson Matthey Technology Centre and was dissolved in 15 
mM sterile sodium chloride solution at a concentration of 1 mM stock.
5.2.2 Cell culture 
• Reagents
Phosphate Buffer Saline (PBS)
RPMI-1640 medium (Gibco)
Penicillin G 100 UI/500 ml (Sigma)
DMEM medium (Gibco)
Foetal calf serum 10% (Gibco)
Gentamicin 5% (Gibco)
Anti-PPLO agent 5% (Gibco)
Trypsin-EDTA IX (Gibco)
• Procedure
L1210-Murine Leukaemia and CHI-Human Ovarian Carcinoma cells, resistant and 
sensitive to cisplatin, were a gift from the CRC-Centre for Cancer Therapeutics, The 
Institute of Cancer Research (Sutton, Surrey, UK).
Murine leukaemia cells, grown in suspension, were maintained in RPMI-1640 medium 
supplemented with 10% foetal calf serum and penicillin G at 37°C with 5% CO2. Under 
these conditions the doubling time of the cell culture was 14 hours (Ormerod et a l, 
1994). Cells were grown in 75 cm^ culture flasks at a concentration of 4 to 5 x 10^/ml 
for not more than 20 passages, they were constantly monitored and medium was 
changed twice a week after washing with PBS.
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Human ovarian carcinoma cells, a monolayer culture, were maintained with DMEM 
medium supplemented with 10% foetal calf serum, 5% gentamicin and 5% anti-PPLO 
agent at 37°C with 5% CO2. Under these conditions the doubling time of the cell culture 
was 15 hours (Ormerod et a l, 1996). Cells were kept in an exponential growth and 
subcultured 24 hours before treating them. Cell cultures were harvested as a suspension 
by incubation for 5 minutes with trypsin after washing with PBS (O’Neill et a l, 1996).
5.2.3 Drug treatment and experimental design
Murine leukaemia cells were seeded at a density of 5 x 10  ^cells/ml for 24 hours before 
treatment to obtain a cell density of 10  ^cells/ml. Human ovarian carcinoma cells were 
subcultured in 75 cm^ flasks 24 hours before treatment to obtain a 70% confluent 
culture. A time course and dose response curves were performed for both cell lines 
after exposure to a range of doses of casiopeina II.
To obtain the final concentration when treating the cells the 1 mM stock solution of 
casiopeina II was first diluted 1:10 dilution and this 100 pM ‘working solution’ was 
further diluted 1:100 in the culture media to obtain a 1 pM treatment concentration. 
The range of doses were prepared by making appropriate dilutions from the ‘working 
solution’ in order to obtain final concentrations of 2 pM, 3 pM and 4 pM in the 
medium. Cells were incubated with casiopeina II for the entire period of treatment.
Besides casiopeina II treatment both cell lines were also treated with cisplatin, which 
was used as a positive control for apoptotic induction; the 1 mM stock solution was 
diluted 1:10 to obtain a 100 pM concentration in the medium. Cells were incubated for 
2 hours, washed with sterile PBS and fresh media was added. They were then incubated 
for 22 hours.
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Dose response and time course treatment with casiopeina II was performed as follows: 
L1210 cisplatin resistant and sensitive cells
Time (hours) Casiopeina II
8 1 pM 2 pM 3 pM
16 1 pM 2pM 3 pM
24 1 pM 2 pM 3 pM
32 1 pM 2 pM 3 pM
Cisplatin
2 /2 4 100 pM
CHI cisplatin resistant and sensitive cells
Time (hours) Casiopeina II
8 1 pM 2 pM 4 pM
16 1 pM 2 pM 4 pM
24 1 pM 2pM 4 pM
48 1 pM 2 pM 4 pM
Cisplatin
2 /2 4 100 pM
5.2.4 Cell viability
• Reagents 
Trypan Blue 4% (Sigma)
• Procedure
Cell viability and numbers were counted twice in a 10 pi volume using a Modified- 
Fuch’s Rosenthal counting chamber (haematooffometer) (Weber Scientific Ltd, UK) 
slide and their viability determined at the end time point by the exclusion of trypan blue, 
at a concentration of 1:1% under phase contrast light microscopy. Non-coloured cells 
were scored as live cells and blue cells were scored as dead cells. Samples of cell 
suspension were kept with different fixatives or solution according to the methodology 
to be performed.
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5.2.5 Assessment o f apoptosis
• Reagents
Formaldehyde 4% (BDH)
Hoescht Fluorescent DNA-binding dye 33342 1 mg/ml (Aldrich)
• Procedure
After treatment, approximately 1 x 10  ^ cells were fixed in 4% formaldehyde (1:1 %  
concentration) and kept at room temperature until analysis. After fixation nuclear 
integrity (intact or fragmented) was estimated by staining cells with Hoescht 33342. A 
20 pi volume of cell sample was put into an eppendorf tube and 3 pi of the Hoescht 
33342 (6 pg/ml) fluorophore were added. After a gentle mix a 10 pi volume of cell 
sample was put on a clean glass slide with a cover-slip on top and visualised using a 
Zeiss Axiovert fluorescence microscope (Jones et a l, 1998a). Apoptotic cells were 
identified by showing a distinctly fragmented and condensed nuclei, whereas non- 
apoptotic cells showed an intact and homogenous nuclei. The percentage of apoptotic 
cells was determined by identifying the number of apoptotic cells in a total of 200 cells 
and dividing by two. Each experiment was repeated twice and cells were counted twice 
in each experiment, to obtain a mean + S.D.
5.2.6 Annexin V
• Reagents
ApopNexin™ FITC in DMEM or RPMI 1% (Oncor® Appligene, UK)
(IX Annexin V)
Propidium Iodide in DMEM or RPMI 1% (Oncor® Appligene, UK)
(IX PI)
Lab Tek® Chambers slides (Catalogue No.4812) LabTek
• Procedure
For the purpose of these test CHI cells, resistant and sensitive to cisplatin, were grown 
in chamber slides at a concentration of 1 x 10  ^cells and 24 hours later, when cells were 
approximately 70% confluent, treatment was performed as described. Murine 
leukaemia cells, resistant and sensitive to cisplatin, were grown in 25 cm^ tissue
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culture flasks, at a concentration of 5 x 10 cells and 24 hours later when cells were 
approximately at a concentration of 1 x 10  ^cells treatment was performed as follows:
Treatment Dose
CHI
L1210
Control 
Casiopeina H 
Cisplatin 
Control 
Casiopeina U 
Cisplatin
2pM  
100 pM
2 pM 
100 pM
After 24 hours of treatment attached and detached CHI cells were labelled with IX 
Annexin V and IX PI as described below. Annexin V labelling of attached cells was 
performed with the cells grown in cultures chamber slides and in the case of detached 
cells it was performed by transferring the supernatant (containing detached cells) into an 
eppendorf tube.
Detached Attached
Spin down at 1500 g for 5 minutes 
Wash with ftresh media 
Spin down at 1500 g for 5 minutes 
Wash with PBS
Spin down at 1500 g  for 5 minutes 
Re-suspend in 1ml of IX ApopNexin™ 
FITC and incubate for 10 minutes 
Spin down at 1500 g  for 5 minutes 
Re-suspend in 1 ml of IX PI in DMEM 
and incubate in ice for 15 minutes
Wash with PBS
Add 1ml of IX ApopNexin™ FITC and 
incubate for 10 minutes 
Dispose medium
Add 1 ml of IX PI in DMEM and 
incubate in ice for 15 minutes
For L1210 cells 1ml of cell suspension was put into an eppendorf tube and the same 
procedure as with detached cells was performed.
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Samples were immediately observed using a Zeiss Axiovert fluorescence microscope. 
Attached CHI cells were observed directly from the slide after removing the chamber. 
A 10 pi volume per sample of detached cells was put on a clean glass slide with a 
coverslip on top and observed. L1210 cells were observed following the same 
procedure as detached cells. Green colour cells were scored as apoptotic, green colour 
cell with orange stains were scored as primary necrosis (1° necrosis) and orange cells 
were scored as secondary necrosis (2° necrosis). Control samples with no treatment and 
where cells are almost 100% viable did not exhibit any fluorescence (Product Profile, 
ApopNexin™ Apoptosis Detection Kits, Oncor®, Appligene, U.K.)
5.2.7 Western blot analysis o f  PARP cleavage
• Reagents
❖ Reducing -loading buffer
❖ SDS-polyacrylamide gel
❖ Nitro-cellulose membranes-Hybond-C
❖ Ponceau S
: TBS-T (pH 7.4)
MilliQ water 50%
TRIS (pH 6.8) 62.5 mM (BDH)
Urea 6M (Sigma)
Glycerol 10% % (BDH)
SDS 2 % % (Biorad)
Pyronin Y 0.003% % (Sigma)
p-mercaptoethanol 5% % (Sigma)
7 .5% % (Biorad)
(Amersham)
Ponceau S 0.1% % (Sigma)
Acetic acid 5% % (BDH)
Sodium chloride 137 mM (BDH)
TRIS 20 mM (BDH)
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Tween-20 0 .1% %  (Sigma)
❖ Blocking solution
(pH 7.4) TBS-T
Non-fat milk powder 5% %
❖ Anti-PARP monoclonal antibody C-2-10 Gift from Prof. G.G. Poirier
❖ Horseradish peroxidase (Amersham)
❖ ECL detection system (Amersham)
❖ Polaroid film (Sigma)
❖ Equipment and materials
Hybond-nitrocellulose membrane (Amersham)
Ready Gel Cell Mini Protean II Kit (BioRad)
Mini Trans-Blot Electrophoretic Transfer Cell (BioRad)
LKB Power Supply 2301 (LKB)
❖ Procedure
Western blot analysis was used for the detection of PARP cleavage. Protein 
concentration was estimated by the Lowry protein assay (section 5.2.8) in each sample 
to have the equivalent amount of protein per sample. Following drug treatment aliquots 
of cell suspension were washed in cold PBS, after centrifugation the pellet was re­
suspended in 100 pi of reducing-loading buffer, and sonicated on ice for 20 seconds 
before SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in 7.5% gels. After 
blotting, the nitro-cellulose membranes were stained with Ponceau S for 1 minute and 
washed with MilliQ water and TBS-T to check protein profile of the samples. 
Immediately, membranes were blocked for 1 hour with blocking solution followed by 
probing with PARP antibody (immunoblotting with anti-PARP monoclonal antibody C- 
2-10) in TBS-T for 2 hours. After washing and incubation for 1 hour with the 
secondary antibody labelled with horseradish peroxidase the blot was visualised with 
ECL detection system as described in Jones et a l (1998a).
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5.2.8 Lowry protein assay
• Reagents
Bovine serum albumin (BSA) stock standard
BSA 400 pg/ml (Sigma)
Lowry “A’
Na2COs
Potassium sodium tartrate 
Copper sulphate 
Sodium hydroxide
100 g/L 
2gÆ. 
0.5 g/L 
20 g/L
(BDH)
(BDH)
(BDH)
(BDH)
Lowry “B”
Folin Ciocalteu’s phenol reagent 1:15 (%) (Sigma)
• Equipment and materials 
Labsystems iEMS reader MF 
Microtitre sorbiplates (96 wells)
(Labsystems)
(Nunc)
• Procedure
After constructing a standard curve of BSA, 50 pi of sample were mixed in a 
microtitreplate with 50 pi of Lowry “A” and left at room temperature for 10 minutes. 
Then 200 pi of Lowry “B” were added to get a final volume of 300 pi per well and 
incubated for 30 minutes at room temperature. Absorbances were read in iEMS reader 
MF at 650 nm using Genesis Software (Labsystems).
5.2.9 Caspase activation
• Reagents
Lysis buffer (pH 7.0)
HEPES
p-glycerophosphate 
Sodium chloride 
Magnesium
10 mM 
40 mM 
50 mM 
2 mM
(Sigma)
(Sigma)
(Sigma)
(Sigma)
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chlorideMgCE
EGTA 5 mM (Sigma)
Z-DEVD-AFC (stock solution was dissolved in 100 mM (Alexis
DMSO) Corporation)
AFC-assay buffer (pH 7.25)
HEPES 
Sucrose 
Nonidet P-40 
Dithiohtreitol (DTT)
100 mM 
10%% 
0.1%% 
10 mM
(Sigma)
(BDH)
(Sigma)
(Sigma)
• Equipment and materials 
WellFluor microplate fluorescence reader (Denley)
• Procedure
Measurement of caspase activation by casiopeina II and cisplatin treatment was 
performed as described in Nicholson et a l (1995). Following drug treatment, control 
and apoptotic cell pellets were washed in ice-cold PBS, and re-suspended in 30 pi lysis 
buffer. Cells were then disrupted by four cycles of freezing and thawing using a bath 
mix of ethanol and dry ice. Following centrifugation for 30 minutes at 15,800 g  at 4°C 
the supernatant was removed and caspase activity was measured in cell cytoplasm at 
room temperature using a microplate fluorescence reader as described in Jones et a l 
(1998a). The reaction mixture contained 4 pi of Z-DEVD-AFC (40 pM), 0.20 mg of 
cellular protein, in AFC buffer in a final volume of 200 pi. After a gentle mix the 
samples were read over a period of 30 minutes at room temperature by 
microfluorimetry. Enzyme activity is expressed as nanomoles of AFC liberated per 
milligram of protein per minute. Using a calibration curve expressed as nanomoles of 
AFC liberated per minute per mg of protein caspase activity of each cell extract was 
determined.
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Protein concentration of supernatants was estimated with the Lowry protein assay 
(section 5.2.8) to normalise the cell extracts on a protein basis of 0.20 mg of protein 
prior to the caspase activity assay.
5.2.10 Caspase inhibition
• Reagents
Z-VAD-FMK
Methanol
100 mM (Calbiochem)
(BDH)
• Procedure
The caspase inhibitor Z-VAD-FMK was dissolved in methanol to make a stock solution 
of lOOmM and kept at -20°C, for further use it was diluted in PBS. A 30 minute pre­
treatment with Z-VAD-FMK at three concentrations, 10 pM, 50 pM and 100 pM were 
used to test the inhibition of apoptosis induction with a 24 hour-treatment with 
casiopeina II and cisplatin in L1210 and CHI cisplatin sensitive cells.
5.2.11 Detection o f  Low-Molecular-Weight DNA fragments by gel electrophoresis
• Reagents
TBE buffer lOx (pH8.0)
TRIS 89 mM (BDH)
Boric acid 890 mM (Sigma)
EDTA 2.5 mM (Sigma)
Agarose gel
Multipurpose agarose 1.8%%
TBE buffer Ix
(Gibco)
TE8 buffer (pH 8.0)
TRIS 10 mM
EDTA-disodium salt 1 mM
(BDH)
(Sigma)
SDS (dissolved in MilliQ water) 10% % (Biorad)
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Proteinase K (dissolved in MilliQ water) 25 mg/ml (Sigma)
RNase A (dissolved in 15 mM sodium chloride) 50 mg/ml (Sigma)
X DNA EcoR I Hind m  Digest (Sigma)
DNA Loading Buffer (Blue-Orange) (Promega)
Ethidium bromide 10 mg/ml (Sigma)
• Procedure
The fragmentation of DNA to oligonucleosomal-fragments was analysed by agarose gel 
electrophoresis as described by Weis et a l (1995) and Jones et ah (1998a). Following 
drug treatment aliquots of 1 x 10  ^ cells were fixed in 100% %  ice-cold ethanol and 
stored at -20°C. Cells were collected by centrifugation at 800 g for 10 minutes, and the 
pellet re-suspended in 10 pi of PBS and mixed with 6 pi of RNase A and left at room 
temperature for 20 minutes. A 1.8% agarose gel was prepared and poured into a gel 
cast, approximately a 1 cm strip between the comb and the upper end of the gel was cut 
to pour the 0.8% agarose SDS and proteinase K digestion gel. A 20 pi volume of DNA 
loading buffer was added to each cell suspension before loading 25 pi in each well. The 
molecular weight markers for DNA laddering were purchased from Sigma- X DNA 
EcoR I Hind HI Digest. The gel was electrophoresed overnight at 10 V followed by 4 
hours at 70 V. After staining with ethidium bromide (0.25 pg/ml) for 20 minutes and 
destained in TE8 buffer the DNA was visualised and photographed under short 
wavelength UV light.
5.2.12 Detection o f large DNA fragments by Field Inversion Gel Electrophoresis 
(FIGE)
• Reagents
DNA lysis buffer
TRIS
EDTA
SDS
200 mM 
100 mM
(BDH)
(Sigma)
(Biorad)
TBE buffer 20x (pH 8)
TRIS 90 mM (BDH)
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Agarose gel
Boric acid 90 mM (Sigma)
EDTA 2 mM (Sigma)
Low melting point agarose 1% %  (Gibco)
TBE buffer Ix
❖ Proteinase K 10 mg/ml (Sigma)
❖ RNase A 1 mg/ml (Sigma)
❖ TAE buffer Ix (pH 7.2)
TRIS 40 mM (BDH)
Sodium acetate 20 mM (BDH)
EDTA 1 mM (Sigma)
❖ Bromophenol blue
Bromophenol blue 1 mg/ml (Sigma)
Sucrose Saturated solution (BDH)
❖ Lamda DNA Hind III fragment plus pulse- 0.1-200 kb (Sigma) 
field marker
❖ Procedure
Following drug treatment control and treated 5 x 10  ^ cells were washed with ice-cold 
PBS, centrifuged at 800 g for 5 minutes and the pellet re-suspended in 100 pi of DNA 
lysis buffer before adding 10 pi of RNase A to each sample and storing at 4°C. 
Bromophenol blue 0.1% %  in saturated sucrose was added to add weight and colour to 
the samples at a concentration of 1:1 cell suspension and bromophenol blue. A gel of 
low melting point agarose was casted and after a gentle mix a volume of 35 pi of 
sample was poured into each well. Low melting point agarose was added on top of each 
well after the sample and was let to solidify to seal the wells. Field inversion gel 
electrophoresis was performed using Ix TAE using a BioRad FIGE Mapper. The gel 
ran for 20 hours with a forward voltage of lOV cm"^  and reverse of 7V cm‘  ^ with linear
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ramping T% = 1 second to T2 = 12 seconds. The temperature of the buffer was 
maintained at 14°C with a BioRad 1000 milli-chiller. DNA was visualised by staining 
with ethidium bromide (0.25 pg/ml) for 30 minutes and then photographed under short 
wavelength UV light (O’Neill et a l, 1996).
5.2.13 Flow Cytometry
• Reagents
RNase A 1 mg/ml (Sigma)
Propidium Iodide (PI) 200 pg/ml (Sigma)
• FACScan Instrument
Flow Cytometry was performed on an Ortho Cytofluorograf 50H (Coulter Elite) 
equipped with a Spectra-Physics argon-ion laser with an output of 200Mw at 488nm
• Procedure
For cell cycle analysis a time course with a range of casiopeina 11 doses was performed 
in CHI and L1210, resistant and sensitive to cisplatin, cells. In addition dose response 
effect experiment using Z-VAD-FMK was performed in both cell lines. Cultures of 
CHI cells were washed twice in ice-cold PBS, incubated 5 minutes with trypsin and 
collected by centrifugation at 800 g  for 5 minutes at various time points. L1210 cells 
were centrifuged at 800 g  for 5 minutes and washed twice with ice-cold PBS. 
Following centrifugation the supernatant was discarded and the cell pellets were re­
suspended in 200pl of ice-cold PBS and fixed for at least 30 minutes in 1.8 ml of ice 
cold 70% ethanol. Fixed cells were centrifuged and the pellet re-suspended in 800pl 
PBS, lOOpl (Img/ml) RNase A and lOOpl of PI (200pg/ml) and left to incubate at 37°C 
for at least 30 minutes and the stored at 4 °C.
Data from 2 x 10"^  cells were analysed with forward and orthogonally scattered light red 
fluorescence (peak and integrated area) recorded. Pulse shape analysis was performed 
to eliminate any cell clumps and data were gated on light scatter before recording a 
histogram of red (Pl-DNA) fluorescence. Data were analysed as described in Ormerod 
et a l (1996).
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5.3 RESULTS
5.3.1 Cell Morphology and assessment o f  apoptosis
Murine leukaemia, resistant and sensitive to cisplatin, cells (L1210 S; L1210 R) and 
human ovarian carcinoma, resistant and sensitive to cisplatin, (CHI S; CHI R) cells 
were treated with a range of doses of casiopeina IL In all four cell lines cell death by 
necrosis was evaluated by trypan blue exclusion (cell viability) and cell death by 
apoptosis was assessed by fluorescence microscopy. The time-course of the apoptotic 
response of L1210 and CHI cells to casiopeina II treatment varied according to the 
compound concentration, A maximum induction of apoptosis after casiopeina U 
treatment in L1210 S and L1210 R was observed to be between 10 to 30% with a 2pM 
dose, and 40 to 50% with a 3pM dose of casiopeina n  for 24 hours (Figure 5.1). In 
addition cell membrane permeability, measured by trypan blue exclusion, was observed 
to be between 10 to 20% higher than apoptosis. Apoptotic cells showed the typical 
morphological changes of cytoplasm shrinkage, chromatin condensation and nuclear 
fragmentation (Martin, 1997) (Figure 5.2).
Apoptosis morphology was observed in 15% of CHI S and CHI R cells after 48 hours 
of casiopeina 11 treatment at a 1 fiM concentration. Casiopeina 11 at a concentration of 
2 pM induced apoptosis in 25 to 30% of the cells in 24 hours and 35% with 4 pM after 
8 hours (Figure 5.3). Similar to L1210 cells, membrane permeability of CHI cells was 
observed to be between 10 to 20% higher than apoptosis, and cells also exhibited the 
typical morphological apoptotic features (Figure 5.4). Treatment with 100 pM of 
cisplatin for 2/22 hours, which was used as a positive control for apoptosis in L1210 
and CHI cells, induced some 60 to 80% apoptosis in L1210 S and CHI S cells and 30 
to 60% in L1210 R and CHI R, these data are in agreement with previous studies 
(Ormerod et a l, 1994; O’Neill et a l, 1996; Ormerod et a l, 1996). The induction of 
apoptosis with casiopeina n  in the four cell lines was lower than that by cisplatin. 
However casiopeina n  proved to be have the same effect in both resistant and sensitive 
to cisplatin L1210 and CHI cells, whereas cisplatin induction of apoptosis in the 
sensitive lines was 30% higher than in the resistant lines (Figures 5.5 and 5.6). 
Consequently these two protocols were chosen as the equitoxic doses of casiopeina 11 
and cisplatin for further studies presented in this chapter.
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Figure 5.1. Time course and dose response curves of cell viability (A) (C) and 
apoptosis induction (B) (D) of L I210 S and L1210 R cells respectively after treatment 
with 0 (0), 1(0), 2(A) and 3(A) pM of casiopeina II for 0, 8, 16, 24 and 32 hours. 
Results are the mean ± S.D. of 3 independent experiments.
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F ig u r e  5 .2 . Intact and fragm ented nuclei v isu a lised  under tlu o rescen ce  m icro sco p y  
from  casio p ein a  11 (A ) and cisp latin  (B ) treated L I 210  c e lls  
X 7 0 3 .
O verall m agn ifica tio n
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Figure 5.3. T im e cou rse  and d o se  resp on se  curves o f  c e ll v ia b ility  (A )  (C ) and  
ap op tosis in d u ction  (B ) (D ) o f  C H I S and C H I R  c e lls  resp ec tiv e ly  after treatm ent w ith  
0 ( 0 ) ,  1 (D ) , 2 ( A )  and 4 ( # )  p M  o f  casio p e in a  II for 0, 8, 16, 2 4  and 4 8  hours. R esu lts  
are the m ean  ±  S .D . o f  3 in d ependent experim ents.
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Figure 5.4. T ypical apoptotic nuclei sh o w in g  m orp h olog ica l ch an ges in C H I c e lls  after  
treatm ent w ith eq u itox ic  d o ses  o f  casio p e in a  II (2 p M ) and c isp la tin  (lO O pM ) for 24  
hours. N u cle i from  (A ) non-treated  c e lls , (B ) ca sio p e in a  11 and (C ) c isp la tin  ce lls . 
O verall m agn ification  o f  X 703 .
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Figure 5.5. P ercentage o f  c e ll v ia b ility  and ap op tosis  in d u ction  o f  L 1 2 1 0  S and L 1 2 1 0  
R  c e lls  after treatm ent w ith  3 p M  o f  ca sio p ein a  II co n tin u o u sly  for 2 4  hours and 100  
p M  o f  c isp la tin  for 2 hours and incubated  w ith  fresh  m ed ia  until 2 4  hours. R esu lts  are 
the m ean  ±  S .D . o f  4  in d ep en d en t experim ents. *  P < 0 .0 5  CII vs. C is. ♦ P  < 0 .0 5  
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Figure 5.6. P ercentage o f  c e ll v iab ility  and a p op tosis  in d u ction  o f  C H I S and C H I R  
c e lls  after treatm ent w ith  2 p M  o f  casiop e in a  II co n tin u o u sly  for 2 4  hours and w ith  100  
p M  o f  c isp la tin  for 2 hours and incubated  w ith  fresh m ed ia  until 2 4  hours. R esu lts  are 
the m ean  ±  S .D . o f  4  independent experim ents. *  P < 0 .0 5  CII v s. C is. ♦ P < 0 .0 5  C H I  
S vs. C H I R.
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5.3.2 Cell membrane transformation - Annexin V
To further investigate the mechanism of apoptosis induced by casiopeina II we used the 
phospholipid binding protein assay ApopNexin™ FITC (Annexin V). The principle is 
based on the observation that phosphatidylserine, normally localised on the cytoplasmic 
side of the plasma membrane, becomes translocated to the outer surface in an apoptotic 
cell. The assay consists of comparing apoptotic cells that express phosphatidylserine 
and are stained positive with the FITC antibody to phosphatidylserine visualised by 
fluorescence microscopy against necrotic cells that bind propidium iodide and fluoresce 
orange. In figure 5.7 binding of Annexin V to apoptotic attached and detached CHI 
cells can be observed, the attached cells show mainly apoptotic death and detached cells 
show apoptotic and necrotic death.
Cell death of L1210 S and L1210 R assessed with the binding of Annexin V after 
casiopeina II and cisplatin treatment showed that a 40 to 50% of cells died by apoptosis 
(Figure 5.8). After casiopeina II treatment about a 38% of the CHI S attached cells 
were apoptotic, whereas from the detached cells about a 45% died by apoptosis. In 
addition from the CHI R attached cells that died there was an approximately 50/50% 
cell death by apoptosis and primary necrosis respectively, whilst most of the detached 
cells died by apoptosis (Figure 5.9).
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Figure 5.7. M orphology  o f  hum an ovarian carcin om a attached (A ) and detach ed  (B )  
c e lls  after treatm ent w ith  2 p M  o f  casiop ein a  II for 24  hours u sin g  A n n ex in  V -FIT C  
flu orescen ce  binding. A p op to tic  ce lls  sh o w  a bright green co lour, primary n ecro tic  ce lls  
sh o w  a green co lou r w ith so m e orange stains and secondary necrotic  c e lls  sh o w  o n ly  a 
bright orange colour.
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Figure 5.8. Apoptosis and necrosis expressed as percentage of the total number of dead 
cells by counting Annexin V-FITC and PI stained fluorescent L1210 cells (S and R 
forms) treated with casiopeina II or cisplatin. Results are from a single experiment.
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Figure 5.9. Quantified apoptosis/necrosis expressed as percentage of the total number 
of dead cells using Annexin V-FITC and PI fluorescence staining in attached and 
detached CHI S and CHI R cells treated with casiopeina II. Results are from a single 
experiment.
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5.3.3 Assessment o f caspase activation with casiopeina ll-induced apoptosis
Recent studies suggest that the activation of caspases plays an important role in cell 
death by apoptosis, the activity of caspases was therefore assessed during casiopeina II- 
induced apoptosis.
It has been demonstrated that the proteolytic cleavage of poly(ADP-ribose)polymerase 
(PAR?) can be used as an early marker of chemotherapy-induced apoptosis and as a 
direct event resulting from caspase activation (Kaufrnann et a l, 1993). fri order to 
investigate further whole cell lysates from casiopeina II and cisplatin treated L1210 and 
CHI cells were examined by immunoblotting using C-2-10 monoclonal antibody. 
Cleavage of PARP into the «86-kd fragment was observed in L1210 cells after 24 hours 
of casiopeina II and cisplatin treatment (Figure 5.10). Similar results can be observed in 
CHI cells after a 24-hour treatment with casiopeina II and cisplatin (Figure 5.11). In 
both cell lines the «86-kd band indicative of PARP cleavage is somewhat weaker in 
cells treated with casiopeina II when compared with those treated with cisplatin.
In addition to the cleavage of PARP, caspase activity can also be assessed by a more 
conventional assay method using specific fiuorogenic substrate. With the purpose of 
investigating caspase activation during casiopeina fi-induced apoptosis, cytosols of 
L1210 S, L1210 R, CHI S and CHI R were incubated with the fiuorogenic substrate of 
DEVD-AFC and the activity measured by microfluorimetry. The caspase activity of 
DEVD-AFC was increased by 2.3-fold following treatment with casiopeina II in LI210 
S and LI2I0 R cells when compared with that of the untreated cells. However the 
increase after cisplatin treatment was some 15-fold higher in L1210 S and 4.8 fold in 
L1210 R cells than non-treated cells (Figure 5.12). Treatment of CHI cells with 1 pM 
of casiopeina II for 48 hours resulted in a 11-fold increase of DEVD-AFC in CHI cells 
and 9.3-fold in CHIR cells, while treatment with 2 pM of casiopeina II for 24 hours 
resulted in only a 3-fold increase for both cell lines. This lower concentration of 
casiopeina II and longer period of treatment resulted in a higher enzyme activity being 
observed. In addition treatment with 100 pM of cisplatin for 24 hours resulted in a 10- 
fold increase of DEVD-AFC activity compared to non-treated cells (Figure 5.13).
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The involvement of caspases in the induction of apoptosis by casiopeina II was further 
confirmed with the caspase inhibitor Z-VAD-FMK. CHI and L1210 cells were 
incubated with Z-VAD-FMK at 10 pM, 50 pM and 100 pM thirty minutes prior 
treatment with casiopeina II and cisplatin. The effect of 100 pM Z-VAD-FMK 
following treatment with casiopeina II in L1210 S cells (Figure 5.14) was of a 50% 
inhibition and 40% in L1210 R cells (Figure 5.15). In CHI cells a 100 pM Z-VAD- 
FMK had a 60% inhibition in CHI S cells (Figure 5.16) and about 70% in CHI R cells 
(Figure 5.17). The effect of 100 pM Z-VAD-FMK in L 1210 cells treated with cisplatin 
was 80% inhibition in L1210 S and 50% inhibition in L1210 R cells, whereas in CHI S 
and CHI R the inhibition of apoptosis was almost of a 100%.
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Figure 5.10. Immunoblotting analysis of PARP cleavage in L1210 cells treated with 
3pM of casiopeina II and lOOpM of cisplatin for 24 hours. The lanes contained two 
different protein concentrations 30 and 60 pg. Cells undergoing apoptosis show PARP 
cleavage with the appearance of the »86-kd band.
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Figure 5.11. Immunoblotting analysis of PARP cleavage in CHI cells treated with 
2pM of casiopeina II and lOOpM of cisplatin for 24 hours. The lanes contained two 
different protein concentrations 25 and 50pg. Cells undergoing apoptosis showed 
PARP cleavage with the appearance of the »86-kd band.
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Figure 5.12. DEVD-AFC cleavage activity in cell cytosol from L1210 S and L1210 R 
cells after treatment with equitoxic doses of casiopeina II and cisplatin. Data shown are 
from a single experiment chosen as a representative of two separate experiments. 
Upper right hand histogram shows apoptotic induction from the same samples and 
scored by fluorescence microscopy.
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Figure 5.13. DEVD-AFC cleavage activity in cell cytosol from CHI S and CHI R 
cells following treatment with equitoxic doses of casiopeina II and cisplatin. Data 
shown are from a single experiment chosen as a representative of two separate 
experiments. Upper right hand histogram shows apoptotic induction from the same 
samples and scored by fluorescence microscopy.
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Figure 5.14. Inhibition of apoptosis with Z-VAD-FMK in L1210 S cells treated with 
casiopeina II or cisplatin. Cells were pre-treated with three different concentrations of 
the caspase inhibitor Z-VAD-FMK before drug treatment. Apoptosis was assessed by 
fluorescence microscopy and each point represents the mean ± S.D. of 3 independent 
experiments. * Represents P<0.Q5. Upper right hand histogram represents cell viability
assessed by the exclusion of trypan blue.
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Figure 5.15. Inhibition of apoptosis with Z-VAD-FMK in L1210 R cells treated with 
equitoxic doses of casiopeina II or cisplatin. Treatment and assessment details are 
exactly as in the legend to Figure 5.15. Each point represents the mean ± S.D. of 3 
independent experiments. * Represents P<0.05. Upper right hand histogram represents 
cell viability.
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Figure 5.16. Inhibition of apoptosis with Z-VAD-FMK in CHI S cells treated with 
equitoxic doses of casiopeina II and cisplatin. Treatment and assessment details are 
exactly as in the legend to Figure 5.15. Each point represents the mean of 2 
independent experiments. Upper right hand histogram represents cell viability.
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5.3.4 Detection o f  DNA fragmentation in apoptotic cells
A hallmark of apoptosis is the cleavage of DNA oligonucleosomal sized fragments 
multiples of 180-200-bp according to DNA content, these low molecular weight 
fragments are determined by a characteristic laddering by gel electrophoresis. Larger 
fragments can only be fractionated and visualised on FIGE. Intact cells do not show 
DNA laddering and necrotic cells only produce a smear of randomly degraded DNA.
Isolated DNA from L1210 cells following treatment with a range of doses of casiopeina 
II was separated by gel electrophoresis, stained with ethidium bromide and observed 
under UV light. The result shows that DNA from untreated L1210 cells remained intact 
and presented no laddering whereas cells treated with casiopeina II showed degradation 
of DNA in a dose response form confirming induction of apoptosis (Figure 5.18). Data 
in Figure 5.19 also show that both cisplatin-resistant and sensitive cells exhibit DNA 
fragmentation after casiopeina II treatment indicating that no cross-resistance towards 
casiopeina II is present in both cell lines. Treatment with cisplatin also exhibited the 
formation of DNA ladders indicating apoptosis. However with CHI cells no DNA 
laddering was detected after induction of apoptosis by casiopeina II or cisplatin (Figure 
5.20). Although CHI cells did not show any evidence of DNA intemucleosomal 
degradation after casiopeina II treatment, large length DNA fragments of about 50 to 
60-kbp were detected by field inversion gel electrophoresis after casiopeina II or 
cisplatin treatment (Figure 5.21).
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Figure 5.18. Dose response formation of oligonucleosomal-length DNA fragments of 
L1210 S and L1210 R cells after treatment with different doses of casiopeina II for 24 
hours. Lanes 1 to 4  are from L1210 S cells and lanes 5 to 8 are from L1210 R cells. 
Lanes 1 and 5-non-treated cells; lanes 2 and 6-cells treated with IpM CII; lanes 3 and 
7-cells treated with 2pM CII; lanes 4  and 8-cells treated with 3pM CII.
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Figure 5.19. Dose response of L1210 S and L1210 R cells induced formation of 
oligonucleosomal-length DNA fragments after treatment with casiopeina II for 24 hours 
or cisplatin 2/22 hours. Lanes l_to 6 are from L1210 S cells and lanes 7  to 12 are from 
LI210 R cells. Lanes 1 and 7-non-treated cells; lanes 2 and 8-0.5pM CII; lanes 3 and 
9- 1 pM CII; lanes 4  and 10- 1.5pM CII; lanes 5 and 11- 2 pM CII; lanes 6 and 12- 
lOOpM cisplatin.
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Figure 5.20. Gel electrophoresis of CHI S and CHI R cells showing no DNA 
fragmentation and formation of oligonucleosomal-length DNA fragments of L1210 S 
cells after treatment with casiopeina II or cisplatin. Lanes 1 to 3 are from CHI S cells, 
lanes 4  to 6 are from CHI R cells and lanes 7  to 10 are from L1210 S cells. Lanes 1^  4  ^
and 7  - non-treated cells; lanes 2 and 5 -2 pM CII; lanes 3 and 6- lOOpM cisplatin;
lanes ^  9 and 10-1, 2, 3pM of casiopeina respectively. Lanes with L1210 cells were 
included to demonstrate DNA laddering.
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Figure 5.21. Field inversion gel electrophoresis of DNA from CHI S and CHI R cells 
after treatment with equitoxic doses of casiopeina II and cisplatin. The arrow shows the 
48.9 kbp fragment from the X marker.
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5.3.5 Cell cycle analysis following casiopeina II treatment
To further investigate the mechanism of cell death induced by casiopeina II cell cycle 
analysis of L 1210 and CHI, resistant and sensitive to cisplatin, cells was performed 
using Flow Cytometry. Following casiopeina II or cisplatin treatment cells were 
labelled with a fluorescent dye that binds indiscriminately to DNA, propidium iodide 
(PI), and then analysed by flow cytometry (which measures the fluorescence intensity of 
each cell). Figure 5.22 illustrates normal cell cycle distribution of non-treated LI210 
and CHI cells respectively, showing the progression through the different phases of the 
cell cycle.
©2 / M 02 / M
PI-DNA fluorescencePI-Dn A fluorescence
Figure 5.22. Flow cytometry histogram of DNA content of non-treated L1210 (A) and 
CHI (B) cells showing cell cycle progression through the Gi, S and G2/M phases of the 
cycle, respectively.
Figure 5.23 shows flow cytometry data of L1210 S and L1210 R showing changes in 
the cell cycle progression after treatment with casiopeina II for different time intervals. 
The major effect of casiopeina II on the cell cycle of L1210 cells is the presence of a 
‘subGT peak in the DNA content, at 16, 24 and 32 hours after treatment. In addition at 
24 and 32 hours there is an accumulation of cells in the S phase suggesting a delay into 
G] progression. Cisplatin, used as a positive control, shows a ‘subGi’ peak arrest, a 
delay to S phase and a G2/M block.
188
Chapter 5. Mode of cell death
CONTROL
Time (hours)
16 24 32
CII
CIS
I
C II
CIS
256 256 128
256
S\h61
il â
256
256
128
128
128
$ub61
128
)i661
L1210 S
L1210 S
L1210 R
L1210 R
-t-HHIIII+HHIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIMII
PI-DNA fluorescence 1023
Figure 5.23. Flow cytometry data showing a sub Gi peak in DNA from L1210 S 
(upper graph) and L1210 R (lower graph) cells after treatment with casiopeina II for 
different time intervals. Cisplatin, used as a positive control, shows a typical sub Gi 
peak arrest and G: block. Changes with time and different doses of casiopeina II.
Slight changes in cell cycle progression of CHI S and CHI R cells with 2 pM and 4 pM 
of casiopeina II for different time intervals were observed (Figure 5.24). The major 
effect of casiopeina II treatment with 4 pM for 8 hours showed an arrest of cells in the 
Gi phase in CHI S cells, which can also be seen when using 2 pM for 24 hours. In 
CHI R treated with 2pM of casiopeina II showed an arrest of cells in the phase Gi cells 
at 16 hours of treatment and which continued at 24 hours. An increase of cell 
accumulation in S phase can be observed after casiopeina II treatment, this is 
corroborated by the percentage of cells calculated by computer analysis using the 
Watson algorithm as modified by in Ormerod et al. (1987) (Figure 5.25).
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Figure 5.24. DNA histograms showing an arrest of the Gi phase from CHI S (upper 
graph) and CHI R (lower graph) cells after treatment for different time intervals with 
casiopeina II at two doses. Changes with time and different doses of casiopeina II.
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Figure 5.25. Percentage of cells in the different phases of the cell cycle, Gi, S and 
Gi/M obtained by computer analysis of DNA histograms after treatment with two doses 
of casiopeina II at different time intervals.
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Flow cytometry analysis of L1210 S and L I210 R cells was also used to investigate 
further into the involvement of caspases in casiopeina II apoptosis induction. In the 
presence of Z-VAD-FMK the major effect after treatment with casiopeina II for 24 
hours is a clear loss of the casiopeina-induced ‘subGi’ peak indicating inhibition of the 
apoptotic process in L1210 S and L1210 R cells. The same effect can be observed in 
cisplatin treated L1210 S and L1210 R cells. By 48 hours a certain accumulation of 
cells at the ‘sub GL stage can be observed in the presence of Z-VAD-FMK in L1210 S 
cells after casiopeina II or cisplatin treatment (Figure 5.26).
L1210 S cells
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Figure 5.26. Flow cytometry data of L1210 S (upper graph) and L1210 R (lower 
graph) cells and the effect of Z-VAD-FMK on apoptosis after treatment with casiopeina 
II or cisplatin.
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5.4 DISCUSSION
The induction of apoptosis by chemotherapeutic agents is now a well established mode 
of cell death in vivo and in vitro (Hannun, 1997). Induction of cell death by apoptosis 
with casiopeina II treatment was investigated in (CHI) human ovarian carcinoma cells 
and (LI210) murine leukaemia cells (in both cisplatin resistant and sensitive cell lines).
Nuclear morphology of L1210 and CHI cells after casiopeina II treatment indicates that 
casiopeina II triggered apoptosis in a dose dependent manner, chromatin condensation 
and nuclear fragmentation were clearly observed (Wyllie, 1997). It should be noted that 
late apoptotic cells display increased plasma membrane permeability towards trypan 
blue, hence a possible overestimate in the percentage of necrotic cells when assessing 
cell viability. Additionally the externalisation of PS is apparently an early event in the 
apoptotic process, it happens before any changes on membrane permeability and it has 
been reported to also function as a recognition signal of macrophage phagocytosis in 
vivo (Martin, 1997). Following casiopeina II treatment a positive Annexin V-FITC 
labelling to PS was observed in both cell lines providing corroborating evidence by a 
different method for apoptosis induction assessed by nuclear morphology.
Previous studies suggest that caspases play a crucial role in the apoptotic process 
induced by chemotherapeutics (Martins et a l, 1997). Evidence of activation of CBD-3 
related caspases, was observed in the apoptotic response to casiopeina H. Furthermore, 
the cleavage of PARP (116 kDa) into the -86 kDa fi’agment confirms this as an 
indicator of in situ proteolysis of proteases that are substrates for CED-3 related 
caspases (Kaufinann et a l, 1993; Duriez and Shah, 1997). The relatively low level of 
activation of caspases together with reduced inhibition by Z-VAD-FMK suggest that 
non-caspase-dependent or alternative pathway(s) of apoptosis may be triggered by 
casiopeina II. In addition Annexin V data and caspase inhibition point to very early 
events in apoptosis being triggered by casiopeina II.
The exact mechanism by which casiopeina II activates caspases in the two cell lines 
tested is at present unclear. Preliminary data suggests that caspase activation occurs via 
the release of an intracellular signal such as cytochrome c (Kroemer et a l,  1997; Green 
and Reed, 1998) as a result of intracellular or even intramitochondrial ROS generation
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by the moiety of casiopeina II (Rivero-Müller, 1999). The generation of ROS and 
free radical-induced damage has been associated with the induction of cell death by 
apoptosis, probably through mitochondria activation (Zamzami et ah, 1995; Mignote 
and Vayssiere, 1998; Shaikh et ah, 1998). Furthermore preliminary studies showed 
inhibition of casiopeina Il-apoptotic induction in the presence of Zn (Francois, 1999), 
probably by the induction of metallothionein or heat shock proteins that avoid cell 
damage by ROS (Wong et a l, 1996), corroborating the induction of apoptosis via the 
generation of ROS with casiopeina II treatment. Alternatively, and at this stage purely 
speculative, upregulation of the CD95L ligand on the plasma membrane could be an 
effective process of apoptosis induction (Ashkenazi and Dixit, 1998), however it is 
difficult to predict how a molecule such as casiopeina II could directly act as a Fas 
ligand.
DNA laddering was observed in L1210 cells but not in CHI cells. The reason for the 
lack of degradation of the DNA in CHI cells into oligonucleosomal-length fragments, 
despite full morphological evidence of apoptosis and caspase activation, is not clear. 
However, absence of DNA laddering in apoptosis has been reported in the case of some 
cell lines (Oberhammer et a l, 1993; Ormerod et a l, 1996). While the classical 
laddering is not evident with CHI cells, high molecular weight DNA fragmentation 
(assessed by FIGE, see Figure 5.21) in CHI cells confirms that both casiopeina II and 
cisplatin lead to the activation of apoptosis specific endonucleases.
The major cell cycle effect in both cell lines, L1210 and CHI, treated with casiopeina II 
appeared to be an arrest in the Gi phase, the presence of a ‘subGi’ peak, and a 
slowdown of passage through S phase. A G% block and Gi/S phase arrest have been 
related with an impaired function of Rb protein, which results in an overexpression of 
E2F family of transcription factors with subsequent alterations in cell cycle progression, 
and probably favouring cell death by apoptosis (Fotedar et a l, 1997). Moreover in 
some cases p53 can increase sensitivity to chemotherapeutic agents and result in a Gi 
arrest. High concentrations of chemotherapeutic agents, such as cisplatin (or its later 
derivatives) and doxorubicin, induce delays in Gi/S phase before a Gi block leading to 
an impaired progression through the cycle and subsequent cell death probably by 
apoptosis (Ormerod et a l, 1994; O’Neill et a l, 1996; Souhami, 1997). In addition 
L1210 cells also showed a delay in the S/G2 transition and then death, which is an effect
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also seen with low doses of cisplatin treatment, yet not necessarily by apoptosis 
(Ormerod et a l, 1996). However similar cell damage induced by bleomycin, 
doxorubicin and anthracyclin treatment results in a block and thus it appears that G2 
phase is a particularly vulnerable to DNA strand segregation and chromatin 
condensation, which are indeed apoptotic events (Souhami, 1996). Thus casiopeina II- 
induced intracellular or intramitochondrial ROS-induced damage may then result in a 
distortion of the cell cycle and lead to cell death by apoptosis (Uslu and Bonavida, 
1995; Mignote and Vayssiere, 1998; Shaikh et a l, 1998; Schmitt et a l, 1999).
It is notable that the cisplatin resistant and susceptible forms of both cell lines were 
equally sensitive to casiopeina It. This clearly indicates that the mechanism by which 
L1210 and CHI cells gain resistance to cisplatin is not operative against casiopeina. 
Furthermore it has been reported that CHI cisplatin resistant cells exhibit a higher 
tolerance of DNA cisplatin binding as well as the apparent ability to avoid interstrand 
cross-links formation (O’Neill et a l, 1995). It appears that the mode of action of 
casiopeina operates at a more fundamental metabolic level and therefore would be less 
susceptible to cross-resistance. Casiopeina II effectively kills cells by apoptosis and 
necrosis in L1210 and CHI, resistant and sensitive to cisplatin, cells lines.
Cell death by apoptosis in several cell lines with cisplatin and its derivatives has been 
shown by various groups (Huschtscha et a l, 1995; O’Neill et a l, 1996; Ormerod et a l, 
1996; Henkels and Turchi, 1997) therefore apoptotic induction with cisplatin in L1210 
and CHl cells was used as a positive control during the whole of this study. In order to 
investigate whether casiopeina II would induce cell death by apoptosis an equitoxic 
treatment concentration protocol of cisplatin and casiopeina II apoptotic induction were 
used (as described in Section 5.2.3). However preliminary data with L1210 cells treated 
with equimolar concentration and same protocol treatment (4pM for 24 hours) of 
cisplatin and casiopeina II showed more susceptibility of apoptotic cell death assessed 
by nuclear morphology with casiopeina II than with cisplatin. Suggesting a higher 
cytotoxicity with casiopeina II than cisplatin, and perhaps a more effective apoptotic 
induction. To conclude the evidence found -  nuclear morphology, Annexin V positive 
binding, DNA fragmentation, caspase activation and flow cytometry analysis -  clearly 
indicates that casiopeina It induces apoptotic cell death in CHI and L1210 cells.
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The data obtained in this study have been discussed v^ithin the framework of each 
chapter, however in this final section a condensed discussion and conclusions are 
presented in order to summarise the importance and relevance of this project.
In the light of the promising anticancer properties of casiopeina II complex (Ruiz- 
Ramirez et a l, 1993c and 1995) the in vivo handling and toxicity post administration of 
casiopeina II at a dose of 5 mg/kg in the rat were investigated, as well as the in vitro 
mode of cell death induced in two cancer cell lines (L1210 and CHI).
Casiopeina II employed in all the in vivo studies of this project was administered 
intravenously in the rat at a dose of 5 mg/kg. This dose represents a third of the LD50 
dose in mice and was chosen as a compromise between a high therapeutic dose and that 
allowing the detection of casiopeina Il-derived copper above endogenous copper levels. 
Casiopeina II at 5 mg/kg showed acute haemolytic toxicity determined by the reduction 
of haemoglobin concentration, haematocrit and red blood cell counts at 12 hours, which 
were aggravated 5 days post administration. These findings represent the clinical 
picture of haemolytic anaemia accompanied by leukocytosis and neutrophilia in 10 
week-old rats. The toxic haemolytic side effects observed after casiopeina II 
administration are consistent with the known effects associated with copper toxicity 
(Bremner, 1998; Linder et a l, 1998). As a consequence of the haemolysis caused by 
casiopeina II an extensive filtration of red blood cells by the spleen as well as a 
haematopoietic process were observed. Spleen weight increase, infiltration of nucleated 
cells into the red pulp of the spleen, presence of normoblasts in peripheral circulation 
and the rise in circulating reticulocyte levels indicate an effective spleen erythropoiesis 
as a response to the haemolytic damage caused by casiopeina II (Greaves, 1990). Acute 
toxicity studies of casiopeina II in mice indicate that the main toxic effects associated 
with the administration of casiopeina II were of haematological origin, which correlate 
with the haematotoxicity observed in the rat (Quiroz-Rocha et a l, 1996). No 
morphological changes were observed in the liver, kidney and heart after casiopeina II 
administration, suggesting that the target organ of casiopeina II toxicity was the blood, 
mainly erythrocytes. Despite the haematotoxicity caused by casiopeina II treatment a 
significant improvement in the haemolytical parameters and a responsive recovery in 
spleen morphology were observed 15 days after administration, suggesting a positive
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recovery from the haemolytic damage caused by a single intravenous administration of 
casiopeina II.
The changes in red cell morphology after casiopeina II administration could be due to 
cell damage from casiopeina II or its copper component due to the ability of copper to 
oxidise proteins and lipids and enhance the formation of toxic intra- and extracellular 
free radicals from the reduction of Cu(II) to Cu(I) (Koropatnick and Leibbrandt, 1995). 
In vitro data suggests that after administration casiopeina II immediately enters the red 
blood cell (Rivero-Müller, 1999). Moreover once in contact with the erythrocyte 
membrane casiopeina II or its copper component can cause the generation of oxygen- 
derived free radicals and lipid peroxidation leading to the haemolytic damage (Linder 
and Hazegh-Azam, 1996). Subsequently the breakage of erythrocytes results in the 
release of intracellular contents, such as deoxy-haemoglobin, lipases, proteases and 
other enzymes as well as some casiopeina II complex producing damage to other 
adjacent cells in a chain reaction manner, which correlates with the leukocytosis and 
neutrophilia observed (Williams et a l, 1983; Rice-Evans, 1990; Hoffbrand and Pettit, 
1993).
Differences in species and age influence the toxic effect of casiopeina U in vitro and in 
vivo. In vitro studies of the partitioning of casiopeina II in human and rat blood suggest 
that casiopeina II immediately enters the red blood cell (Rivero-Muller, 1999). 
Furthermore both components of ^H-casiopeina II exhibit a similar binding to the high 
molecular weight fragment of an albumin solution from rat, dog, sheep and human 
blood. However a higher percent of tritium was bound to low molecular weight 
fragment in the rat and sheep compared to the dog and human whereas the amount of 
copper bound to the low molecular weight fragments was almost the same for the four 
species. Therefore ^H-casiopeina II was more stable in an albumin solution from rat 
and sheep blood, suggesting that the in vivo handling and stability of ^H-casiopeina II 
would vary between the different species (Moran, 1999). In addition and consistent 
with albumin binding of ^ H-casiopeina II the complex was rapidly distributed into RBC 
in rat and human blood, compared to the dog and sheep where copper was found in 
RBC whilst tritium was distributed between both plasma and RBC (Moran, 1999). 
Treatment with casiopeina n  of mongrel dogs with a venereal tumour treated at UNAM, 
Mexico indicated susceptibility to the compound, manifested by haemolysis and
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leukocytosis, to casiopeina II at the relatively low dose of 4 mg/kg (De Vizcaya-Ruiz et 
a l, 1996). Despite the acute toxicity, presumably attributable to the well established 
toxicity of copper in dogs, casiopeina II proved to be a potential effective treatment for 
neoplastic diseases in dogs (Ruiz-Ramirez et a l, 1994a).
Six week-old rats showed a higher tolerance to the haematotoxic effect caused by the 
intravenous administration of casiopeina II in contrast with the acute toxicity described 
previously for 10-week old rats. Although the difference in age from the two groups 
was only 4 weeks, a marked difference in the haemolytical response was observed. 
This difference could be attributed to the turnover of erythrocyte life span. In older rats 
more erythrocytes could be reaching an older stage, where they have a lower cellular 
plasticity due to an inability to replace or repair membrane proteins and lipids and thus 
becoming more rigid and more susceptible to damage. In younger rats although there is 
also some red cell destruction because of the normal erythrocyte life-span most of the 
red blood cells are in an earlier stage of their life span, where they are more flexible and 
less susceptible to damage (Benirschke et a l, 1978; Kessel and Kardon, 1979). 
Additionally individuals may respond differently to copper toxicosis, specially the rat, 
such as the LEG rats with some 40% developing fulminant hepatitis from the copper 
overload and the surviving 60% developing a chronic hepatitis and subsequently liver 
cancer much later in their life span (Mori et a l, 1994).
Although pretreament with copper chelators, trientine and penicillamine, should have 
resulted in elevated levels in plasma and presumably tissue there was no significant 
amelioration of the haematotoxic effects of casiopeina II. Both chelators usually act 
within the cellular copper transport system in cases of excess copper from the liver but 
not necessarily on circulating copper (Jong-Hon et a l, 1993; Kodama et a l, 1997). 
This suggests that casiopeina II damage occurs within the erythrocyte and before it is 
transported to tissues. Once in tissues the excess copper from casiopeina II may bind to 
metallothionein becoming non-toxic. Despite the fact that ascorbic acid in vivo in some 
cases acts as an antioxidant, it can also have pro-oxidant properties in the presence of 
metal ions (Halliwell, 1996). However no significant improvement or aggravation of 
the haematological effect of casiopeina II was observed with ascorbic acid pretreament, 
suggesting that the toxic effect from casiopeina II is produced directly to red cells in 
vivo and was not affected by copper chelators or ascorbic acid.
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Pretreatment with erythropoietin before casiopeina H administration enhanced 
erythropoiesis stimulating red blood cell formation as well as an increase in red blood 
cell reserves, and thus improving the haemolytic toxicity caused by casiopeina II. 
Reports indicate that the use of erythropoietin during cancer chemotherapy can improve 
the response to therapy by strengthening the general condition of the patient as well as 
ameliorating haemolysis caused by chemotherapeutic agents (Abels, 1993).
Casiopeina II seems to bind to plasma proteins, mainly albumin, and is rapidly 
distributed by blood into tissues as an apparently intact complex. However once in 
tissues, liver, kidney, spleen and heart, the excretion of the two components of 
casiopeina It differed, tritium being rapidly released whereas copper was retained. The 
copper retention in tissues (except spleen) can be attributed to metallothionein binding 
and storage of the copper component from casiopeina II. In the case of the liver, copper 
that would not be bound to metallothioneins or incorporated into caeruloplasmin was 
probably excreted into bile by lysosomes, glutathione incorporation and ATPase efflux 
(Harada et a l, 1993; Sugawara et a l, 1995; DiDonato and Sarkar, 1997). Copper was 
excreted via faeces, which is the normal route of copper excretion and tritium was 
excreted via urine and faeces. The differences in tissue distribution and excretion 
between both components of ^ H-casiopeina II suggest a dissociation of the complex.
From the data obtained in this study it appears that casiopeina II has a rapid cellular 
uptake and distribution, remaining in circulation as a complex for approximately 6 to 12 
hours. Time in which it could exhibit its anticancer potential by inducing apoptotic cell 
death. Casiopeina II effectively induced apoptosis in CHI and L1210, resistant and 
sensitive to cisplatin, cells observed by changes in nuclear morphology, positive 
Annexin V-FITC labelling, caspase activation and DNA fragmentation. In addition the 
presence of a ‘subGi’ peak arrest of the Gi phase of the cell cycle in both cell lines was 
observed after casiopeina II treatment, indicative of an apoptotic cell death process. 
L1210 cells also displayed a delay in the S/G2 transition, which is an effect also 
observed in apoptotic cell death with cisplatin treatment (Ormerod et a l, 1996). Thus 
from the in vivo data, which clearly indicates a cellular uptake of the intact Cu(II) 
complex, it can be inferred that the mechanism of apoptotic cell death induced by 
casiopeina II is through the intracellular generation of ROS and free radicals (Sarafian 
and Bredesden, 1994; Zimowska et a l, 1997). Furthermore triggering of apoptosis with
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casiopeina II treatment is probably through an intracellular mitochondrial signal 
resulting in the release of cytochrome c from the generation of ROS and free radicals 
(Rivero-Müller, 1999). However studies of apoptotic cell death in cancer tumours 
induced by casiopeina II in vivo would provide further evidence of the anticancer 
potential of casiopeina II. Additionally cisplatin resistant and susceptible forms of CHI 
and L1210 cell lines were equally sensitive to casiopeina II, suggesting the mechanism 
by which CHI and L1210 cells gain resistance to cisplatin does not operate against 
casiopeina.
Complexes that donate copper may be more effective despite their low stability, on the 
other hand if the complex was highly stable it would be inert, such as the magnetic 
resonance imaging agent Gd(III)-DTPA , and result in minimising its anticancer 
potential. The current data suggest that casiopeina II could be an effective anticancer 
agent for leukaemias due to its rapid cellular uptake and distribution and its effective 
induction of apoptotic cell death, however against solid tumours it may not be as 
effective. An exchange of the aminoacid component with different ligands (serine, 
valine, histidine or even dipeptides) of casiopeina II molecule could improve the 
stability of the complex in vivo and thus increase its anticancer potential. However, 
there is no clear evidence that such a strategy to increase the stability, would necessarily 
correlate with increased antineoplastic activity. It is unfortunate that within the scope of 
this project we were unable to test some of the later complexes being developed at 
UNAM.
In conclusion the in vivo data from copper and ^H suggests that ^H-casiopeina II is 
initially bound to albumin as a complex and is rapidly distributed through the body 
mainly into liver and kidney by blood circulation, and further redistributed to other 
tissues. Copper was retained in tissues, probably bound to metallothioneins, and was 
excreted via bile whilst tritium was rapidly excreted via urine and faeces. These data 
suggests that casiopeina II complex is readily dissociated in vivo. In addition casiopeina 
n  mainly targets erythrocytes causing oxidative damage and breakage. The toxic effect 
of casiopeina II may be due to the generation of free radicals and oxidative stress from 
the reduction of Cu(II) to Cu(I). The acute toxic effect of casiopeina II in erythrocytes 
lead to an effective splenic erythropoietic process in order to compensate the haemolytic
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damage, recovery from the acute toxicity of casiopeina II was observed 15 days after 
administration. Moreover the evidence found -  nuclear morphology, Annexin V- 
binding, DNA ftragmentation, caspase activation and flow cytometry analysis -  clearly 
indicates that casiopeina II induced apoptotic cell death in sensitive and resistant to 
cisplatin CHI and L1210 cells, probably by the generation of free radicals and ROS 
from the reduction of Cu(It) to Cu(I).
FURTHER STUDIES
Design a treatment protocol to test a more realistic repeated dosing therapeutic regime 
of casiopeina II in the rat using a 1 mg/kg as the starting point. The aim would be to 
check the haematological parameters, in addition to other possible changes in spleen, 
liver and kidney. In addition test the effectiveness of erythropoietin in ameliorating the 
haematology toxicity of casiopeina II in the repeated dose regime.
Evaluate urinary parameters in order to characterise the haemaglobinuria and 
haemosiderin and develop a rapid and sensitive biomarker for the acute toxicity of 
casiopeina II.
Since the most acute toxicity of casiopeina II is elucidated in erythrocytes it would be 
prudent to investigate in more detail:
Erythrocyte (and whole blood) oxidative stress, measured by the production of 
reactive oxygen species (ROS).
Erythrocyte damage by measurement of its functional enzymes, pyruvate kinase, 
hexokinase and glucose-6- phosphate dehydrogenase (G-6-PD).
Erythrocyte glutathione and vitamin E status.
Study the potential of promotion of intracellular glutathione as an aid to reduce 
casiopeina II toxicity to erythrocytes.
Examine the bone marrow and spleen erythropoietic cells to confirm the erythropoietic 
response after a repeated course of casiopeina II treatment and particularly for assessing 
recovery.
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With the repeat dose protocol it would be important to check the long term tissue copper 
disposition and effect on other essential metals. Determine the levels of metallothionein 
(MT) in tissues after repeated doses of casiopeina II treatment, to evaluate copper 
retention and tolerance in the liver. Does MT induction mean a potential for resistance 
to the therapeutic activity of casiopeina It?
Although there appears to be no clear link between selenium and the metabolism of 
casiopeina II it would be advisable to test the potential of selenium in the amelioration 
of the toxicity of casiopeina II because of its general anticancer activity and as an active 
component of glutathione-peroxidase.
The evaluation of the in vivo stability and haematological toxicity of other members of 
the Casiopeinas series, would be extremely useful in correlating structure against 
toxicity and thus in the development of less toxic complexes.
Examine in more detail the effect of casiopeina n  on mitochondria activity and 
cytochrome c release during apoptotic cell death to establish route and mechanism by 
which casiopeina II may trigger and induce apoptosis. Determine the activation of 
caspase 8 and 9 and the downstream 6 and 7, to explain and confirm whether casiopeina 
n  induces apoptotic cell death through the caspase cascade. As a component of the 
mitochondrial membrane, expression of Bcl-2 protein in apoptosis induction with 
casiopeina II would also be worthy of further consideration and the expression of the 
p53 tumour supressor gene as an indicator of casiopeina II chemosensitivity in cancer 
cells.
Assessment of apoptotic cell death by the reduction of mitochondrial transmembrane 
activity from the generation of ROS in cancer cells treated with casiopeina II. It is not 
clear if the expression of CD95/Apol/Fas receptor/ligand in various cancer cell lines 
plays a role in the apoptotic cell death induced with casiopeina II.
Evaluate the role of zinc in vivo as a possible ameliorating agent in the toxicity of 
casiopeina II, and in the process of apoptosis induced in cancer cell lines by casiopeina 
n. The latter is important, as zinc is known to inhibit apoptosis and may thus reduce the 
therapeutic activity of casiopeina II.
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APPENDIX I
RAT 
& MOUSE
AU
DIE
OCLAVABLE
This diet is based on our rat and mouse feed with 
boosted vitamins and essential fatty acids to 
withstand the rigours of steam sterilizing.
The diet Is “Cab-o-Sil" coated and may be 
autocfaved in the bag.
Fixed Formula 
Wheat meal 
Soya meal 
Barley meal 
Wheatfeed 
Fish meal 
Full fat soya 
Fats and oils 
Minerals
Vitamins and trace elements
CÛ
B&K Universal Limited 
The Field Station 
Grimston Aldbrough Hull 
N. Humberside HU11 4QE 
Tel. 0964 527555 
Fax 0964 527006
A B&K Universal Company
Nutrient Feed Nutrient
Supplem ent Level Supple
Proxim ate an a lysis
Dry Matter % 68.0 Fatty A cids
Crude Protein % 20.0 Saturated
Crude Oil % 4.0 Fatty Acid % 1,19
Crude Fibre % 4.0 Unsaturated
Nitrogen Free Fatty Acid % 2,10
Extract % 54.4 UnoieicAcid % 1,32
Ash % 5.6 1.7
A m ino Acids
Energy % 1,16 0,10
Gross Energy 16.16 Methionine % 0.33
Methionine +
Minerals Cystine % 0.63
Calcium % 0.95 0.39 Threonine % 0.72
Total Phosphonjs % 0.68 0.185 Tryptophan % 0.25
Av. Phosphoois % 0.43 0.185 Arginine % 1,28
Sodium Chloride % 0.71 0.40 Glycine % 1,02
Magnesium % 0.17 0.01 Glycine + Serine % 1,98
Sodium % 0.31 0.16 Histidine % 0,47
Chloride % 0.40 0.24 Isoleudne % 0,85
Potassium % 0.70 Leucine % 1,40
Phenylalanine +
Trace Elem ents Tyrosine % 1,44
Selenium 0.36 0.20 % 0,97
Cobalt 0.46 0.40
Iodine 1.42 1,30 Vitam ins
98,0 60,0 Vitamin A iu/kg 15000 1500C
Manganese 68.0 50,0 Vitamin 03 iu/kg 1500 1500
Copper mg/kg 21,0 12,0 Vitamin E iu/kg 113 100
mgrirg 108,0 40,0 Vitamin K mg/kg 15 15
Vitamin B1 17 15
Vitamin B2 14 12
Vitamin B6 19 15
Vitamin B12 mcg/kg 40 40
Vitamin C 0 0
Folic Add 2,6 2,0
Nicotinic Add 76 30
Pantothenic Add 26 15
mcg/kg 340 200
Choline mg/kg 1280 224
OF SUP™
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